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Biomarkers find a wide variety of applications in oncology from risk assessment to 
diagnosis and predicting and monitoring recurrence and response to therapy. Developing 
clinically useful biomarkers for cancer is faced with several challenges, including cancer 
heterogeneity and factors related to assay development and biomarker performance. 
Circulating biomarkers offer a rapid, cost-effective, and minimally-invasive window to 
disease and are ideal for population-based screening. Circulating immune biomarkers are 
stable, measurable, and can betray the underlying antigen when present below detection 
levels or even no longer present. This dissertation aims to investigate potential circulating 
immune biomarkers with applications in cancer detection and novel therapies. Over 
600,000 cancers each year are attributed to the human papillomavirus (HPV), including 
cervical, anogenital and oropharyngeal cancers. A key challenge in understanding HPV 
immunobiology and developing immune biomarkers is the diversity of HPV types and the 
need for multiplexed display of HPV antigens. In Project 1, nucleic acid programmable 
protein arrays displaying the proteomes of 12 HPV types were developed and used for 
serum immunoprofiling of women with cervical lesions or invasive cervical cancer. These 
arrays provide a valuable high-throughput tool for measuring the breadth, specificity, 
heterogeneity, and cross-reactivity of the serologic response to HPV. Project 2 
investigates potential biomarkers of immunity to the bacterial CRISPR/Cas9 system that 
is currently in clinical trials for cancer. Pre-existing B cell and T cell immune responses to 
Cas9 were detected in humans and Cas9 was modified to eliminate immunodominant 
epitopes while preserving its function and specificity. This dissertation broadens our 
understanding of the immunobiology of cervical cancer and provides insights into the 
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CHAPTER 1 : INTRODUCTION 
The study of cellular pathways at the molecular level has revolutionized our understanding 
of mechanisms, markers, and classification of disease. Many conditions previously 
perceived as a single disease are now recognized to have distinct molecular patterns of 
perturbation. Personalized medicine envisions the delivery of treatments tailored to 
individual molecular disorders. This vision requires a transformation in the approaches for 
the discovery of reliable molecular markers of disease. The incorporation of the molecular 
changes observed in disease into clinical practice necessitates establishing validated 
correlations with clinical usefulness.  
The topic of biomarkers has been one of the most exciting applications of the ‘omics’ 
technologies. It has raised hopes for the realization of precision medicine, thus improving 
healthcare quality and reducing treatment costs. For example, routinely screening colon 
cancer patients for K-RAS mutations will spare unresponsive patients costly and 
potentially toxic treatments with EGFR inhibitors and save at least US$600 million annually 
as estimated by the American Society of Clinical Oncology (Behl et al., 2012). Former US 
President Barack Obama announced the Precision Medicine Initiative during the 2015 
State of the Union Address (Obama, 2015). The National Institutes of Health (NIH) leaders 
further explained the initiative goal – to combine large scale clinical data and biomarker 
measurements (Collins & Varmus, 2015; NIH, 2015). The number of large programs 
established by the NIH for biomarker discovery and validation has exceptionally expanded 
in the last decade. The excitement is reflected in the huge investments made in the field 
by both public and private companies, with the global cancer biomarkers market projected 
to reach US$27.63 billion by the end of 2025 from US$10.25 billion in 2016 ("Transparency 
Market Research," 2017).  
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This chapter provides background about biomarker applications in cancer and the process 
of biomarker discovery and validation, with a review of approaches for their identification. 
Focus is given to the current status of biomarkers of HPV-associated cancers, particularly 
cervical cancer, and their clinical utility. Finally, unanswered questions that constitute the 
topics of later chapters of this thesis as well as dissertation contributions are discussed.  
 
1.1. WHAT ARE BIOMARKERS?  
Biomarker is a portmanteau of biological marker and it is a biometric measurement that 
objectively indicates a medical state of the subject being tested. The state indicated could 
be related to disease incidence, outcome, response to interventions, and even unintended 
environmental exposure. The World Health Organization stated a broader definition that 
includes “almost any measurement reflecting an interaction between a biological system 
and a potential hazard, which may be chemical, physical, or biological. The measured 
response may be functional and physiological, biochemical at the cellular level, or a 
molecular interaction” ("Biomarkers and Risk Assessment: Concepts and Principles," 
1993). The National Cancer Institute defines biomarkers as “a biological molecule found 
in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of 
a condition or disease.” 
Biomarkers are biometric measurements that can range from pulse, blood pressure, and 
medical imaging techniques to quantitative analyses of genomic or proteomic analytes 
combined into mathematical models (Paik et al., 2004). The significance of this 
measurement is its capacity to distinguish between two biological states (LaBaer, 2005). 
The fundamental issue is to identify a reliable relationship between the biomarker 
measurement and a relevant clinical endpoint (Strimbu & Tavel, 2010). Often times, with 
enough variables, computational techniques may segregate two groups under 
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investigation only by random chance. Thus, it is important to recognize that establishing 
the distinction ability of the biomarker is not trivial. 
Clinical endpoints are characteristics that indicate how the individual in a study “feels, 
functions, or survives” (Atkinson et al., 2001). Biomarkers, on the other hand, may or may 
not reflect what the subject feels or correlate with their clinical state. The ultimate goal of 
clinical practice and research is related to clinical endpoints (improving morbidity and 
mortality) rather than analytical measurements of biomarkers (Strimbu & Tavel, 2010). 
Thus, there needs to be enough evidence that a biomarker precisely and reliably predicts 
clinical outcome for it to be regarded as a surrogate endpoint, a substitute  for a clinical 
endpoint (Atkinson et al., 2001). This brings up the question of what it takes to develop 
validated, reliable, and clinically useful biomarkers, which is discussed in detail in Chapter 
2.  
Some analyte measurements are designated biomarkers before their reliability and utility 
have been properly validated. A valid biomarker is “a biomarker that is measured in an 
analytical test system with well-established performance characteristics and for which 
there is an established scientific framework or body of evidence that elucidates the 
physiologic, toxicologic, pharmacologic, or clinical significance of the test results (FDA, 
2005)”. Validation refers to the process of verifying the performance of a biomarker and 
the conditions required for reproducible and accurate prediction (J. W. Lee et al., 2006; 
Wagner, 2002). The term ‘evaluation’ has replaced validation to avoid the connotation that 
a relation between the biomarker and the underlying biological process or clinical endpoint 
needs to be established and fully understood (Atkinson et al., 2001; Strimbu & Tavel, 
2010). ‘Qualification’ has recently replaced ‘evaluation’ and it refers to “the evidentiary 
process of linking a biomarker with biological processes and clinical end points (Hunter et 
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al., 2010; Wagner, Williams, & Webster, 2007).” It is not uncommon, however, for these 
three terms to be used interchangeably in the scientific literature.  
 
1.2. APPLICATIONS OF BIOMARKERS IN CANCER 
Biomarkers find a wide variety of applications in oncology from risk assessment and 
screening seemingly healthy individuals to diagnosis, determining prognosis, and 
predicting and monitoring recurrence and response to therapy. Some biomarkers have 
more than one clinical application and can be used for more than one type of cancer. 
Some of these potential applications are detailed below.  
1.2.1. Risk Assessment  
Primary prevention and early detection of cancer are regarded as the most successful 
approaches that can significantly reduce the overall burden of and mortality due to cancer 
(Etzioni et al., 2003; Jemal et al., 2004). One of the classical cancer risk models classifies 
the population into three groups: normal without cancer, asymptomatic cancer (can be 
detected and potentially treated), and symptomatic cancer (Zelen, 1993). Advances in the 
technologies for the identification of risk factors for each cancer type and even subtype 
has led to the development of more refined models for clinical use (NCI, 2018).  
Inherited genetic abnormalities and environmental factors can change an individual’s 
cancer risk over time. However, detection of markers of these factors is only useful if a 
high likelihood of developing cancer is known to occur in the presence of this marker (i.e. 
penetrance) and a potential intervention has been demonstrated to be effective (Calzone, 
2012; X. Li, Blount, Vaughan, & Reid, 2011). Genetic biomarkers of cancer risk can be 
classified into high, moderate, and low penetrance according to the probability of the 
occurrence of cancer when the risk biomarker is detected (Calzone, 2012). The most well 
recognized high penetrance susceptibility genes are BRCA1 and BRCA2 mutations for 
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breast, ovarian, and other cancers (S. Chen & Parmigiani, 2007). A woman with this 
germline mutation and a family history of ovarian and/or breast cancer could benefit from 
more close monitoring, chemoprevention, or prophylactic surgery (Domchek et al., 2010). 
Moderate and low-penetrance markers are useful for research purposes, but more data 
are required, particularly from diverse ethnic populations, before these markers could be 
implemented in the clinical decision (Apostolou & Papasotiriou, 2017; Choi, Kipps, & 
Kurzrock, 2016; Sud, Kinnersley, & Houlston, 2017).  
1.2.2. Early Detection 
Disease diagnosis is the most explored application of biomarkers. Early detection is of 
particular interest in cancer given its potential for aiding in successful intervention before 
the patient succumbs to metastasis. There is an interest in developing minimally invasive 
biomarker tests that indicate disease long before the tumor is large enough to be observed 
for screening of seemingly healthy individuals. Biomarkers for cancer prognosis, 
progression, and response to therapy are currently in clinical use. However, finding 
biomarkers with enough sensitivity and specificity to find utility as population screens has 
been a challenge. One example is the commonly used but controversial prostate specific 
antigen (PSA) for the early detection of prostate cancer. Its implementation for screening 
of men over the age of 50 led to an increase in prostate cancer detection (Catalona, Smith, 
Ratliff, & Basler, 1993). However, recent analyses found insufficient evidence for the 
mortality benefit of early detection (Kim & Andriole, 2015).  
For this purpose, the National Cancer Institute Early Detection Research Network (NCI 
EDRN) was developed for biomarker discovery and validation for cancer and cancer risk 
assessment (NCI, 2000). The EDRN allowed the collaboration of a network of scientists 
from both the academia and the industry for meticulous implementation of systematic 
evidence-based biomarker research for cancer screening and early detection. The result 
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is rigorous validation studies, prioritizing hundreds of biomarkers, and discontinuation of 
unpromising candidates from further development (Srivastava, 2013). The expectations 
of screening biomarkers are higher than those for biomarkers used in established patients 
and a narrower window of variation in measurements is allowed. Thus, combining a panel 
of biomarkers or combining a biomarker with other diagnostic tests could lead to optimal 
performance and certainty (LaBaer, 2005). 
1.2.3. Disease Monitoring and Prognosis 
Using biomarkers for monitoring of cancer progression has some advantages over other 
applications. Because most of these biomarkers are either normal molecules in the body 
that have abnormal changes or the immune response to these abnormalities and due to 
the heterogeneous nature of cancer, these biomarker measurements can vary greatly 
between individuals. This makes it difficult to establish a one-size-fits-all cutoff for 
population screening biomarkers. However, for patients already diagnosed with cancer, 
establishing a correlation between the biomarker level and disease severity for a given 
patient can help detect or predict disease progression, regardless of the absolute quantity 
of the biomarker.  
A well-recognized example is the carcinoembryonic antigen (CEA) that correlates with 
disease progression in many but not all colon cancer patients (Fakih & Padmanabhan, 
2006). If this correlation has been established for a specific patient through other means 
such as monitoring tumor size through imaging in relation with the biomarker level, then 
serial measurements of CEA over several visits can be informative of the cancer 
progression status. Beta-HCG, alpha feto-protein, and lactate dehydrogenase are 
similarly used for the early detection of nonseminomatous germ cell tumor recurrence 
through serial analysis (Gilligan et al., 2010). Additionally, a biomarker detected at higher 
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than normal levels but that has been stable in a given patient could indicate stable disease 
and success of therapy, despite being abnormally elevated (LaBaer, 2005). 
1.2.4. Predicting Response to Therapy and Subtype Classification 
Somatic mutations in KRAS are associated with poor response to the epidermal growth 
factor receptor (EGFR) inhibitors in colorectal cancers (Allegra et al., 2009). Estrogen 
receptor overexpression in breast cancer predicts response to the anti-endocrine drug 
Tamoxifen (Davies et al., 2011). Response to the anti-HER2 monoclonal antibody 
Trastuzumab could be predicted by HER2 overexpression in breast and gastric cancers 
(Bang et al., 2010). The overexpression of these proteins represents a basis for subtype 
classification within a given type of cancer that was once thought to be a single disease. 
This subtype classification influences therapeutic decisions.  
Predicting success of a therapeutic agent is one of the costliest aspects of the drug 
development process. Pharmaceutical companies are interested in investing in biomarker 
tests that predict response to therapy before patients are put on drugs that they do not 
respond to, could lead to adverse events, or are expensive. Markers of ineffective or toxic 
lead compounds are useful for abandoning further research early on before huge 
investments are made. The field of pharmacogenomics focuses on studying how the 
genetic makeup of an individual dictates toxicity due to a certain therapeutic agent. For 
example, homozygosity for the UGT1A1*28 has been associated with increased risk of 
toxicity including severe neutropenia to the topoisomerase I inhibitor irinotecan used in 
colorectal and small cell lung cancers. This led the US Food and Drug Administration to 
change the labeling for this drug (Innocenti & Ratain, 2006).  
Adverse reactions to a certain treatment can also be a function of the individual immune 
response and exposure history, rather than an inherited somatic gene. Pre-existing 
immune response to various components of gene therapies has been investigated as a 
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marker of a potential adverse immune reaction to these therapies (Brunetti-Pierri & Ng, 
2009; Halbert, Standaert, Wilson, & Miller, 1998; H. Jiang et al., 2006; Kay, 2011; 
Nathwani et al., 2011; Nayak & Herzog, 2010). In this thesis, individual immune profiles to 
the CRISPR/Cas9 gene therapeutic is studied with the goal of exploring possible adverse 
reactions or therapy failure in certain individuals.  
 
1.3. CIRCULATING BIOMARKERS: A WINDOW TO DISEASE 
There has been increasing interest in developing circulating biomarkers for cancer, more 
so with the recognition of the concept of “liquid biopsy”. The blood has the potential to 
provide a rapid, cost-effective, and minimally invasive window to molecular changes both 
in the tumor and at distant metastatic sites. Circulating biomarkers may arise from direct 
shedding or secretion of tumor cells, proteins, nucleic acids, or subcellular components 
such as exosomes into the bloodstream (Bardelli & Pantel, 2017; O'Driscoll, 2015). The 
immune response to the tumor microenvironment also gives rise to potential biomarkers 
in circulation such as cytokines or autoantibodies (AAbs) (Anderson & LaBaer, 2005).  
It is now better appreciated that tissue biopsies do not fully capture the full landscape of 
tumor heterogeneity and cancer evolution, the main cause of resistance to therapy (Y. 
Wang et al., 2014). On the other hand, circulating tumor cells (CTCs) and circulating tumor 
DNA (ctDNA) shed by tumor cells into the blood give insights into the genomic landscape 
and overall disease including distinct metastatic sites (Bettegowda et al., 2014; Murtaza 
et al., 2015). Analyses of these changes can be used for cancer risk assessment, early 
detection, or monitoring minimal residual disease and response to treatment (Siravegna, 




1.4. HARNESSING THE IMMUNE SYSTEM  
Besides abnormal molecules contained or released by tumors, the immune response to 
these molecules is of particular interest in the field of biomarkers. In comparison with other 
plasma proteins, antibodies (Abs) are highly stable, specific, and can be detected in 
minimal volume of patient serum using rigorous immune assays by probing with the 
specific protein. Detection of the cellular immune response is more labor intensive as 
discussed later in this chapter. The advances in epitope prediction algorithms and high 
throughput single cell technologies have expedited the process of T cell immunoprofiling 
(Fleri et al., 2017). 
Our immune system is able to distinguish self from non-self antigens, although aberrant 
responses are sometimes manifested as autoimmune diseases. An immune response to 
self-proteins or glycans is often detected in cancer patients. This is because these Ags no 
longer look familiar due to one or more abnormal changes from the native form or the 
noncancerous setting. The alterations in self antigens could be mutations, misfolding, 
overexpression, aberrant location, aberrant glycosylation, or aberrant degradation in the 
protein. Alternatively, defects in tolerance could happen when self-reactive lymphocytes 
escape clonal deletion, which is believed to be a potential consequence of low level 
expression of the self-antigen (Goodnow, Sprent, de St Groth, & Vinuesa, 2005; Zaenker, 
Gray, & Ziman, 2016). 
Aberrant post-translational modifications (PTMs) are one trigger of AAb production in 
cancer. AAbs against glycopeptides of the aberrantly glycosylated MUC-1 Ag have been 
detected in breast, ovarian, and prostate cancers (Wandall et al., 2010). Most tumor Ags, 
however, are the result of the overexpression of self-antigens. This is likely because of 
presentation of their epitopes on MHC molecules at levels higher than the threshold 
required for eliciting a T cell immune response and indirectly an Ab response as well 
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(Watanabe, Arase, Onodera, Ohashi, & Saito, 2000). There is a correlation between the 
expression levels of HER-2/neu in breast tumors and the levels of specific AAbs detected 
in sera (Goodell et al., 2008).  
Other Ag alterations include neoantigen generation and their presentation to the immune 
system, which could elicit a T cell response against the neoepitope or the production of 
AAbs. These could result from somatic mutations that alter the protein immunogenicity or 
expose amino acid regions that were not previously exposed (Zaenker et al., 2016). This 
is further augmented by genetic instability, a hallmark of cancer that leads to more 
mutations and neoantigens. Anti-p53 AAbs are detected more frequently in serous than 
non-serous ovarian cancers, positively correlating with higher frequency of p53 mutations 
(K. S. Anderson, D. W. Cramer, et al., 2015). Two pieces of evidence suggest that p53-
specific Ab production could be the result of p53 accumulation in the cell rather than its 
mutation. First, mutant p53 has a longer half-life than the wild-type protein. Additionally, 
most immunogenic epitopes of p53 are not located in the region that harbors mutations 
(Soussi, 2000).  
Besides host-driven tumor Ags, viral proteins are of particular interest in the study of 
biomarkers of virus-related cancers. Because they are foreign proteins, their levels or the 
immune response to them are likely to be more specific than host-derived proteins. 
However, the existence of benign infections with oncogenic viruses complicates the use 
of their proteins as definitive detection biomarkers. This is in particular when the majority 
of infected people clears the infection without overt disease as in the case of HPV or when 
the virus causes chronic infections that only causes cancer in a proportion of patients such 
as hepatitis B and C viruses. It becomes useful in these cases to integrate a combination 
of test results in the clinical decision making. For example, hepatitis B patients with low 
viral load are more likely to develop cirrhosis and hepatocellular carcinoma if they do not 
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develop Abs against the hepatitis B e antigen (HBeAg) and have high serum levels of the 
hepatitis B surface antigen (HBsAg) (Lin & Kao, 2016). IgA Abs against Epstein-Barr Virus 
(EBV)-specific proteins have been evaluated in combination with EBV viral load for 
diagnosis and monitoring of undifferentiated nasopharyngeal carcinoma in endemic 
regions (Leung et al., 2004; Zhao et al., 2014). For HPV, only 50 – 70% of infected women 
seroconvert (Carter et al., 2000), but the immune profile could still be useful in combination 
with other tests or as an initial screening tool in low-resource settings.  
 
1.5. ADVANCES IN HIGH-THROUGHPUT BIOMARKER DISCOVERY METHODS 
The advent of the omics technologies and high-throughput methods for studying 
biochemical pathways and molecules has revolutionized our understanding of disease 
and medicine. In recent years, these methods have contributed rapid discoveries of 
candidate biomarkers and better recognition of the complexity of cancer. Even though they 
have accelerated the research process, only a handful of clinically useful biomarkers have 
made their way to the clinic. This highlights the importance of recognizing both the 
advantages and limitations of each of these methods for developing biomarkers that truly 
inform the clinical decision.  
1.5.1. Assessment of Ab Biomarkers 
One critical requirement for Ab-based assays is the efficient and reproducible expression, 
purification and display of proteins. Sera are typically screened for Abs to select Ags that 
are known to potentially be immunogenic or play a role in pathogenicity. This Ag selection 
does not measure the diversity of immune recognition (Ji Qiu & Anderson, 2013). To add 
complexity, proteome-wide immune monitoring requires the production of thousands of 
protein structures. 
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The need for tools to study proteins and the significant role they play in health and disease 
have led to the revolutionary advancements in the field of proteomics in the last twenty 
years. Effective targets of immunization and serological testing are best determined using 
a systems approach for monitoring the B cell immune response. Proteomic techniques 
that have been developed for epitope display are reviewed in [8, 11] and can be 
summarized as follows: 
1.5.1.1. Phage display 
Phage display was first described in 1985 (G. P. Smith, 1985). Candidate Ags are 
expressed in lambda phage from cDNA libraries constructed from a given pathogen or 
disease tissue. Phage expressing proteins of interest are subsequently replicated onto 
nitrocellulose membranes and probed with patient sera. Phage display has been applied 
in Ag discovery in various pathogens such as hepatitis C virus (Santini et al., 1998), human 
cytomegalovirus (Beghetto et al., 2008), Mycoplasma pneumoniae (Beghetto, De Paolis, 
Montagnani, Cellesi, & Gargano, 2009) and Streptococcus pneumoniae (Beghetto et al., 
2006). Alternatively, solution-based phage display is used for autoantigen identification.  
Phage-displayed peptide libraries are subjected to affinity purification to isolate phage 
carrying specific peptides. AAb biomarkers of several cancers such as the ovary and 
prostate have been identified using this technique (Chatterjee et al., 2006; G. Chen et al., 
2007; X. Wang et al., 2005). However, because of the nature of cDNA cloned on the 
expression vectors, the major drawback of phage display is the expression of proteins with 
truncations, frame shifts and sometimes improper folding. In addition, PTMs are absent 
and abundant proteins are overrepresented.  
1.5.1.2. Cellular fractionation and immunoblotting 
In this strategy, candidate Ags from lysates of tissues or pathogens are separated by two-
dimensional gel electrophoresis and serum reactivity is determined by immunoblotting or 
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mass spectrometry. Next, bands are excised, and proteins are identified by mass 
spectrometric analysis. This method has the advantage of using proteins with their 
relevant PTMs and it does not require cloning or expression procedures. However, 
proteins found in low concentrations may be masked by more abundant proteins.  
1.5.1.3. Peptide arrays 
Peptides are displayed on a solid surface such as a glass or plastic slide. Relevant 
peptides that have overlapping sequences are determined bioinformatically so as to cover 
the whole ORFeome or a portion of the proteome. This circumvents difficulty with 
expression of full-length proteins, but conformational epitopes and PTMs are not detected. 
Recently, peptide arrays have been used to determine individual immunosignatures that 
can predict the protective efficacy of a given vaccine in mice (Legutki & Johnston, 2013). 
1.5.1.4. Protein arrays 
Protein microarrays enable the display of thousands of proteins on the surface of a 
microscopic slide or in 96-well bead-array format. A wide variety of protein expression 
systems are used including E. coli, yeast or insect cells and then Ags are purified. 
However, these systems can be time-consuming and unsuitable for high-throughput 
proteomic methods. Additionally, bacteria often fail to express most proteins with intact 
tertiary structures or PTMs, particularly those with high molecular weights or multiple 
domains (Jackson, Boutell, Cooley, & He, 2004; Stevens, 2000). In vitro protein 
expression, on the other hand, diminishes the time required to obtain protein from DNA 
but adds the challenges of protein purity and reproducibility of expression (Ji Qiu & 
Anderson, 2013).  
Protein microarrays are currently commercially available from several sources, and are 
provided either as purified, printed proteins, or as printed cDNA that can be expressed 
using in vitro transcription and translation. At this time, the antigenic display on protein 
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microarrays is primarily the protein backbone, so the diversity of displayed antigenic 
structures from PTMs is more limited. As the content of ORFeome collections content and 
the cost of protein expression improves, proteome-wide screening of sera for Ab 
responses is becoming feasible both for human Ags and pathogens. Here, three methods 
and overall strategies for using in situ protein display for detection of Ab responses in 
human sera or plasma are discussed. 
Nucleic acid programmable protein array (NAPPA) 
To improve both the cost of purification of recombinant proteins and the stability of 
displayed protein, the Nucleic Acid Programmable Protein Arrays (NAPPA) was 
developed using printed expression plasmids with an anti-tag Ab on microscopic glass 
slides (N. Ramachandran et al., 2004; Niroshan Ramachandran, Hainsworth, Demirkan, 
& LaBaer, 2006; N. Ramachandran et al., 2008). At the time of the assay, in vitro 
transcription/translation (IVTT) is used for in situ expression of tagged target proteins 
encoded by the arrayed plasmids (Figure 1-1). The use of a human coupled IVTT system 
derived from the human cell line HeLa results in ten times higher protein yields, more 
robust reproducibility, and less background than the previously used rabbit reticulocyte 
lysate system (Fernanda Festa et al., 2013). For immune monitoring, slides are incubated 
with subject sera or plasma to permit binding of Abs to their corresponding protein spot on 
the array. Signals are detected using either a fluorescently-labeled or HRP-labeled 




Figure 1-1. Nucleic Acid Programmable Protein Arrays (NAPPA). Expression 
plasmids with an anti-tag antibody are printed on microscopic glass slides. At the time of 
the assay, in vitro transcription/translation (IVTT) is used for in situ expression of tagged 
target proteins encoded by the arrayed plasmids. Slides are incubated with subject sera 
or plasma to permit binding of antibodies to their corresponding protein spot on the array. 




Printing DNA on the arrays has several advantages over printing proteins. Unlike protein 
arrays, printed plasmids retain their activity following months of storage of the arrays under 
arid conditions. Since the production and purification of thousands of proteins is 
expensive, time-consuming and liable to protein unfolding over the multistep process of 
protein array production, the on-demand IVTT avoids these issues (J.-R. Lee, Magee, 
Gaster, LaBaer, & Wang, 2013). However, IVTT-derived proteins are produced with 
limited PTMs that are a significant component of the immune response. 
A key advance in the field of protein microarrays has been the steady improvement in 
relevant ORFeome collections. The DNASU Plasmid Repository is the source of plasmid 
DNA used for NAPPA array production (Seiler et al., 2013). This plasmid collection first 
started at the Harvard Institute of Proteomics in 2000 and is currently located at the 
Virginia G. Piper Center for Personalized Diagnostics in the Biodesign Institute (AZ, USA) 
(Seiler et al., 2013). The repository comprises and distributes a collection of over 200,000 
plasmids containing the open reading frames (ORFs) of proteins from over 600 organisms, 
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including 12,000 full-length human genes. The DNASU website, database and physical 
repository (http://dnasu.asu.edu or http://dnasu.org) were designed to provide annotated 
and sequence-verified plasmids and online resources to the research community. All 
ORFs are cloned onto a master plasmid (pDONR), sequence verified and stored in the 
DNASU repository. ORFs in DONR plasmids can be moved to a wide array of expression 
vectors using Gateway recombinational cloning. 
NAPPA arrays have been used for the discovery of AAbs in cancer patient sera, such as 
AAbs to p53 in breast and ovarian cancer, BCL2 in prostate cancer and ML-IAP in 
melanoma (Karen S. Anderson et al., 2015; Anderson et al., 2008; Niroshan 
Ramachandran et al., 2008). Examples of screening for infectious disease Ags include 
studies displaying Pseudomonas aeruginosa outer membrane proteins (Wagner R Montor 
et al., 2009) and Mycobacterium tuberculosis proteins (Prados-Rosales et al., 2014) on 
NAPPA to screen sera to identify immunogenic proteins.  
Rapid antigenic protein in situ display (RAPID ELISA)  
NAPPA protein microarrays are an excellent tool for Ag discovery. However, validation 
requires methods for the analysis of a few Ags but using thousands of sera. RAPID ELISA 
was developed as a robust tool that can be performed in most immunology laboratories 
using publicly available reagents. RAPID ELISA can be used to screen hundreds of sera 
rapidly and cost-effectively in order to confirm Ab biomarkers and immunogenicity of 
antigens discovered using protein microarrays (Anderson, 2011; Anderson et al., 2010; 
Niroshan Ramachandran et al., 2008). As with NAPPA assays, tagged proteins are 
expressed using an in vitro transcription and translation system, but then captured in a 96-
well plate through an anti-tag Ab. Sera are then incubated with the displayed proteins, and 
bound immunoglobulins are detected using secondary Abs (Figure 1-2). To overcome the 
background problem encountered with human sera, an optimized serum blocking buffer 
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consisting of E. coli lysate diluted 1:10 in PBST and 5% milk was developed (J. Wang et 
al., 2013). An eight-fold increase in the Relative Light Unit (RLU) ratio of Ag-specific IgG 
compared with control GST protein was observed with the use of this serum blocking 
buffer. Additionally, human HeLa cell lysate IVTT system and automation have further 
enhanced the efficiency, rapidity, and reproducibility of this technique.  
 
Figure 1-2. Rapid Antigenic Protein In Situ Display (RAPID ELISA). Tagged proteins 
are expressed using an in vitro transcription and translation system, but then captured in 
a 96-well plate through an anti-tag antibody. Sera are then incubated with the displayed 
proteins, and bound immunoglobulins are detected using secondary antibodies.  
Magnetic programmable bead ELISA (MagProBE) 
A similar technique as RAPID ELISA for high-throughput serum screening is the Magnetic 
Programmable Bead ELISA, MagProBE (Anderson, 2011). As with RAPID ELISA, tagged 
proteins are expressed by IVTT, but then expressed proteins are captured on anti-tag 
coupled fluorescent magnetic beads (such as Luminex beads) in a 96-well plate. This is 
followed by steps of incubation with sera and then with a secondary Ab (Figure 1-3). 
Beads are coupled with the anti-tag Ab in advance and they are stable for at least one 
year. Coupling efficiency is confirmed using anti-Ig secondary Abs. Chief among the 
advantages of MagProBE is the high reproducibility and automated washing. Additionally, 
bead-array ELISA can be used for multiplex assays by coupling of different Ags on beads 
of different colors and then pooling them. Multiplexing saves both time and volume of 
serum, but the cost per Ag is higher than with RAPID ELISA. This technique has been 
used for multiplex detection of  immunity to a panel of EBV Ags in healthy donor sera 
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(Jessica Wong, Sahar Sibani, Naa Norkor Lokko, Joshua LaBaer, & Karen S Anderson, 
2009) and to investigate potential biomarkers of HPV-associated oropharyngeal 
carcinoma (Anderson, Wong, et al., 2011).  
 
Figure 1-3. Magnetic Programmable Bead ELISA (MagProBE). Tagged proteins are 
expressed by IVTT and expressed proteins are captured on anti-tag coupled fluorescent 
magnetic beads in a 96-well plate. This is followed by steps of incubation with sera and 
then with a secondary antibody. 
 
1.5.1.5. Recent advances in protein display and detection 
Many immune-based biomarkers have clinical applications for early detection of disease. 
The applications require robust, reproducible, and cost-effective assays with improved 
limits of detection, multiplexing and automation, all of which have substantially improved 
in the last decade. For example, chromogenic enzyme substrates have been the 
traditional reporter molecules for ELISAs. The more sensitive chemiluminescent 
substrates can now detect analyte concentrations in the picomolar range (A. H. Wu, 2006). 
Ultrasensitive approaches, such as the Single Molecule Array technology may allow 
detection of femtomolar concentrations of Ab through digital measurements of 
immunocomplexes. Nanoparticle-based ELISAs are reported to detect attograms of 
analytes (de la Rica & Stevens, 2012).  
Because routine laboratory diagnostics are costly and may not be accessible in resource-
poor areas, point-of-care (POC) tests are emerging technologies for health screening, 
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much of which currently depends on detection of Abs. Affordable POC tests that give rapid 
and reliable results, require minimal training, and use no equipment are currently in use 
for HIV, syphilis and malaria (Ferguson et al., 2016). Integration of ELISA assays with 
microfluidics and molecular detection methods may transform vaccine monitoring and 
identification of at-risk individuals for clinical interventions. 
1.5.2. Identification of T Cell Ags  
As previously mentioned, the identification of targets of the T cell immune response is a 
longer and more complicated process compared to B cell Ags. Conventionally, T cells are 
screened for reactivity to peptides spanning candidate Ags, an approach limited by the 
prohibitive cost of synthesizing large numbers of peptides. The advances in the 
bioinformatics of immunogenic epitope prediction has made it possible to narrow down the 
number of screened peptides by prioritizing them according to MHC binding affinity or the 
probability of immunogenicity. Alternatively, the identification of antigenic T cell immune 
response targets depends on screening of peripheral blood or tumor-infiltrating T cells for 
reactivity to antigen presenting cells transfected with cDNA libraries. The tandem minigene 
(TGM) is a more recent approach that involves transfection of APCs with cDNA libraries 
encoding nonsynonymous mutation sequences identified by whole-exome sequencing of 
autologous tumors (Y.-C. Lu et al., 2014).  
The identification of immunodominant T cell targets is useful for designing successful 
adoptive T cell immunotherapies in cancer. This can be achieved by identifying 
neoantigen-specific T cells that are found in the highest frequencies in tumor-infiltrating 
lymphocytes that result in tumor regression. T cell receptors are then identified using 
single-cell sequencing techniques and used for engineering chimeric antigen receptor 
(CAR) T cells (Yong et al., 2016). The detection of Ag-specific T cells can be useful as a 
biomarker to monitor and evaluate the success of adoptive T cell therapy. The presence, 
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homing, bioactivity, and counts of T cells following infusion can be evaluated by the 
detection of surface or intracellular markers by flow cytometry, ELISpot, or qPCR (Kalos, 
2011).  
 
1.6. DEVELOPING RELIABLE AND CLINICALLY USEFUL BIOMARKERS 
The emergence of the omics technologies has raised hopes for delivering the promise of 
precision medicine to deliver therapies tailored to individual molecular phenotypes. Part 
of the reason why this has not been realized yet is the lag in the development of well-
validated biomarkers of reliable clinical utility. These technologies have given rise to 
hundreds of thousands of research publications describing candidate biomarkers, but only 
a tiny fraction of this number is in clinical use (Poste, 2011). Many factors contribute to the 
candidate biomarkers not holding up in validation studies, ranging from specimen quality 
and pre-analytical variables to the complexity conferred by the heterogeneous nature of 
cancer. The first step to improve the validation pipeline is to recognize and control for 
these factors and to implement standardized procedures for every step along the way.  
Breast cancer is the most common type of cancer in the US, accounting for about 15% of 
new cancer cases ("American Cancer Society: Cancer Facts and Figures 2018," 2018; 
NIH, 2017). Compared with other cancer types, breast cancer is widely studied and 
progress in research has made biomarkers an indispensable part of its management. 
Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, 
but there is a need for circulating biomarkers that are clinically available for early detection, 
prognosis, and monitoring for clinical relapse. Guidelines on the use of biomarkers in 
breast cancer were published by both the American Society of Clinical Oncology and the 
European Group on Tumor Markers (Duffy et al., 2017; Harris et al., 2016). As with much 
of biomarker research, despite the significant progress in the discovery of potential breast 
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cancer biomarkers, the vast majority of these biomarkers has not progressed beyond initial 
research discovery. In Chapter 2 of this thesis, breast cancer is used as a model to 
examine the reasons for the disconnect between the number of candidate biomarkers in 
research and those that make it to the clinic.  
 
1.7. HPV-ASSOCIATED CANCERS 
Human papillomaviruses (HPV) are a family of more than 200 closely related viruses with 
small circular double-stranded genomes. The virus is restricted to epithelial surfaces 
where it induces a non-lytic cellular proliferation and minimal immunologic response. The 
estimated number of new cases of cervical cancer worldwide was 528,000 in 2012, with 
an annual global mortality rate of 270,000 deaths (Ferlay et al., 2010; Ferlay et al., 2015). 
Vaccines preventing infection are highly effective for the prevention of type-specific 
cervical and anogenital cancer precursors (vaginal, vulvar, anal), may reduce relapse after 
conization (Kang, Choi, & Kim, 2013), but are not a treatment for pre-existing HPV 
infection. Vaccines are expected to substantially reduce the burden of HPV-associated 
cancers. In the US, even with low vaccine coverage, vaccination has resulted in a 64% 
reduction in the prevalence of types 6, 11, 16, and 18 among females aged 14 to 19 years 
and 34% decrease among those aged 20- 24 years (Lauri E. Markowitz et al., 2016). 
1.7.1. HPV Genome Organization and Life Cycle 
HPV is a circular double-stranded DNA virus, whose genome contains about 8000 base 
pairs. The virus has a limited repertoire of proteins, grouped as early (E1, E2, E4, E5, E6, 
E7) and late (L1, L2) proteins. The late proteins form the viral protein coat during 
productive infections. The early proteins interact with host and viral proteins to maintain 
viral replication and release, and they play a key role in transformation. The E1 protein is 
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a helicase enzyme that is expressed in the early stages of the infection and is important 
for viral DNA replication. E2 is also expressed in the early stages and is a key regulator, 
since it represses the expression of the E6 and E7 oncogenes (L. Wu et al., 2000). Viral 
integration occurs following a break in E2, which derepresses E6 and E7 expression, 
leading to cellular transformation (zur Hausen, 2009).  
The E6 protein promotes cell proliferation by inhibiting p53, a key tumor suppressor and 
regulator of apoptosis (Boulet, Horvath, Broeck, Sahebali, & Bogers, 2007). It also 
promotes division through multiple other targets including telomerase and proteins 
involved in the regulation of the actin cytoskeleton (zur Hausen, 2002). E7 inhibits pRB, 
leading to the release of the transcription factor E2F and the transcription of genes 
involved in the cell cycle (Boulet et al., 2007). Thus, the expression of these two proteins 
is a potential hallmark of malignancy. However, there are cases of cellular transformation 
in the absence of E6 and E7 deregulation. This is the case when the virus has not 
integrated or when its genome breaks at sites other than E2 (Oyervides-Munoz et al., 
2018).  
HPV infects the basal layers of the stratified epithelium of the cervix and the expression 
of viral proteins is confined to keratinocytes. The virus infects the basal cells of the 
epithelium and the virus copy number reaches 50 – 100 copies/cell through a round of 
viral DNA replication that is independent of the cell cycle. The infected cell then moves to 
the proliferative compartment of the epithelium, where viral protein expression (particularly 
E6 and E7) is tightly regulated. As the cell then moves to the differentiating compartment 
of the epithelium and exits the cell cycle, differentiation is accompanied by amplification 
of the viral copy number to 1000 copies/cell and expression of the coat proteins. The 
expression of viral capsid proteins in basal epithelial cells is limited by the low availability 
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of the appropriate tRNAs (Zhou, Liu, Peng, Sun, & Frazer, 1999). The upper layers of the 
squamous epithelia are where viral proteins are expressed in high levels and where viral 
assembly occurs (Evans et al., 2001; Stanley, 2008).  
1.7.2. HPV Integration  
In cervical cells, the HPV virus is either episomal, integrated, or in mixed forms. Transcripts 
derived from integrated forms have higher stability than those from episomal virus. Cells 
with integrated HPV16 have been reported to have selective growth advantage (Jeon, 
Allen-Hoffmann, & Lambert, 1995). Integration is commonly thought of as a late event in 
cervical carcinogenesis, because it is rarely reported in earlier stages of the disease. 
However, technical difficulties associated with studying viral integration challenge this idea 
(Woodman, Collins, & Young, 2007). Integration often happens in the E1 or E2 region of 
the viral genome, thus disrupting the tight regulation on E6 and E7 expression coordinated 
by the E2 protein. Therefore, integration is commonly evaluated by the failure to amplify 
full-length E2 by PCR or by measuring the E2/E6 ratio. This method, however, has been 
shown to be able to distinguish integrated forms only when their frequency is at least 100 
times that of the episomal forms (Arias-Pulido, Peyton, Joste, Vargas, & Wheeler, 2006).   
In cervical cancer cells, integration is almost always detected at only one chromosomal 
site, which supports the proposal that cervical cancer is a clonal disease (Vinokurova et 
al., 2005). However, there is debate about whether integration is a necessary event for 
carcinogenesis to occur (Woodman et al., 2007). The host genetic alterations that result 
from viral integration are another mechanism that has been proposed for carcinogenesis, 
as opposed to the deregulation of E6 and E7 expression. Viral integration into oncogenes 
or tumor suppressor genes may disrupt their normal function, leading to cell proliferation, 
and integration into both types of genes has been reported (Ojesina et al., 2014; Parfenov 
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et al., 2014). Research is ongoing into whether other factors, such as viral load, HPV type, 
or host genetic or epigenetic factors could derive oncogenesis. 
Whether integration can be a useful biomarker of progressive disease is also a matter of 
debate. The technical difficulties of detecting integrated forms in a background of mostly 
episomal forms have challenged answering this question. Additionally, the mere detection 
of integrated forms by PCR provides no insight into whether they are actively transcribed 
in these cells. Active transcription of integrants has been reported in only 37% of CIN3 
women in which integration has been detected (Klaes et al., 1999; Melsheimer, 
Vinokurova, Wentzensen, Bastert, & von Knebel Doeberitz, 2004). Thus, integrant-derived 
HPV transcripts could be a more useful biomarker of progressive disease (Woodman et 
al., 2007).  
1.7.3. Viral Load 
Including HPV viral load measurement in HPV screening has been proposed based on 
the observation that women with high viral load of high-risk HPV are more likely to have 
cytological abnormalities (Heard et al., 2000; Lillo et al., 2005; Swan et al., 1999). 
However, several studies have challenged this conclusion. Some cross-sectional studies 
have reported higher viral load in low-grade than in high-grade CIN (Hall et al., 1996; Nindl 
et al., 1997); and longitudinal studies could not establish a relation between viral load and 
disease progression (Crum et al., 2004; Mark van Duin et al., 2002).  
This inconsistency could be explained by the reduction in infectious viral particles and viral 
load after integration, an event associated with disease progression. Thus, women with 
high-grade CIN who also have low-grade preinvasive lesions could have higher viral load; 
but the vast majority of studies do not report multiple co-existing disease statuses when 
present (Sherman et al., 2003). Similarly, acquiring new HPV infections especially from 
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different HPV types may impact viral load and the development of cytologic lesions 
(Woodman et al., 2007). Therefore, the study of the usefulness of viral load as a marker 
of disease progression requires careful consideration of other factors that may be 
contributing to prognosis. These factors are important to consider when investigating the 
utility of the HPV-specific Ab immune response as a marker of disease, given that there 
is a reported increase in seropositivity in women with higher viral load (Viscidi et al., 1997). 
 
1.7.4. Multiple HPV Infections 
Detecting concurrent infections with multiple HPV types is common and is more frequent 
than to be attributed to random chance (Mendez et al., 2005; Thomas et al., 2000). There 
is no evidence that there is competition between the coinfecting HPV types (Liaw et al., 
2001). Studies report that women who are already infected have a higher chance of 
acquiring an infection with a new HPV type than HPV negative women (Liaw et al., 2001; 
Mendez et al., 2005). Women with an HPV16 or HPV18 infection are seven times more 
likely to acquire an HPV58 infection than women who are negative for these types 
(Mendez et al., 2005). The viral load in women with HPV16 and multiple HPV infections 
was found to be higher than women with only HPV16, suggesting a possible 
interdependence between these viral types (Weissenborn et al., 2003).  
Detecting an infection with a new HPV type that was not previously detected for a given 
individual could be due to the acquisition of a new sexual partner. However, the possibility 
of simultaneous transmission of these different HPV types with a lag in replication of one 
of them is not precluded (Woodman et al., 2007). Detecting an HPV-specific immune 
response to antigens from multiple HPV types is thus not surprising and could reflect 
multiple HPV infections, whether they are all concurrent and active infections or include 
past infections that have been cleared. This can also be explained by cross-reactivity 
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between antigens with a high degree of homology. With the technical challenges of 
studying the immune response to multiple HPV proteomes, this question has not been 
adequately addressed in the literature. 
1.7.5. The Immune Response to HPV and Immune Evasion Strategies 
The HPV replication strategy in the cervix allows viral replication without inducing 
inflammation, given the absence of virally-induced cytolysis or necrosis. E1 is the only 
DNA replication enzyme that the HPV genome encodes. Therefore, the virus depends for 
replication on the cellular machinery, which is active only in dividing cells. For amplification 
of the viral copy number to occur in cells that have exited the cell cycle and are 
differentiating, the virus uses its E6 and E7 proteins to reactivate the cellular DNA synthetic 
machinery in non-dividing cells, delay their differentiation, and inhibit apoptosis. A rare 
consequence of these events is the loss of growth control manifested as cancer (Munger 
et al., 2004).  
Because the virus does not lyse the keratinocytes that it infects, the cervix acts as a 
protective niche for the virus, with minimal virus engulfment by APCs and antigen 
presentation to the immune system. There is also minimal release of proinflammatory 
cytokines that help induce APC migration and activation (Stanley, 2006). Outside the 
epithelium, viral antigens are not likely to be detected due to the absence of viremia. The 
low expression of capsid proteins in the basal layer gives less opportunity for the immune 
system to encounter them and initiate an immune response (Schwartz, 2000).  
Several other factors contribute to the host immune evasion by the virus. IFN-β release 
results in clearance of episomal HPV, but this mechanism is not useful in cells with 
integrated viral DNA (Herdman et al., 2006; Pett et al., 2006). There is a reduction in the 
cell-mediated immune response directed against the E2 and E6 proteins in high-grade 
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pre-invasive cervical lesions and invasive carcinoma (de Jong et al., 2004). Regulatory T 
cells (Tregs) play an important role in counteracting the cytotoxic effect of HPV-specific T 
lymphocytes (Kobayashi et al., 2004). Tregs function to maintain the immune tolerance 
and prevent reactivity to self-antigens. Their activity in cancer patients has been 
associated with decreased immune reactivity to tumor antigens (R. F. Wang, 2006). 
Women with ICC and CIN were found to have increased frequencies of Treg cells in their 
peripheral blood. An increased T cell response against HPV16 E6 and E7 peptides in 
invasive cervical cancer was reported following in vitro depletion of these CD25+ T cells 
(Visser et al., 2007). Along with the localization of Treg cells, the expression of the 
immunoregulatory enzyme indoleamine 2, 3-dioxygenase (IDO) appears to also help 
cancer cells evade the immune response (Nakamura et al., 2007).  
1.7.6. Clearance of Natural HPV Infection  
Despite a high lifetime risk of acquiring an HPV infection (80%), most infections are 
cleared within 1-2 years (Rodriguez et al., 2008). Viral clearance means failure of 
detection of the DNA for a specific HPV type and it is the result of an effective adaptive 
immune response (Coleman et al., 1994). Failure of the immune response to clear the 
virus results in the establishment of a persistent infection, since the host can remain 
ignorant of the virus for a long time. There is an increased chance of progression to high-
grade pre-invasive cervical lesions and invasive cancer in individuals with persistent 
infection (Liaw et al., 1999; Schlecht et al., 2001). The importance of cell-mediated 
immune response is demonstrated by the increased incidence and progression and 
delayed clearance of HPV infections in immunocompromised individuals. Several studies 
in HIV-infected individuals have reported increased incidence of genital warts, recurrences 
of pre-invasive cervical lesions, and progression of subclinical to clinical HPV infection 
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(Chirgwin, Feldman, Augenbraun, Landesman, & Minkoff, 1995; Fennema, van Ameijden, 
Coutinho, & van den Hoek, 1995; Fruchter et al., 1996).  
Immunohistologic studies of naturally regressing genital warts have provided insights into 
the role of the cellular immune response in clearing HPV infections. Compared with non-
regressing genital warts, regressing warts are characterized by a large number of 
infiltrating macrophages and CD4+ and CD8+ T cells in both the stroma and the epithelium 
of the wart. This response is directed against the E proteins, in particular E2 and E6 (de 
Jong et al., 2002; Welters et al., 2003). These lymphocytes release IL-12, TNF-α, and IFN-
γ, which is characteristic of a Th1-based immune response (Coleman et al., 1994). Canine 
studies of oral warts corroborate these findings and report systemic T cell responses 
against peptides of the HPV E2 and E6 proteins that peak at wart regression, then decline 
rapidly (Ghim et al., 2000). During wart regression in both humans and animal models, 
seroconversion and neutralizing antibodies in serum against the major capsid protein L1 
are maximal, which is accompanied by lifelong protection against infection (Ghim et al., 
2000; Stanley, 2006). However, the antibody titers are low, and a significant proportion of 
women do not seroconvert (Carter et al., 2000; Dillner, 1999). 
1.7.7. Diagnosis 
The epidemiology and natural history of HPV infection has been best characterized in the 
cervix where precursor lesions are well recognized, using detection of HPV DNA or 
detection of Abs to HPV as biomarkers of disease pathogenesis (Crosbie, Einstein, 
Franceschi, & Kitchener, 2013). Genital HPV is usually acquired shortly after sexual debut, 
and prevalence is highest in adolescents and young adults (Dunne et al., 2007; Lauri E. 
Markowitz et al., 2016; L. E. Markowitz, Sternberg, Dunne, McQuillan, & Unger, 2009). 
Cervical cancer is a rare consequence of this common infection, with ~50% of the cases 
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worldwide caused by the HPV16 type. While high risk (HR) HPV infection is considered 
necessary for cervical carcinogenesis, additional factors are clearly involved. A small 
fraction of infected women gradually progress to invasive cancer, following a long, 
histologically well-defined pre-invasive phase (cervical intraepithelial neoplasia; CIN), 
ranging from low grade (CIN I) to high grade (CIN II and III) (Woodman et al., 2007). 
Cervical cancer is preventable because high grade lesions are detectable by clinical, 
histopathologic, or molecular alterations and can be surgically removed (Goodman, 2015). 
Current clinical practice in the US relies on regular screening with cytology (Pap test) often 
combined with HR HPV nucleic acid testing to refer women for colposcopy and biopsy. 
Recent data have documented that cytology screening is associated with a significantly 
reduced incidence and risk of death from cervical cancer, with odds ratios ranging from 
0.28 to 0.60 (Vicus et al., 2014; Vicus et al., 2015), despite a reported high false negative 
rate (Soost, Lange, Lehmacher, & Ruffing-Kullmann, 1991). Cytologic screening remains 
subject to sampling errors, problems with cellular preservation, and reader subjectivity. 
Biomarkers are needed in particular to aid in the selection of patients for colposcopy 
screening in resource-limited settings in low and middle-income countries (LMICs), where 
nucleic acid and cytology testing are cost-prohibitive. Efforts are underway by the World 
Health Organization and the Program for Appropriate Technology in Health (PATH) to 
generate cost-effective HPV DNA testing (Qiao et al., 2008). 
Measuring the humoral immune response to HPV Ags has been integral to understanding 
the natural history of infection and efficacy of vaccination (Doorbar et al., 2012; Villa et al., 
2006; Woodman et al., 2007). Despite the potential of HPV serology in disease diagnosis 
and prognosis, its clinical application has been limited by HPV heterogeneity, assay 
variability, and viral immune evasion. The serologic response to genital HPV infection is 
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primarily directed at conformational epitopes on the viral major capsid protein L1. As the 
infection is non-lytic, the host Ab response to L1 is weak and may persist for years, as an 
indication of past infection but not malignancy (Luevano et al., 2010; Stanley, 2010). 
Although anti-L1 Abs are an indication of past infection, only 50 – 70% of infected women 
seroconvert (Carter et al., 2000; Dillner, 1999).  
Abs to both HPV16 E6 and E7 proteins have been detected at low levels in both serum 
and cervical-vaginal secretions of invasive cervical cancer (ICC) patients (Bierl et al., 
2005). Their levels increase with cervical disease progression, but they are not detectable 
in a subset of patients with cervical cancer (Gutierrez-Xicotencatl et al., 2016; Luevano et 
al., 2010; Reuschenbach et al., 2008; Stanley, 2003). They develop later in the course of 
ICC and are correlated with disease outcome (Gutierrez-Xicotencatl et al., 2016; Ravaggi 
et al., 2006; Silins et al., 2002). Studies of sera collected prior to the diagnosis of cervical 
cancer have shown that the presence of E6 and E7-specific Abs is associated with an 
increased relative risk (RR=2.7) for cervical cancer, and can be detected, albeit 
infrequently, up to 5 years prior to diagnosis (Lehtinen et al., 2003). The percentage of 
women with false negative serology is dependent on the method of Ab detection (Achour 
et al., 2009; Combes et al., 2014; Kontostathi et al., 2016; Luevano et al., 2010; Waterboer 
et al., 2005; Zumbach et al., 2000). There is a clinical need for circulating biomarkers that 
identify high-risk HPV infection for early detection and treatment of cervical disease. Thus, 





1.8. BIOMARKERS OF IMMUNITY TO THE CRISPR/CAS9 GENE THERAPY 
SYSTEM 
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 
technology has raised hopes for developing personalized gene therapies for complex 
diseases such as cancer. In October 2016, a Chinese group at Sichuan University in 
Chengdu was the first to inject CRISPR/Cas9-gene edited cells into a human to treat 
aggressive lung cancer (Cyranoski, 2016). Another trial by the University of Pennsylvania 
to treat sarcoma, multiple myeloma, and melanoma is currently under way. The trial will 
engineer T cells by CRISPR to delete PD-1 and create a tumor-specific T cell receptor 
(ClinicalTrials, 2018). Despite a not-so-distant history of disappointment with gene 
therapy, these trials reflect fast-paced strides toward the use of human gene editing in 
medicine. 
The human experience with gene therapy has witnessed an excitement phase about the 
potential for curing diverse life-threatening diseases, especially genetic disorders, which 
was sparked by many success stories. However, the scientific community backtracked 
after the death of Jesse Gelsinger in 1999 at the age of 18 due to a massive immune 
reaction to the gene therapy he received (Marshall, 1999). Since then, several studies 
have evaluated the efficacy and safety of gene therapy in humans to treat genetic 
disorders (Cavazzana-Calvo et al., 2000; Gaspar et al., 2004; Hacein-Bey-Abina et al., 
2002; Howe et al., 2008; Manno et al., 2006). One important finding is that healthy 
individuals have pre-existing immunity to adeno-associated viral vectors, some of the most 
widely used gene therapy vectors (F. Mingozzi et al., 2007; Thwaite, Pages, Chillon, & 
Bosch, 2015). AAV-specific CD8+ T cells detected were also shown to expand following 
gene delivery (F. Mingozzi et al., 2007). 
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The expression of the bacterial CRSIPR-associated protein 9 (Cas9) nuclease in humans 
for cancer gene therapy raises concerns over safety and potential adverse reactions. Both 
cellular and humoral immune responses were reported in response to the expression of 
Streptococcus pyogenes Cas9 protein (SpCas9) in mice (Chew et al., 2016; D. Wang et 
al., 2015). Given the ubiquity of the S. pyogenes bacteria, it is possible that healthy 
individuals have pre-existing immunity to the SpCas9 protein, which could have 
implications for using this system in humans. Biomarkers of immunity to this protein could 
be used to guide gene therapy decisions in patients, particularly as this system moves to 
cancer clinical trials and possibly to in vivo treatment approaches. Chapter 5 of this 
dissertation seeks to address this gap in knowledge and aims to identify these markers 
for the most common human HLA type in North America.  
 
1.9. THESIS CONTRIBUTIONS 
This dissertation addresses several questions in HPV immunology, cancer biomarkers, 
and immunity to the CRISPR/Cas9 system. The primary contributions of this dissertation 
are: 
1. Generating custom HPV Nucleic Acid Programmable Protein Arrays 
(NAPPA) displaying 98 proteins, representing the proteomes of two low-
risk and ten oncogenic high-risk HPV types for studying serology in HPV-
associated cancers. A high correlation of HPV16-specific serum IgG 
detection with the previously described RAPID ELISA for HPV-associated 
oropharyngeal cancer was confirmed. 
2. Profiling the HPV Ab response to the proteomes of 12 HPV types in serum 
samples from women with invasive cervical cancer, high-grade pre-
invasive cervical lesions (CIN II/III) and low-grade pre-invasive cervical 
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lesions (CIN 0/I; no CIN to grade I CIN). The arrays allowed the systematic 
analysis of HPV serology in cervical disease and detection of the breadth, 
specificity, and changing levels of HPV-specific antibodies with disease 
progression.  
3. Detecting pre-existing B cell and T cell immune responses to the S. 
pyogenes Cas9 protein in humans. Two immunodominant T cell epitopes 
for HLA-A*02:01 were identified and a single mutation in the anchor residue 
of one or both of these epitopes significantly reduced the protein 
immunogenicity while maintaining its function and specificity in the 
CRISPR/Cas9 system. The identified epitopes have the potential to serve 
as a biomarker of pre-existing immunity to SpCas9 in the studied HLA 
haplotype that can help guide gene therapy decision making. 
4. Reviewing the crucial considerations of developing pipelines for the rapid 
evaluation of circulating cancer biomarkers, with a focus on breast cancer 
as a case study.   
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CHAPTER 2 : CRUCIAL CONSIDERATIONS FOR PIPELINES TO VALIDATE 
CIRCULATING BIOMARKERS: BREAST CANCER AS A CASE STUDY 
This chapter has been published: 
Radwa Ewaisha, Chelsea D. Gawryletz, and Karen S. Anderson (2016). Crucial 
considerations for pipelines to validate circulating biomarkers for breast cancer. Expert 
Review of Proteomics, 13(2), 201-211. doi: 10.1586/14789450.2016.1132170 
 
ABSTRACT 
Despite decades of progress in breast imaging, breast cancer remains the second most 
common cause of cancer mortality in women. The rapidly proliferative breast cancers that 
are associated with high relapse rates and mortality frequently present in younger women, 
in unscreened individuals, or in the intervals between screening mammography. 
Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, 
but there is a need for circulating biomarkers that are clinically available for early detection, 
prognosis, or monitoring for clinical relapse. There has been significant progress in the 
discovery of potential circulating biomarkers, including proteins, AAbs, nucleic acids, 
exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not 
progressed beyond initial research discovery, and none have yet been approved for 
clinical use in early stage disease. Here, the crucial considerations of developing pipelines 
for the rapid evaluation of circulating biomarkers for breast cancer are reviewed.  
 
2.1. INTRODUCTION AND BACKGROUND 
There has been significant effort toward the development of circulating biomarkers for the 
diagnosis and management of cancers. Breast cancer, as with other solid malignancies, 
is associated with alterations in systemic proteomic (Pernikarova & Bouchal, 2015), 
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glycoproteomic (Boersema, Geiger, Wisniewski, & Mann, 2013), immune (Kroemer, 
Senovilla, Galluzzi, Andre, & Zitvogel, 2015), and nucleic acid biomarkers 
(Schwarzenbach, 2013) that can be measured in the blood. Many of these biomarkers are 
thought to arise from the shedding or secretion of proteins or nucleic acids directly from 
tumor cells, such as the glycoprotein MUC1 (Paoletti & Hayes, 2014), circulating tumor 
DNA (ctDNA) (Dawson et al., 2013; Garcia-Murillas et al., 2015; Gingras, Salgado, & 
Ignatiadis, 2015), or within subcellular components such as exosomes (O'Brien et al., 
2013; O'Driscoll, 2015; Yu, Cao, Shen, & Feng, 2015), or circulating tumor cells (CTCs) 
(Z. F. Jiang et al., 2013; M. C. Liu, 2014). Other biomarkers, such as cytokines (Gunter et 
al., 2015; Patel et al., 2015) or AAbs (Anderson, Sibani, et al., 2011; Chapman et al., 2007; 
J. Wang et al., 2015), are measures of the systemic immune reaction to the local tumor 
microenvironment. The blood, or a “liquid biopsy”, has the potential to provide a rapid, 
cost-effective, and minimally invasive window to molecular changes both in the breast and 
at distant metastatic sites. The development of highly sensitive molecular diagnostics is 
now providing the opportunity to evaluate these biomarkers for clinical management. 
As with much of biomarker science, thousands of potential breast cancer biomarkers have 
been identified by research laboratories, but few of these have reached clinical practice 
(Poste, 2011; Poste, Compton, & Barker, 2015). Only the circulating biomarkers CEA, 
CA27.29, and CA15-3 are in clinical use for the management of metastatic breast cancer 
(Van Poznak et al., 2015). There are several reasons for the delays in clinical translation 
of many of these biomarkers. First, unlike cancer therapeutics, there have been few 
established pipelines and standards for the rigorous selection and validation of biomarkers 
for breast cancer. Second, the risk of false discovery in the early stages of research is 
significant. The scientific literature contains many circulating biomarkers that fail in 
validation steps. This false discovery is due, in part, to recurrent biases in the research 
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design of discovery science, such as pre-analytic variables in sample collection and the 
routine use of small sets of convenience samples without appropriate controls. As a 
consequence, the time, effort, and materials needed to eliminate false biomarkers are 
significant. Third, the intra-patient and inter-patient heterogeneity of breast cancer 
contribute to the limited quantity of circulating biomolecules in early stage disease and 
false-negative elimination of potentially useful markers. Fourth, detection of secreted 
proteins that are diluted in plasma need is difficult due to the complexity and the wide 
dynamic range of the plasma proteome (Rifai, Gillette, & Carr, 2006). We need a 
systematic assessment of the target clinical applications for circulating biomarkers, 
recognizing that clinical care is a dynamic process with evolving needs, technologies, 
therapeutic outcomes, and economic feasibility.  
This chapter will focus on the emerging scientific technologies that are used to detect 
circulating biomarkers for breast cancer, with an emphasis on protein and immune 
biomarkers. Critical elements in biomarker study design and assay development will be 
identified, both at the discovery and the validation stages, to increase the identification of 
clinically useful markers (Figure 2-1). Factors that are needed to establish pipelines for 
the rapid translation of these biomarkers to clinical practice across multiple clinical 
applications will also be identified.  
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Figure 2-1. A Sample Pipeline of the Sequential Steps from Biomarker Discovery to 
Validation. The initial discovery usually involves screening many potential biomarkers 
with fewer samples but requires a strong statistical plan and matching of cases and 
controls to limit false discovery. Potential biomarkers should be verified using a larger 
number of samples from an independent, blinded sample set prior to publication. Prior to 
large-scale retrospective and prospective studies, migration of the assay to a highly 
reproducible, precise, and clinically-applicable platform is usually needed. Subsequent 
independent multicenter validation studies (both retrospective and prospective) require 
samples collected in the context of the intended clinical application.  
 
2.2 THE CLINICAL APPLICATIONS OF BIOMARKERS FOR BREAST CANCER 
Perhaps the most important process in biomarker discovery is the identification of the 
target clinical need (J. Chen et al., 2014; Zeidan, Townsend, Garbis, Copson, & Cutress, 
2015). Circulating biomarkers have potential applications for risk assessment, early 
detection, prognosis, detection of early relapse, molecular profiling for treatment selection, 
and monitoring disease progression and evolution. The study design, selection of cases 
and controls, and validation strategy all depend on the intended use of the proposed 
biomarkers. 
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2.2.1. Biomarkers for Breast Cancer Risk Assessment 
The current clinical practice in the United States is to provide population-based general 
breast cancer screening mammography and physical exams, in accordance with 
recommendations provided by the US Preventive Task Force guidelines ("US Preventive 
Task Force,"), the National Comprehensive Cancer Network (Bevers et al., 2009) and 
others. Patients at increased risk based on clinical, familial, and epidemiologic risk factors 
are routinely identified using the Breast Cancer Risk Assessment tool ("Breast Cancer 
Risk Assessment Tool,"), with additional risk factors (i.e. body mass index, breast density) 
being integrated into the current models (Tice et al., 2015). Patients with deleterious 
germline mutations in BRCA1 and BRCA2 are recommended to undergo more intensive 
screening, such as breast MRI (Narod, 2010). Emerging breast imaging tools, including 
tomosynthesis and contrast-enhanced digital mammography (CEDM), are rapidly 
changing the landscape of breast cancer screening (Chou et al., 2015). The role of 
additional genetic markers of risk (Garcia-Closas et al., 2013; Michailidou et al., 2013) 
identified from Genome-Wide Association Studies (GWAS) is being evaluated. As genetic 
screening becomes more prevalent and cost-effective, population-based genetic 
screening will become feasible (Manchanda et al., 2015).  
In addition to genetic and epigenetic biomarkers of breast cancer risk, other circulating 
biomarkers of risk, such as protein, glycoprotein, and immune-based molecular changes 
may help inform targeted screening strategies. The systematic proteomic evaluation of 
blood from high risk women may lead to the discovery of biomarkers for risk stratification, 
to understand the molecular basis of tumor initiation and early development, and for 
selection of patients for targeted screening and prevention clinical trials. For both the 
discovery and validation of these biomarkers, early collaboration with epidemiologists and 
biostatisticians is necessary to design biorepositories that are technically compatible with 
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proteomic and immunomic analysis, and to identify appropriate samples (both circulating 
and tissue) with matching criteria of controls based on known and emerging breast cancer 
risk factors. 
2.2.2. Biomarkers for Early Detection 
Perhaps the greatest unmet need is for circulating biomarkers for early breast cancer 
detection. Screening mammography improves breast cancer survival (Harding et al., 
2015), but the majority of breast cancers detected with mammography are ductal 
carcinomas in situ (DCIS) or low-grade, endocrine-responsive tumors where the timeline 
for early detection is less critical. High-grade, highly proliferative cancers, such as Her2+ 
breast cancer, triple-negative breast cancer (TNBC), and estrogen-receptor (ER) positive 
luminal B cancers frequently present as palpable masses in premenopausal women, 
women with increased breast density, or in the interval between screening mammography 
(Kirsh et al., 2011). There is a need for the specific detection of these cancers to reduce 
breast cancer mortality, in conjunction with radiographic imaging for tumor localization. In 
both the underserved and global health settings, mammography is rarely used as a 
primary screening tool, in part due to the cost and logistics of population-based 
mammographic screening. Circulating biomarkers, in conjunction with physical exams, 
could provide a rapid, cost-effective method for selection of patients for mammographic 
screening.  
2.2.3. Biomarkers for Monitoring Breast Cancer 
There is significant clinical interest in the use of liquid biopsies for monitoring breast 
cancer, either for the early detection of clinical relapse, for molecular profiling of metastatic 
tumors, or for monitoring metastatic disease response (Garcia-Murillas et al., 2015). Since 
the most common sites of metastatic spread are bone, liver, and lung, tissue-based 
diagnostics are associated with the morbidity of biopsies of relatively inaccessible 
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anatomic sites. The intra-patient heterogeneity of breast cancer evolution often results in 
mixed clinical responses that may be captured with deep molecular profiling. These 
circulating biomarkers could be used in conjunction with imaging for disease monitoring 
or for early detection of relapse. The clinical utility of detection of microscopic disease prior 
to relapse is not known but may identify patients for targeted clinical trials. In this setting, 
tissue-based genomic or proteomic alterations are a potential source of highly 
personalized marker profiles for tracking disease. 
 
2.3. KEY FACTORS TO IMPROVE THE PIPELINE OF CIRCULATING BREAST 
CANCER BIOMARKERS 
2.3.1. Incorporating PRoBE principles early in the biomarker discovery process 
To improve the performance criteria of biomarkers in validation studies, it is important to 
limit hidden biases early in the design of discovery studies (Bohm et al., 2011; Marks et 
al., 2015; Opstal-van Winden et al., 2011; Pietrowska et al., 2010; Riley et al., 2011). The 
usual approach to the discovery of biomarkers is to measure markers in a small sample 
set of convenience, which usually contains serum or plasma samples of cases obtained 
from a single institution biorepository. Control samples often obtained from a separate 
collection from healthy people, with an inadequate sample size and unmatched for age, 
gender, race/ethnicity, location, or method of collection.  
The prospective specimen collection, retrospective blinded evaluation (PRoBE) design, 
first described by Pepe et al. (Pepe, Feng, Janes, Bossuyt, & Potter, 2008) and updated 
in (Pepe, Li, & Feng, 2015), provides guidance for the strategic design of biomarker 
studies. PRoBE relies on well-designed prospective specimen collections that are fit-for-
use, such as early diagnosis, prognosis, or serial samples for monitoring of early relapse. 
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The key element in the prospective study design is planned incorporation of relevant 
controls within the design of the biorepository, so that the comparison group is collected 
using standardized laboratory procedures in similar time frames and locations as the 
cases. For both discovery and validation studies, selection of the cases and controls from 
biorepositories should follow, as closely as possible, the biomarker development phase 
and the intended clinical use. The five phases of biomarker discovery progress from the 
preclinical exploratory phase, a clinical assay and validation phase, then onto 
retrospective longitudinal and prospective screening phases (Pepe et al., 2001). Following 
rigorous study design guidelines minimizes false discovery of biomarkers and streamlines 
the efficiency of the validation process.  
2.3.2. Recognizing Breast Cancer Tumor Heterogeneity 
Given the striking clinical and molecular differences between breast cancer subtypes, 
many circulating breast cancer biomarkers will have differential expression between the 
subtypes. Breast cancers are clinically divided into endocrine –responsive tumors that 
express the estrogen receptor (ER) and/or the progesterone receptor (PR), erbB2-
expressing tumors (Her2+), and triple-negative breast cancers (TNBCs). Further 
molecular definitions based on RNA expression profiling have led to additional clinically 
relevant subtypes within these broad categories ("Comprehensive molecular portraits of 
human breast tumours," 2012). Use of a mixed collection of breast cancer sera in the 
discovery or validation phases of biomarker research is likely to over-represent the subset 
of low-grade ER+ Her2- breast cancers, for which survival rates are highest, 
mammographic screening is most effective, and circulating biomarkers for detection and 
relapse are less clinically needed. With this approach, biomarkers for the less common 
high-grade cancers are more likely to be eliminated early in discovery due to low overall 
sensitivity. There are two solutions to this challenge. One solution is to incorporate larger 
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numbers of samples within both the discovery and validation phases, to ensure adequate 
representation of the under-represented high-grade subtypes of breast cancer. This 
requires different statistical analysis strategies (Skates, 2014; Skates et al., 2013) that 
permit the initial selection of biomarkers with low clinical sensitivity (Wallstrom, Anderson, 
& LaBaer, 2013). The second solution is to focus the discovery (and validation) studies on 
a specific subtype of breast cancer. Our own strategy has evolved from broad, multiple-
subtype screening for breast cancer (Anderson, Sibani, et al., 2011) to focused discovery 
and validation based on individual subtypes, such as basal-like breast cancers (J. Wang 
et al., 2015). As with all biomarker research, circulating biomarkers that are associated 
with changes in tumor biology (such as tumor mutation, gene expression, or alterations in 
the tumor microenvironment) may have a greater likelihood of validating in later phases of 
development. 
2.3.3. Selection of Relevant Controls 
The size, number, and selection of samples from cases and controls for both discovery 
and validation studies depends on the overall clinical use, so that early involvement of 
biostatisticians and epidemiologists throughout the discovery and validation pipeline is 
essential. For breast cancer, controls are usually matched by gender, age (+/- 5 years), 
which indirectly addresses menopausal status, and regional location of the collected 
samples, which limits confounding variables in sample collection (see below) and 
race/ethnicity variances. For early detection, incorporation of appropriate benign breast 
disease controls and follow up are needed to limit both false positive and false negative 
discovery. Ideally, both cases and controls are collected in similar clinical settings 
(screening mammography or diagnostic mammography), prior to treatment, at the time of 
biopsy or resection (for prognostic markers), or at defined time intervals post-surgery (for 
early relapse markers). The impact of stress, diet, concomitant medications, and systemic 
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therapy on biomarker levels are hidden potential confounders that can be minimized with 
a planned study design. Even with careful selection, a certain number of healthy controls 
may be positive for a biomarker, and it may be difficult to determine an analytical false 
positive from an asymptomatic early cancer diagnosis.  
2.3.4. Minimizing Pre-analytic Variability 
Standardization of specimen collection procedures and clinical annotation for biomarker 
research is an essential component of a reliable pipeline. The current significant variation 
in quality and suitability of samples collected impacts research quality and the ultimate 
clinical utility of identified biomarkers. Protocols that detail procedures (Dash et al., 2012) 
with defined clinical annotation (Robb et al., 2014) are available and can be generalized 
across the biomarker pipeline. Funding agencies and peer-reviewed publications have an 
emerging recognition of the value of high quality samples prepared using standard 
protocols and the need for detailed description of sample collection methods. This includes 
protocols for collection, processing and storage, time delays to collection and processing, 
batch numbers and reference sets, validation of tissue pathology data linked to blood 
samples, inventory management, sample distribution and standardized equipment (Dash 
et al., 2012). Hundreds of pre-analytic variables may be considered for annotation in 
biorepositories (Robb et al., 2014).  
2.3.5. Assay Migration to a Clinically-Compatible Platform 
Once the early discovery and verification studies have identified a discrete number of 
potential biomarkers for an intended clinical use, proteomics, immunomics, and genomics 
assays usually need to be migrated to a clinically-compatible platform prior to further 
validation studies. This process may take 1-2 years to establish standardized procedures, 
precision and variability, and to replicate the prior data obtained from the discovery 
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platform. Typically, at this stage the numbers of biomarkers are limited, and the assay 
becomes cost-effective for large-scale serum or plasma screening. 
2.3.6. Leveraging Existing Biorepositories 
Once the single-institution discovery and initial independent blinded verification study is 
completed, the next phase is to perform further validation studies using larger cohorts of 
multi-institutional, blinded specimens. There are multiple biorepositories already available 
for select clinical applications. To meet the needs for early detection, the NCI Early 
Detection Research Network (EDRN, ("The Early Detection Research Network,")) has 
created the Breast Cancer Reference Set (BCRS), a prospective, multicenter annotated 
collection of over 700 sera and plasma from women undergoing screening mammography 
and diagnostic mammography (Marks et al., 2015). This is an invaluable resource 
collected in compliance with PRoBE principles that are available for distribution to 
researchers upon request (Feng et al., 2013; Marks et al., 2015). In a recent evaluation of 
90 potential protein biomarkers using the BCRS, only CA 125 was found to have potential 
utility for the discrimination of ER- breast cancers (Marks et al., 2015).  
A key question for any early detection biomarker is the lead time of biomarker detection 
prior to clinical diagnosis. Several large multicenter biorepositories have blood collections 
from healthy individuals, annotated for subsequent cancer diagnosis. This includes the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), the Women’s 
Health Initiative (WHI), the Health Professionals Study, Janus, ROCA (Risk of Ovarian 
Cancer Algorithm), EPIC (European Prospective Investigation into Cancer), the Carotene 
and Retinol Efficacy Trial (CARET) and the Nurses’ Health Study (NHS), all of which have 
blood samples obtained prior to clinical diagnosis (Bohm et al., 2011; Chan, Bandera, 
Greenwood, & Norat, 2015; Feng et al., 2013; Gonzalez, Daly, Tan, Marks, & Zangar, 
2011; Gunter et al., 2015; J. Wang et al., 2015). Fewer biorepositories exist for evaluating 
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biomarkers for the early detection of clinical relapse, which requires prospective collection 
of serial samples after clinical diagnosis. Overall, other than early detection, there is a 
need for rapid, adaptable, multicenter, annotated specimens for targeted validation 
studies available to the research community. 
 
2.4. SPECIFIC CLASSES OF BIOMARKERS 
2.4.1. Proteins 
A number of proteomic platforms have been used to identify novel circulating protein 
biomarkers for breast cancer (Table 2-1). Targeted sandwich ELISA microarrays have 
been used to identify novel proteins in pre-diagnostic plasmas for early detection of 
ER+/PR+ ductal breast carcinoma (Buas et al., 2015), and a separate panel of proteins 
were detected for triple-negative breast cancer (C. I. Li et al., 2012). In an independent 
microarray platform, ten proteins were altered in at least one breast cancer subtype, 
including elevated expression of RANTES (Gonzalez et al., 2011). Plasma proteomic 
profiling has also been used to identify breast cancer biomarkers that are differentially 
detected in patient plasma. Elevated EGFR levels have been detected in plasma samples 
collected up to 17 months prior to ER+ breast cancer diagnosis in post-menopausal 
hormone therapy users (Pitteri et al., 2010). Elevated glycolysis pathway proteins have 
also been detected in pre-diagnostic plasma compared with controls (Amon et al., 2012). 
A panel of 14 biomarkers that distinguish primary non-metastatic breast cancer and 
healthy controls have been reported using mass spectrometry of serum samples (Bohm 
et al., 2011). Serum levels of 20 peptides were found to change one year after the end of 
chemotherapy in breast cancer patients subjected to tumor surgical resection (Pietrowska 
et al., 2010). A large LC-MS proteomics dataset has been generated from plasma samples 
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prospectively collected from breast cancer patients and controls (Riley et al., 2011), 
providing a valuable resource for comparative analysis.  
 
Table 2-1. Examples of Protein Biomarkers for Breast Cancer. 







CCL27, CCL28 TNBC Early detection Phase 3 
 












ER+ Early detection Phase 3 
 
(Amon et al., 
2012) 




Unselected Early detection Phase 3 (Opstal-van 
Winden et al., 
2011) 






Intrinsic Diagnosis Rat model (Brauer et al., 
2014) 
14 proteins Unselected  Diagnosis Phase 1/2 (Bohm et al., 
2011) 
20 peptides Unselected Monitoring 
response to 
therapy 
Phase 1/2 (Pietrowska 
et al., 2010) 
*Glutathione (GSH)-modified ceruloplasmin and 4-hydroxynonenal (HNE)-
modified PDGF 
 
Two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry 
(2D-Nano LC-MS/MS) has been used to detect elevated levels of afamin, apolipoprotein 
E and the isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 (ITIH4), as well as 
decreased levels of alpha-2-macroglobulin and ceruloplasmin in sera collected prior to 
breast cancer diagnosis (Opstal-van Winden et al., 2011). Subcellular fractionation of 
plasma membranes (Leth-Larsen, Lund, & Ditzel, 2010), and secretome analysis 
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(Zawadzka et al., 2014) have also been applied for biomarker selection. There has been 
increasing interest in exploring the tumor interstitial fluid (TIF) as an enriched source of 
the tumor secretome (Gromov et al., 2010; Turtoi et al., 2011). TIF has the potential 
advantage of local detection of disease-specific biomarkers in high concentrations before 
they are diluted in the blood. (Haslene-Hox, Tenstad, & Wiig, 2013; Rifai et al., 2006).  
Other potential biomarkers include angiogenic factors, cytokines, metalloproteases 
(Gonzalez et al., 2011), and circulating C-reactive protein (Chan et al., 2015; Cheng, Liu, 
& Zhang, 2015; Gunter et al., 2015). Dermcidin and the related host defense peptide 
psoriasin (S100A7 (Anderson, Wong, Polyak, Aronzon, & Enerback, 2009)) function in 
mammary carcinogenesis, and dermcidin levels are increased prior to breast cancer 
diagnosis in a Japanese study (Brauer et al., 2014), but S100A7 levels are not elevated 
(Anderson et al., 2009). PTMs have also been evaluated as potential circulating 
biomarkers. Alterations in mucin glycoproteins are common, functional molecular changes 
in breast cancer (Vester-Christensen et al., 2013), and MUC1 glycoproteins are currently 
used in clinical practice for monitoring advanced disease (Paoletti & Hayes, 2014). 
Additional PTMs have been evaluated, such as oxidized ceruloplasmin and platelet-
derived growth factor (PDGF) which are differentially detected in plasma from breast 
cancer patients and benign controls (Jin et al., 2013). Overall, the majority of these 
circulating proteins have not yet been validated in blinded, retrospective or prospective 
multi-center clinical studies.  
2.4.2. Autoantibodies (AAbs) 
Abs to tumor-associated antigens are induced in cancer patients in response to altered 
structure or expression of proteins or glycans. Because of their stability, high specificity 
and ease of detection in cancer patient sera, they represent a class of circulating 
biomarkers that can be rapidly adapted to clinical diagnostic platforms and may reflect 
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underlying immune surveillance of tumors. A number of these AAbs have been identified 
(Table 2-2). Since individual AAbs often have low clinical sensitivity, AAb combinations 
may improve the sensitivity of detection (Anderson, Sibani, et al., 2011; Chapman et al., 
2007; Katayama et al., 2015; Lacombe, Mange, Bougnoux, Prassas, & Solassol, 2014; 
Ladd et al., 2013; H. Lu et al., 2012; J. Wang et al., 2015). For example, a three-phase 
screening approach was used to identify an immunosignature of 28 AAbs in early stage 
breast cancer (IBC) for potential early diagnosis (Anderson, Sibani, et al., 2011). In a 
subsequent study focused on basal-like breast cancer, 10,000 antigens were screened 
using protein microarrays and identified a panel of 13 AAbs that can distinguish between 
cancer cases and controls (J. Wang et al., 2015). A separate phase 3 study using plasma 
derived from the Women’s Health Initiative cohort identified AAbs to proteins involved in 
BRCA1, TP53 and cytokeratin networks prior to TNBC diagnosis (Katayama et al., 2015). 
Additional autoantigens include plasminogen (Goufman, Iakovlev, Tikhonova, & Lokshin, 
2015), centrosomal antigens (Maroun et al., 2014), nuclear antigens (Mohammed & 
Abdelhafiz, 2015), and Alpha 1-antitrypsin (Lopez-Arias et al., 2012). Using sera from 
primary breast cancer patients, DCIS and healthy controls for Abs against P53, c-myc, 
NY-ESO-1, BRCA1, BRCA2, HER2 and MUC1, AAbs against at least one of these 6 
proteins were associated with early-stage breast cancer (Chapman et al., 2007).  
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2.4.3. Circulating Tumor Cells (CTCs) 
Circulating tumor cells are cancer cells that have disseminated into the peripheral blood, 
but are rare in healthy individuals and patients with local disease (Bidard et al., 2013). 
Their identification and enumeration in blood is minimally invasive and have been 
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evaluated for prognosis and treatment selection. Detection of 5 or more CTCs per 7.5 mL 
of blood is associated with increased metastatogenesis, decreased progression-free 
survival and overall survival (Bidard et al., 2010; Giuliano et al., 2014; Z. F. Jiang et al., 
2013). CTCs have been detected from multiple molecular subtypes, but at low frequencies 
in early stage disease (Bidard et al., 2014). Very high counts were observed more 
frequently in Luminal A and TNBC subtypes (Peeters et al., 2014). At this time, their 
primary use is to identify molecular changes in metastatic tumors (M. C. Liu, 2014). 
Ongoing clinical trials to investigate CTC clinical utility are reviewed in (Castle, Shaker, 
Morris, Tugwood, & Kirwan, 2014). 
2.4.4. Exosomes 
Exosomes are nano-sized vesicles released from all types of cells, present in almost all 
body fluids and are involved in intercellular communication (O'Driscoll, 2015). They are 
rich in proteins, DNA, mRNA, lncRNA and miRNA and their constituents provide insights 
into the contents of their cells of origin (Yu et al., 2015). Tumor-derived exosomes transfer 
information to other cells and can thus actively enhance cancer progression and 
metastasis, which has been demonstrated for TNBC (O'Brien et al., 2013). Sera from 
cancer patients may have both increased quantity and altered content of exosomes 
compared with exosomes in healthy control sera. Unlike normal exosomes, breast cancer-
derived exosomes were found to convert pre-miRNA into miRNA including the two breast 
cancer-related miRs, miR-10b and miR-21 (Melo et al., 2014), and to contain unique 
tRNAs (Guzman et al., 2015).  
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2.4.5. MicroRNA (miRNA) 
miRNAs function to modulate post-transcriptional regulation of gene expression in 
cancers, including breast cancers, and can be classified as oncogenes (oncomiRs) or 
tumor suppressor genes (oncosuppressor-miRs) depending on the genomic context 
(Andorfer, Necela, Thompson, & Perez, 2011; Jansson & Lund, 2012). Many circulating 
miRNAs are differentially detected in the blood of breast cancer patients (reviewed in 
(Bertoli, Cava, & Castiglioni, 2015)). These miRNAs are potential biomarkers for breast 
cancer diagnosis (Hu et al., 2012; E. J. Jung et al., 2012; Kleivi Sahlberg et al., 2015; Q. 
Wu et al., 2011), prognosis (Hu et al., 2012; Joosse, Muller, Steinbach, Pantel, & 
Schwarzenbach, 2014; Kleivi Sahlberg et al., 2015; Q. Wu et al., 2011) and prediction of 
response to therapy (E. J. Jung et al., 2012; Sun et al., 2012). A recent study identified 
upregulation of miR-106a-5p and miR-454-3p and downregulation of miR-195-5p and 
miR-495 (p < 0.05) in PBMCs from patients with early stage breast cancer (Mishra, 
Srivastava, Suman, Kumar, & Shukla, 2015). In addition to the widely used RT-qPCR, 
exploring other highly sensitive techniques such as small RNA sequencing (Kelly et al., 
2015) and droplet digital PCR (Mangolini et al., 2015) will help detect specific, low 
abundance analytes within complex biologic fluids. 
2.4.6. Circulating Tumor DNA (ctDNA) 
Circulating cell-free DNA was originally identified in the 1970s in the blood of advanced 
cancer patients (Chapman et al., 2007; Goufman et al., 2015). Because of low plasma 
concentrations, reliable detection required the later development of highly sensitive 
fluorescent dye and PCR assays (K. Jung, Fleischhacker, & Rabien, 2010). Initially, cell-
free DNA was used to measure copy number alterations in tumors (Skates, 2014) as well 
as acquired resistance to drugs (Pepe et al., 2001; Tripathy et al., 2014; Wallstrom et al., 
2013). However, total circulating DNA content has not been consistent between studies 
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(K. Jung et al., 2010; Mohammed & Abdelhafiz, 2015), and the association with tumor 
stage and metastasis in breast cancer has been variable.  
More recently, methods have evolved to detect tumor-specific aberrations within total 
DNA, termed circulating tumor DNA (ctDNA). ctDNA provides a unique insight into the 
tumor genomic profile, including mutations, loss of heterozygosity, gene amplification, 
chromosomal aberrations and epigenetic changes. High levels (95-100%) of similarity of 
PIK3CA mutation between tumor and plasma DNA have been reported in breast cancer 
(Board et al., 2010; Higgins et al., 2012). HER2 amplification in circulating DNA was 
detected in sera from patients with HER2 negative tumors at diagnosis (Pepe et al., 2008). 
ctDNA has been detected in the majority of blood samples from patients with advanced 
breast cancer (Bettegowda et al., 2014) and may have applications as liquid biopsies for 
monitoring minimal residual disease (MRD) and predicting relapse (Garcia-Murillas et al., 
2015). In one study, the sensitivity of ctDNA was superior to both CA 15-3 (85% vs 59%) 
and circulating tumor cells (90% vs 67%) (Dawson et al., 2013).  
In addition to somatic mutations and copy number alterations, tumor-specific epigenetic 
modifications within ctDNA have also been observed. De novo DNA methylation is often 
conserved through disease progression and are highly stable analytes (Wittenberger et 
al., 2014). Methylation of the tumor suppressor RASSF1 gene was detected in 80% of 
tumors and 40% of sera from 52 breast cancer patients using a methylation sensitive PCR-
based method, and may change with response to therapy (Avraham et al., 2012). Recent 
advances in the detection of whole genome methylated DNA (reviewed in (Wittenberger 
et al., 2014)) may broaden the scope of potential circulating epigenetic biomarkers for 
breast cancer. Overall, rigorous prospective validation of ctDNA biomarkers will be 
required, and protocols for processing, storage and enrichment of ctDNA will need 
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standardization to create biorepositories for their evaluation (Mohammed & Abdelhafiz, 
2015; Skates et al., 2013).  
  
 54 
CHAPTER 3 : PROGRAMMABLE PROTEIN ARRAYS FOR IMMUNOPROFILING HPV-
ASSOCIATED CANCERS 
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Anderson (2016). Programmable protein arrays for immunoprofiling HPV-
associated cancers. PROTEOMICS, 16(8), 1215-1224. doi: 
10.1002/pmic.201500376 
ABSTRACT 
Over 600,000 cancers each year are attributed to the human papillomavirus (HPV), 
including cervical, anogenital and oropharyngeal cancers (OPC). A key challenge in 
understanding HPV immunobiology is the diversity of oncogenic HPV types and the need 
for multiplexed display of HPV antigens to measure Ab responses. Custom HPV protein 
microarrays displaying 98 proteins as C-terminal GST fusion proteins, representing 8 
antigens of two low-risk HPV types (HPV6 and 11) and ten oncogenic high-risk HPV types 
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52 and 58) were generated. Robust and reproducible 
protein expression of 96/98 of the antigens was demonstrated using a human cell lysate 
expression system. The target epitopes and specificity of four monoclonal Abs were 
identified. Using sera from 10 patients with newly diagnosed OPC and 10 controls, specific 
IgG seroreactivity to HPV16 E1, E2, and E7 (a fold increase of 1.52, 2.19 and 1.35 in 
cases vs controls, respectively, all p<0.005) was demonstrated, confirming our prior data 
on an ELISA platform. HPV52 E7 Abs were also detected in serum from a patient with 
cervical cancer. The HPV protein array has potential for rapid identification of serologic 
responses to 12 HPV types. 
 
 55 
3.1. INTRODUCTION AND BACKGROUND 
Approximately 79 million Americans are currently infected with human papillomavirus 
(HPV) ("HPV Factsheet,"). While most infections are subclinical or result in benign 
neoplastic growth, HPV infection is a necessary event for the development of cervical 
cancer (Bosch & de Sanjose, 2003) and is strongly associated with anogenital and 
oropharyngeal cancers. Cervical cancer is the most common cancer among women in 
Eastern and Middle Africa and fourth in women worldwide (Ferlay et al., 2013), with an 
estimated 528,000 new cases in 2012 and an annual mortality rate of 270,000 deaths 
(Ferlay et al., 2010; Ferlay et al., 2015). The majority of these cases occurs in less 
developed countries due to limited resources for cytologic screening and HPV vaccination 
(Jemal, Ward, & Thun, 2010). In the US, there has been a recorded rise in incidence of 
HPV-positive oropharyngeal cancers among men in the last decade (Marur, D'Souza, 
Westra, & Forastiere, 2010).  
Although HPV is a small double-stranded DNA virus, a major challenge to the detection 
of specific immune responses is the diversity of over 200 HPV types. These vary from 
non-oncogenic low-risk types such as HPV 6 and 11 that cause anogenital warts, to high-
risk types that are oncogenic. HPV16 is responsible for 85-90% of HPV-associated OPCs 
(D'Souza et al., 2007; Marur et al., 2010), but only 50-55% of cervical cancers (Bosch et 
al., 2008). Eight high-risk types (HPV16, 18, 31, 33, 35, 45, 52 and 58) are responsible for 
90% of invasive cervical cancer (Bosch et al., 2008; Woodman et al., 2007).  
The humoral immune response to HPV plays a significant role in the settings of natural 
infection, vaccination and cancer. Type-specific IgG Abs to the L1 coat protein are induced 
in response to acute HPV infection, and the HPV vaccines are designed to induce high 
levels of protective anti-L1 IgG Abs (Villa et al., 2006). In contrast to HPV infection, the 
development of HPV cancers is associated with IgG Abs, primarily to the oncogenic 
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antigens E6 and E7, best studied for the most common subtype, HPV16. Serum Abs to 
HPV16 E6 and E7 proteins have been detected in sera of 30-40% of patients with invasive 
cervical cancer (Achour et al., 2009; Reuschenbach et al., 2008). Abs to HPV16 E6 and 
E7 were similarly detected in 30-50% of HPV-positive OPC patients (K. S. Anderson, K. 
R. Dahlstrom, et al., 2015; K. S. Anderson, J. E. Gerber, et al., 2015; E. M. Smith et al., 
2010) and Abs to E6 have been detected 10 years before OPC diagnosis (Kreimer et al., 
2013). Using a mammalian-based method of antigen display of the full HPV16 proteome 
(8 antigens), our laboratory has observed that the immune response to HPV16 is 
heterogeneous in OPC and also includes strong immune responses to HPV16 E1, E2, 
and E4 antigens (K. S. Anderson, K. R. Dahlstrom, et al., 2015; K. S. Anderson, J. E. 
Gerber, et al., 2015; Anderson, Wong, et al., 2011), highlighting the significance of 
exploring the immune response across the HPV proteome.  
The primary methods for measuring HPV-specific IgG across multiple HPV types have 
used multiplexed bead arrays coupled with HPV fusion proteins expressed in E. coli 
(Combes et al., 2014; Kreimer et al., 2013). One extensive study of an HPV protein slide-
based array displaying multiple HPV proteomes expressed in E. coli identified IgG Abs to 
HPV16 E7 in the sera of 60% of patients with HPV16+ invasive cervical cancer, but limited 
detection of other Abs (Luevano et al., 2010). Our experience with mammalian expression 
of HPV16 proteins suggest that the method of protein display markedly impacts both yield 
and epitope presentation (F. Festa et al., 2013). However, when used in bead- and ELISA- 
formats, this method is cost-ineffective for detecting Abs across a wide range of viral 
proteins. We predicted that custom protein arrays displaying a broad spectrum of HPV 
antigens in a slide-based format may improve the detection of serologic responses to 
HPV. 
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Here, we have generated the first HPV programmable protein microarrays (termed 
NAPPA) displaying eight antigens from 2 low-risk and 10 high-risk HPV types. Expression 
plasmids were co-printed on glass slides with anti-GST Abs using human cell lysate (N. 
Ramachandran et al., 2004; N. Ramachandran et al., 2008). We demonstrate robust and 
reproducible protein expression across 96 of 98 viral antigens, and rapid mapping of the 
specificity of four HPV-specific monoclonal Abs (MAbs). The arrays permitted rapid 
mapping of Ab responses in sera from 11 patients with HPV-associated malignancies. 
These high-risk HPV protein arrays are designed to rapidly and specifically detect a wide 
array of serum Abs to multiple HPV types and may be useful to identify biomarkers for the 
detection and prognosis of HPV-associated malignancies.  
 
3.2. MATERIALS AND METHODS 
3.2.1. Patient Sera 
The HPVOPC sera used in this study are a subset of the serum collection used in the 
HOTSPOT study previously described (K. S. Anderson, J. E. Gerber, et al., 2015; D'Souza 
et al., 2014). Samples were collected from newly diagnosed, histopathologically confirmed 
oropharyngeal cancer (OPC) patients (n = 10) from four study sites prior to initiation of 
treatment between October 2009 and May 2013. Healthy control sera (n = 10) used in this 
study, previously described (K. S. Anderson, K. R. Dahlstrom, et al., 2015), are a subset 
of a molecular epidemiology study of head and neck cancer at the MD Anderson Cancer 
Center, collected between January 2006 and September 2008. Serum from one patient 
with invasive cervical cancer serum was obtained from Biorepository for Molecular 
Signatures of Cervical Cancer developed by the Centers for Disease Control and 
Prevention as a Clinical Epidemiology and Validation Center for NCI’s Early Detection 
Research Network (EDRN). Samples were collected using a standardized sample 
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collection protocol and stored at -80°C until use. Written informed consent was obtained 
from all participants under institutional review board approval. The HPVOPC sera used in 
this study are a subset of the serum collection used in the HOTSPOT study previously 
described (K. S. Anderson, J. E. Gerber, et al., 2015; D'Souza et al., 2014). Samples were 
collected from newly diagnosed, histopathologically confirmed oropharyngeal cancer 
(OPC) patients (n = 10) from four study sites prior to initiation of treatment between 
October 2009 and May 2013. Healthy control sera (n = 10) used in this study, previously 
described (K. S. Anderson, K. R. Dahlstrom, et al., 2015), are a subset of a molecular 
epidemiology study of head and neck cancer at the MD Anderson Cancer Center, 
collected between January 2006 and September 2008. Serum from one patient with 
invasive cervical cancer serum was obtained from Biorepository for Molecular Signatures 
of Cervical Cancer developed by the Centers for Disease Control and Prevention as a 
Clinical Epidemiology and Validation Center for NCI’s Early Detection Research Network 
(EDRN). Samples were collected using a standardized sample collection protocol and 
stored at -80°C until use. Written informed consent was obtained from all participants 
under institutional review board approval. 
3.2.2. Gene Design, Codon Optimization, and Cloning 
DNA constructs of all genes for 10 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, and 58) 
and 2 low-risk (6 and 11) HPV types were commercially prepared by GenScript 
(Piscataway, NJ) in the pDONR221 vector. For HPV types 6 and 11, both variations of E5 
(denoted E5a and E5b) found naturally due to alternative reading frames, were generated. 
To use the Gateway cloning system, attB1 (5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACC–3’) and attB2 (3’– 
GACCCAGCTTTCTTGTACAAAGTGGTCCCC–5’) linkers were added to flank the genes. 
The ORFs were transferred by recombination cloning into the pANT7-cGST vector, which 
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is optimized for maximal in vitro expression of proteins with a C-terminal glutathione S-
transferase (GST) fusion tag (N. Ramachandran et al., 2004). DNA sequences were 
obtained from the Papillomavirus Episteme (PaVE), an online database maintained by the 
National Institute of Allergy and Infectious Disease (NIAID) (http://pave.niaid.nih.gov). The 
sequences were codon optimized by the manufacturer using the proprietary 
OptimumGene Algorithm that optimized codon usage, as codon adaptability, mRNA 
structure, and cis-elements in transcription and translation (X. LIU et al., 2012). Plasmids 
were sequence verified and deposited in the DNASU Plasmid Repository (Seiler et al., 
2013) and will be made available upon request. 
3.2.3. HPV Microarray Generation 
Highly purified plasmid DNA was prepared using a high-throughput DNA factory robotic 
system as previously described (J. Qiu & LaBaer, 2011) and DNA concentration was 
normalized to 1200 ng/µl prior to printing. Protein arrays were generated as previously 
described (Anderson, Sibani, et al., 2011; J. Qiu & LaBaer, 2011). Briefly, plasmid DNA 
was incubated overnight at 4°C with a printing mix of capture anti-GST Ab (50 μg/mL, GE 
Healthcare Biosciences, Piscataway, NJ), BS3 protein cross-linker (2 mM, Pierce, 
Rockford, IL) and Bovine Serum Albumin (BSA) (3 mg/mL, Sigma-Aldrich) before arraying 
onto aminosilane-coated glass slides using a Genetix QArray2 with 300 μm solid tungsten 
pins. Positive controls included the highly immunogenic EBV-derived antigen EBNA-1 
(Rickinson & Kieff, 2001) and purified human IgG protein. Negative controls included no 
spotted material (nonspots) and all material except DNA (no DNA). Each sample was 
spotted in duplicate and in non-adjacent positions. Three subarrays, each printed with 98 
genes in duplicate, were printed on each slide. Two sequential printing batches were run 
on the same day using the same source plate of plasmid DNA preps. Arrays were stored 
in an air-tight container at room temperature and protected from light. Array quality control 
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was performed using both picogreen DNA staining and anti-GST staining of IVTT-
expressed proteins. A 1:200 dilution of anti-GST MAb (Cell Signaling Technology, MA, 
USA) was used to confirm expression of proteins from the plasmids printed on the arrays. 
The correlation of protein expression was compared within (intra-batch) and between 
(inter-batch) printing runs and between subarrays on the same slide (intra-array) to 
determine the reproducibility of slide production. Highly purified plasmid DNA was 
prepared using a high-throughput DNA factory robotic system as previously described (J. 
Qiu & LaBaer, 2011) and DNA concentration was normalized to 1200 ng/µl prior to 
printing. Protein arrays were generated as previously described (Anderson, Sibani, et al., 
2011; J. Qiu & LaBaer, 2011). Briefly, plasmid DNA was incubated overnight at 4°C with 
a printing mix of capture anti-GST Ab (50 μg/mL, GE Healthcare Biosciences, Piscataway, 
NJ), BS3 protein cross-linker (2 mM, Pierce, Rockford, IL) and Bovine Serum Albumin 
(BSA) (3 mg/mL, Sigma-Aldrich) before arraying onto aminosilane-coated glass slides 
using a Genetix QArray2 with 300 μm solid tungsten pins. Positive controls included the 
highly immunogenic EBV-derived antigen EBNA-1 (Rickinson & Kieff, 2001) and purified 
human IgG protein. Negative controls included no spotted material (nonspots) and all 
material except DNA (no DNA). Each sample was spotted in duplicate and in non-adjacent 
positions. Three subarrays, each printed with 98 genes in duplicate, were printed on each 
slide. Two sequential printing batches were run on the same day using the same source 
plate of plasmid DNA preps. Arrays were stored in an air-tight container at room 
temperature and protected from light. Array quality control was performed using both 
picogreen DNA staining and anti-GST staining of IVTT-expressed proteins. A 1:200 
dilution of anti-GST MAb (Cell Signaling Technology, MA, USA) was used to confirm 
expression of proteins from the plasmids printed on the arrays. The correlation of protein 
expression was compared within (intra-batch) and between (inter-batch) printing runs and 
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between subarrays on the same slide (intra-array) to determine the reproducibility of slide 
production. 
3.2.4. Detection of Serum Abs using HPV Arrays 
Serum Ab detection was performed as previously described (K. S. Anderson, D. W. 
Cramer, et al., 2015; Anderson, Sibani, et al., 2011; J. Qiu & LaBaer, 2011). Slides were 
incubated with rocking for 1 h at room temperature with SuperBlock (Thermo Fisher 
Scientific, Waltham, MA). Proteins were expressed by injecting 150 μl 1-Step Human 
Coupled in vitro Expression system (Thermo Fisher Scientific) into slides sealed with 
HybriWell (Grace BIO-LABS, OR) and incubating for 1.5 h at 30°C for protein expression 
followed by 30 min at 15°C for protein capture. Slides were rinsed twice with PBST (0.2% 
tween), washed 3 times for 5 min each with 5% w/v milk powder (MP Biomedicals, LLC, 
CA, USA) in 0.2% PBS-Tween (5% milk-PBST) and then blocked in milk for 1 h. Serum 
was diluted 1:80 in 25% E. coli lysate prepared in 5% milk-PBST (0.2% tween) (J. Wang 
et al., 2013) and rotated for 2 h at room temperature. The serum was added to individual 
subarrays separated by a multi-well gasket (Grace BIO-LABS). Slides were incubated with 
serum for 16 h at 4°C with rocking, washed 3 times with 5% milk-PBST (0.2% tween) then 
incubated for 1 h at room temperature with Alexa Fluor 647 goat anti-human IgG (#109-
605-008, Jackson Immunoresearch Laboratories, PA, USA). Slides were washed, dried, 
and scanned by Tecan PowerScanner (Tecan Group, Männedorf, Switzerland). 
3.2.5. Protein Array Image Analysis and Quantification 
Signal intensity of individual spots on the scanned slides was measured using ArrayPro 
Analyzer version 6.3 (MediaCybernetics, Bethesda, MD). Normalization of raw intensity 
values was done by subtracting the slide background signal and dividing by the 
background signal subtracted from intensity of noncontrol spots. The slide background 
signal was determined by the first quartile of signal intensity of nonspots (spots with no 
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printed DNA). In addition, array images were qualitatively examined to identify and confirm 
positive responses by adjusting raw images to extreme brightness and contrast using 
ArrayPro Analyzer and visual inspection of diffused signal (ring) as described previously 
(W. R. Montor et al., 2009). 
3.2.6. Detection of Expressed Proteins using Anti-HPV Monoclonal Antibodies 
RAPID ELISA was performed as described in (D'Souza et al., 2014) to evaluate the 
binding of specific MAbs raised against HPV16 E2 (Abcam, UK), HPV16/18 E6, HPV16 
E7 or HPV16 E1/E4 (Santa Cruz Biotechnology, TX). GST-tagged E1, E2, E6 or E7, 
proteins from 12 HPV types were expressed by IVTT from 200 ng cDNAs in pANT7-cGST 
vectors using human HeLa lysate. A plasmid expressing GST was used as a positive 
control. Expressed proteins were diluted 1:100 with 5% Milk PBST 0.2% and 100 μL of 
diluted antigen were added to the specified wells. MAbs were diluted 1:3000 in blocking 
buffer and bound Abs were detected using a 1:6250 dilution of secondary HRP goat anti-
mouse IgG Ab (Life Technologies, Carlsbad, CA). Luminescence detection was done 
using Glomax 96 Microplate Luminometer (Promega, WI).  
3.2.7. Statistical Analysis 
For the RAPID programmable ELISA, proteins were expressed in duplicate and RLU 
measurements were plotted as mean values. Each protein was expressed from DNA 
spotted in duplicate and signal intensities were plotted as mean values. The correlation of 
raw signal intensities of protein expression between the arrays randomly selected for 
quality control was determined with scatter plots and the correlation coefficient (R) was 
calculated to determine consistency. Levels of protein expression on the arrays were 
determined by calculating the mean values of raw signal intensities of duplicate spots from 
2 arrays. Mean values of normalized signal intensity for serum Ab reactivity on protein 
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arrays were plotted for cases and controls and compared using unpaired t-test (Graphpad 
Prism version 5.0c, San Diego, CA). 
 
3.3. RESULTS 
3.3.1. Gene Design and Codon Optimization 
A total of 98 proteins derived from 12 HPV PaVE reference sequence genomes (Van 
Doorslaer et al., 2013), including 10 high risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 58) and 
2 low risk (6, 11) were generated for this study. All genes were codon optimized, 
commercially synthesized and sequence confirmed. All reference and codon optimized 
DNA sequences, the percentage of nucleotide change as well as translated amino acid 
sequences are provided in Appendix A. We evaluated the difference between codon 
optimized or non-codon optimized sequences for the HPV16 and HPV18 genomes. 
Overall, protein expression levels of antigens from these 2 HPV types were similar 
following codon optimization (Figure 3-1), and three antigens (HPV16 E4, HPV16 L2 and 
HPV18 E5) had a fold increase of 1.19, 1.48 and 37.62, respectively (all p<0.05) after 
codon optimization. Non-codon-optimized HPV16 E2 has been difficult to express and 
was previously used as N-terminal (NE2) and C-terminal (CE2) fragments (K. S. 
Anderson, J. E. Gerber, et al., 2015); the codon-optimized gene is strongly expressed. In 
contrast, HPV16 L1 expression decreased after codon optimization. 
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Figure 3-1. Comparison of Levels of Protein Expression Before and After Codon 
Optimization for Antigens from HPV16 (Top) and HPV18 (Bottom). Protein expression 
levels of antigens from HPV16 and HPV18 were similar following codon optimization. Non-
codon optimized HPV16 E2 (not shown) was previously difficult to express but expressed 
at high levels after codon optimization. Protein expression levels markedly improved after 
codon optimization of HPV16 E4 (p<0.03), HPV16 L2 (p<0.0031) and HPV18 E5 




3.3.2. Generation and Quality Control of Custom HPV Protein Microarrays 
HPV protein microarrays comprising all 98 HPV proteins from 12 HPV types (Appendix 
A) were generated from printed cDNAs with IVTT and in situ protein purification using the 
C-terminal GST tags. The quality of the array printing was evaluated with picogreen DNA 
staining and the protein expressed was measured with anti-GST Abs. The reproducibility 
of array printing and protein display are shown in Figure 3-2A. Correlation coefficients of 
anti-GST signal intensities were determined for intra-array, intra-batch, and inter-batch 
replicate arrays (R>0.90) from two subarrays on the same slide or two randomly selected 
slides within a print run or between two print runs (Figure 3-2B). There were two 
independent printing batches and from each, one slide for DNA staining and two for protein 
staining were randomly selected. Scatter plots showing the variability in the correlation of 






Figure 3-2. Reproducibility of Printing and Protein Expression on NAPPA. (A) Left: 
Picogreen to detect content of DNA printed on the microarrays. Right: Image of anti-GST 
binding to measure the level of protein display. (B) Plots of protein signal intensities from 
all spots from two subarrays on the same slide or two randomly selected slides within a 




Figure 3-3. Plots of Protein Signal Intensities from All Spots on All Four Protein 
Staining Controls Used. Slides 1 and 2 were randomly selected from batch 1 while 3 
and 4 from batch 2. These plots show signal intensities from two subarrays on the same 





3.3.3. High-level HPV Protein Expression across Viral Types and Antigens 
Expression of C-terminal GST-tagged HPV Ags on the arrays was confirmed by IVTT 
expression followed by anti-GST detection (Figures 3-4, 3-5). We determined that 96/98 
antigens had detectable protein signal over background, defined as five times the average 
signal of blank spots (dotted line, Figure 3-5). The C-terminal portion of the EBV-derived 
protein EBNA-1 was expressed as a positive control. Only HPV16 L1 and HPV35 E2 
antigens had low expression signals, and IgG Abs to these proteins were not detected in 
patient sera (data not shown). Since the non-codon-optimized HPV16 L1 gene is well-
expressed, future arrays will contain this version. 
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Figure 3-4. Detection of GST-Tagged HPV Antigens on the Arrays. Mean values of 
raw signal intensity from individual spots on the arrays are shown for all antigens from 







Figure 3-5. Detection of GST-tagged HPV Antigens on the Arrays. Protein signal was 
detected over background for 98% of antigens, defined as five times the average signal 
of blank spots (dotted line). 
 
 
3.3.4. HPV Viral Proteins Retain Antigenic Specificity 
To evaluate whether the displayed proteins retain their antigenic specificity, the 
immunoreactivity was evaluated using four commercially-available mouse monoclonal IgG 
antibodies (MAbs) that were raised against specific HPV Ags (HPV16 E1/E4, HPV16/18 
E6, HPV16 E2 and HPV16 E7). HPV antigens were displayed in RAPID ELISA format, 
which uses the same expression system in a 96-well format for focused antigen display. 
The MAbs were added and mouse IgG was detected using secondary Abs and 
luminescence (relative light units, RLU, Figure 3-6). All expressed proteins were detected 
using anti-GST MAb, confirming expression of full-length proteins with C-terminal GST 
tags (data not shown). The anti-HPV16 E2 MAb was raised to amino acids 2-17 
(ETLCQRLNVCQDKILT) of HPV16 E2 and was specific for HPV16 E2 with cross-
reactivity to HPV51 E2. HPV51 E2 has a similar epitope as the parent HPV16 E2 protein 
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types (Bell, Martin, & Roberts, 2007), and the anti-HPV16 E4 MAb reacted specifically 
with HPV16 E4 with no cross-reactivity with other E4 proteins (Figure 3-6B). The anti-
HPV E6 MAb was raised for cross-specificity with HPV16 and HPV18 E6 proteins (Figure 
3-6C). As expected, the HPV E6 MAb was specific, but weakly reactive, for both HPV16 
E6 and HPV18 E6. The HPV16 E7 MAb showed strong cross-reactivity with HPV35 E7, 
which is highly homologous to HPV16 E7 (Figure 3-6D). Overall, these data demonstrate 
the display of seroreactive epitopes from the proteins expressed using human cell lysate, 
and demonstrate the utility of the protein display for rapid mapping of the specificity of 





Figure 3-6. Mapping Monoclonal Antibody Reactivity Using Arrays of Displayed HPV 
Antigens. Antibody specificity to GST-tagged HPV antigens were detected using the 96-
well RAPID ELISA format. Monoclonal antibodies specific for HPV16 E2 (A), HPV16 E4 
(B) HPV16/18 E6 (C) and HPV16 E7 (D) were detected with anti-mouse IgG secondary 
antibodies. 
 
3.3.5. Detection of HPV-Specific Abs in Patient Serum Using HPV Protein Arrays 
The primary goal of generating HPV protein arrays is to develop methods for the rapid 
detection of a broad-spectrum of Abs in sera to multiple HPV types. We displayed all 98 
HPV proteins from 12 HPV types in duplicate in protein microarray format, with the C-
terminal portion of EBNA-1 included as a positive control. Each individual subarray on 
microarray slides was incubated with selected serum from patients with HPV-associated 
malignancies, either oropharyngeal cancer, invasive cervical cancer, or healthy controls, 
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to demonstrate the detection of HPV-specific Abs. In Figure 3-7A, reactivity of serum from 
a patient with known HPV16 positive oropharyngeal cancer is shown. In this serum, we 
observed IgG Abs to the HPV16 E1 and E2 proteins, which is found in 56% of newly-
diagnosed OPC patients [14]. We also observed seroreactivity to HPV31 E2 protein, which 
likely represents epitope cross-reactivity, as infection with HPV31 is present in <5% of 
OPC. Serum from a healthy control subject only showed reaction with the EBNA-1 positive 
control protein (Figure 3-7B). We also identified a patient with HPV16-negative invasive 
cervical cancer who had seroreactivity to the HPV52 E7 protein, (Figure 3-7C), suggesting 
that Abs to different HPV types may be detectable with the arrays.  
Serum Ab reactivity to four early HPV16 antigens (E1, E2, E4 and E7) was determined for 
serum from 10 HPVOPC cases and 10 healthy controls by measuring normalized signal 
intensity values from protein arrays probed with serum. These HPVOPC cases were 
previously shown via a RAPID ELISA assay to have Abs to at least one early HPV16 
protein, while the negative healthy control sera did not (K. S. Anderson, K. R. Dahlstrom, 
et al., 2015; K. S. Anderson, J. E. Gerber, et al., 2015). The geometric mean signal 
intensities of cases vs controls and fold change were E1 (1.82 vs 1.20, p<0.0016), E2 
(1.50 vs 0.69, p<0.0001), E4 (1.42 vs 1.26, not significant) and E7 (1.23 vs 0.91, 
p<0.0083), respectively (Figure 3-8 and Table 3-1). On visual inspection, patients who 
had Abs to HPV16 E7 showed no cross-reactivity to E7 proteins from other HPV types, 
while all patients who had anti-HPV16 E4 Abs cross-reacted with E4 from HPV types 31 
and 35. Four of the eight sera that had Abs to HPV16 E1 had Abs to HPV 11 E1 and one 
had Abs to HPV39 E1. All patients who had Abs to HPV16 E2 except one showed cross-
reactivity to E2 Ag from at least two of the HPV types 18, 31, 39 or 58.   
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Figure 3-7. Detection of IgG in Human Serum Using HPV Protein Arrays. (A) 
Detection of IgG Abs in sera from a patient with HPV16 OPC. Antibodies to EBNA-1 
protein, HPV16 E1 and E2 and HPV35 E2 proteins are detected. (B) Healthy control serum 
with specificity for EBNA-1 protein. (C) Detection of IgG Abs in sera from a patient with 
HPV16-negative invasive cervical cancer. Strong immunoreactivity to the HPV52 E7 






Figure 3-8. Normalized Proteome Microarray Antibody Reactivity Against Four Early 
hpv16 Antigens: E1 (A), E2 (B), E4 (C) and E7 (D) in Sera from 10 HPVOPC Cases 
and 10 Healthy Controls. Box-and-whisker plots of antibody reactivity are presented as 
normalized signal intensity value on the vertical axis. The top and bottom of the box 
indicate the 75th and 25th percentiles, respectively, while the line within the box indicates 






Table 3-1. Normalized Signal Intensities of HPVOPC Sera on ELISA Compared with NAPPA 
Protein Arrays.  
  RAPID ELISA NAPPA 
 HPV16 
Antigen 
E1 NE2a CE2a E4 E7 E1 E2 E4 E7 
 Case 1 19.14 4.45 6.70 1.13 70.84 1.78 1.28 2.42 1.86 
 Case 2 7.99 8.15 11.52 1.25 1.22 1.33 1.75 1.22 0.84 
 Case 3 36.50 2.21 1.88 1.14 42.43 1.74 0.88 1.08 1.16 
 Case 4 0.84 17.74 31.80 25.34 0.78 1.12 1.79 2.08 1.03 
 Case 5 26.44 13.29 15.12 0.42 46.64 2.70 1.45 1.51 1.68 
 Case 6 7.05 1.94 8.44 1.89 0.98 2.61 1.68 2.26 0.94 
 Case 7 42.27 18.63 37.61 1.33 41.25 2.37 2.02 1.08 1.39 
 Case 8 25.94 2.16 19.46 1.05 39.23 1.74 1.50 1.15 1.37 
 Case 9 38.86 4.91 26.75 3.83 87.85 1.60 1.28 1.17 1.34 
 Case 10 25.61 4.01 25.57 1.66 1.43 1.82 1.80 1.03 1.04 
 Control 1 1.79 1.55 1.51 1.33 0.90 1.27 0.70 1.31 0.82 
 Control 2 0.94 0.95 1.06 0.88 0.99 1.21 0.73 1.52 0.90 
 Control 3 1.08 0.98 1.74 0.81 0.83 1.31 0.69 1.26 0.90 
 Control 4 1.39 1.09 0.85 1.00 1.08 1.13 0.78 1.14 0.81 
 Control 5 0.67 0.95 0.89 0.77 0.71 1.22 0.70 1.27 0.98 
 Control 6 1.01 0.99 1.21 1.09 1.05 1.27 0.70 1.22 1.11 
 Control 7 1.43 1.16 1.36 1.26 1.35 1.22 0.73 1.24 0.82 
 Control 8 1.27 1.16 1.41 1.21 1.09 1.12 0.56 1.37 1.00 
 Control 9 0.92 0.81 0.94 1.00 1.16 1.19 0.74 1.19 0.94 
 Control 10 0.76 0.82 1.01 1.17 1.01 1.04 0.58 1.15 0.89 
Median Cases 25.77 4.68 17.29 1.29 40.24 1.76 1.59 1.20 1.25 
 
Controls 1.04 0.99 1.14 1.05 1.03 1.21 0.70 1.25 0.90 
Mean Cases 23.06 7.75 18.49 3.91 33.27 1.88 1.54 1.50 1.27 
 
Controls 1.13 1.05 1.20 1.05 1.02 1.20 0.69 1.27 0.92 
Geometric 
mean 
Cases 15.76 5.58 14.03 1.76 11.03 1.82 1.50 1.42 1.23 
Controls 1.08 1.03 1.17 1.04 1.00 1.20 0.69 1.26 0.91 
Standard 
deviation 
Cases 14.21 6.48 11.73 7.59 31.43 0.52 0.34 0.54 0.33 
Controls 0.34 0.21 0.30 0.19 0.18 0.08 0.07 0.11 0.09 
Cut-off 
 




14.60 5.42 12.03 1.70 11.02 1.52 2.19 1.13 1.35 
p value 
 
0.0043 0.0396 0.0028 0.768 0.3263 0.0016 0.0001 0.3719 0.0083 
Highlighted numbers are above the established cut-off values. Fold increase was calculated for the corresponding geometric means 





The marked advances in proteomic technologies for display of antigenic structures have 
led to novel tools for proteome-wide immune monitoring. Protein microarrays have 
enabled profiling of the Ab immune response to the proteomes of pathogens and self-
antigens in human sera. These advances are rapidly changing our understanding of the 
disease biology and the heterogeneity of the immune response. Programmable protein 
display (NAPPA) permits rapid flexibility and high-throughput protein production for 
custom pathogen protein arrays which retain activity following months of storage (N. 
Ramachandran et al., 2004; N. Ramachandran et al., 2008). Our current method of using 
human cell lysate results in high levels and reproducible protein expression for multiplexed 
antigen display. 
We have generated custom programmable HPV protein microarrays displaying 98 
antigens of two low-risk HPV types that are associated with anogenital warts, and ten 
oncogenic high-risk HPV types that are the most prevalent types in cervical and HPV-
associated oropharyngeal cancers. We demonstrate robust protein expression for all the 
protein antigens except HPV16 L1 and HPV35 E2. The variation in protein expression was 
not associated with antigen size or hydrophobicity (data not shown). The displayed 
antigens retained antigenic specificity of target epitopes, as measured by four HPV-
specific MAbs. Ab reactivity to multiple early HPV proteins were detected in sera from 
patients with HPV-associated malignancies using the arrays (Figures 3-7 and 3-8).  
The serologic response to HPV has been well-characterized for HPV16. Abs to the major 
capsid protein HPV16 L1 are an indication of past HPV infection but are not a reliable 
marker of HPV-associated tumors (Dillner, 1999). Since HPV early antigen expression, 
especially E6 and E7, is restricted to the later stages of viral progression, there is high 
frequency of seropositivity to HPV16 E6 and E7 in patients with an underlying HPV-
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associated malignancy but not in controls (Combes et al., 2014; D'Souza et al., 2014; 
Zumbach et al., 2000). We confirmed a high correlation of HPV16-specific serum IgG 
detection between our ELISA (K. S. Anderson, K. R. Dahlstrom, et al., 2015; K. S. 
Anderson, J. E. Gerber, et al., 2015) and the custom HPV protein microarrays for Abs to 
E1, E2 and E7 proteins (R=0.66-0.86, Supplemental Table 2 and Figures 4 and 5). Abs to 
HPV16 E2 were detected in all 10 cases while only 4 cases showed reactivity to HPV16 
E4 (Figure 5). This heterogeneous immune response is similar to our prior ELISA-based 
data using these sera (K. S. Anderson, K. R. Dahlstrom, et al., 2015; K. S. Anderson, J. 
E. Gerber, et al., 2015; Anderson, Wong, et al., 2011), but antigenic specificity in patient 
sera will need to be confirmed using large well-annotated and matched serum 
biorepositories. As compared with OPC, immunoreactivity to E1, E2 and E4 is uncommon 
in cervical disease (unpublished observations). The biology and clinical significance 
underlying the immune response within the same HPV type and between different 
anatomic sites is unknown at this time.  
A key challenge in HPV serology is the diversity of oncogenic HPV types and the potential 
for serologic cross-reactivity on the arrays. We observed immunoreactivity to non-HPV16 
Ags in HPV16+ OPC (Figure 3-7A), which could be due to epitope cross-reactivity 
between HPV types that have close phylogenetic linkage (Combes et al., 2014). 
Approximately half of invasive cervical cancers are caused by non-16 HPV types (Bosch 
et al., 2008). In a multiplex bead assay, Abs to HPV52 E6 and HPV 58 E7 were associated 
with invasive cervical cancer (Waterboer et al., 2005). Here, we detected seroreactivity of 
an HPV16 negative invasive cervical cancer patient to HPV52 E7 protein with no cross-
reactivity with HPV16 Ags (Figure 3-7C). These data support the need for multiplexed 
detection of multiple high-risk HPV types for biomarker discovery. 
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To our knowledge, only one prior study displayed the proteomes of multiple HPV types on 
slide-based protein microarrays, and Abs to E7 were the immunodominant response in 
cervical cancer patient sera (Luevano et al., 2010). In that study, Abs to E6 and L1, 
although previously reported (Achour et al., 2009; Reuschenbach et al., 2008; Waterboer 
et al., 2005), were not strongly detected, which may be attributable to the larger size of 
these proteins compared with E7, or the difficulties associated with expression, folding, 
and stability using E. coli for protein array generation. No significant difference was 
observed between seroreactivity of patients with precancerous lesions (HSIL) and healthy 
controls, but this needs to be confirmed using independent approaches. Based on our 
experience with autoantigens (K. S. Anderson, D. W. Cramer, et al., 2015; Anderson, 
Sibani, et al., 2011), we predict that the high protein expression levels, antigenic specificity 
and the on-demand cell-free expression system used here may improve detection of HPV 
antigen-specific Abs.  
Programmable protein arrays have also been used to investigate the humoral immune 
response to proteomes of other infectious agents including Pseudomonas aeruginosa (W. 
R. Montor et al., 2009) and Mycobacterium tuberculosis (Prados-Rosales et al., 2014). 
With the advancement in ORFeome collections and consequent reduction in the cost per 
antigen studied, display of full proteomes of pathogens is becoming more feasible. The 
DNASU Plasmid Repository (http://dnasu.asu.edu), comprising a collection of over 
200,000 plasmids encoding proteins from over 600 organisms, was the source of plasmid 
DNA used for these arrays and is widely available for researchers (Seiler et al., 2013). 
Once in the expression vectors, these methods permit rapid conversion from gene panels 
to displayed proteins for immune monitoring within two weeks. In our data, batch-to-batch 
variation was limited and known HPV16 antigenic epitopes were detected. Proteins can 
be displayed in native or denatured forms, which may result in the display of unique 
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epitopes (J. Wang et al., 2013). At this time, PTMs of the in vitro expressed proteins are 
limited. In our experiment, careful attention to quantitative printing of cDNA is important to 
minimize variation.  
The clinical importance of understanding the immunobiology of HPV infection is striking. 
Despite decades of research, the biologic basis by which the majority, but not all, of 
infected individuals clear HPV infections prior to cancer development remains largely 
unknown (M. van Duin et al., 2002; Woodman et al., 2007). In 2012, approximately 
270,000 women died from cervical cancer (Ferlay et al., 2013), and the incidence of 
oropharyngeal cancer is rapidly rising in the US and Europe (Marur et al., 2010; Nasman 
et al., 2009). Biomarkers for the rapid detection of HPV-associated cancers are needed 
for targeted health care delivery on a global scale. Proteome-wide immune monitoring of 
HPV has the potential to identify novel biomarker of diagnosis and prognosis and facilitate 
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ABSTRACT 
The most recent (2012) worldwide estimates from International Agency for Research on 
Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are 
attributed to cervical cancer worldwide. The disease is preventable with HPV vaccination 
and with early detection and treatment of pre-invasive cervical intraepithelial neoplasia, 
CIN. Abs to HPV proteins are under investigation as potential biomarkers for early 
detection. To detect circulating HPV-specific IgG Abs, we developed programmable 
protein arrays (NAPPA) that display the proteomes of two low-risk HPV types (HPV6 and 
11) and ten oncogenic high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52 and 
58). Arrays were probed with sera from women with CIN 0/I (n=78), CIN II/III (n=84), or 
invasive cervical cancer (ICC, n=83). Abs to any early (E) HPV protein were detected less 
frequently in women with CIN 0/I (23.7%) than women with CIN II/III (39.0%) and ICC 
(46.1%, p<0.04). Of the E Abs, anti-E7 Abs were the most frequently detected (6.6%, 
19.5%, and 30.3%, respectively). The least frequently detected Abs were E1 and E2-Abs 
in CIN 0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC (7.9%). HPV16-specific Abs 
correlated with HPV16 DNA detected in the cervix in 0% of CIN 0/I, 21.2% of CIN II/III, 
and 45.5% of ICC. A significant number (29 – 73%) of E4, E7, L1, and L2 Abs had cross-
reactivity between HPV types. HPV protein arrays provide a valuable high-throughput tool 
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for measuring the breadth, specificity, and heterogeneity of the serologic response to HPV 
in cervical disease.  
 
4.1. INTRODUCTION AND BACKGROUND 
Measuring the humoral immune response to HPV Ags has been integral to understanding 
the natural history of infection and efficacy of vaccination (Doorbar et al., 2012; Villa et al., 
2006; Woodman et al., 2007). Despite the potential of HPV serology in disease diagnosis 
and prognosis, its clinical application has been limited by HPV heterogeneity, assay 
variability, and viral immune evasion. HPV has a limited repertoire of proteins, grouped as 
early (E1, E2, E4, E5, E6, E7) and late (L1, L2) proteins. The late proteins form the viral 
protein coat during productive infections. The early proteins interact with host and viral 
proteins to maintain viral replication. The serologic response to genital HPV infection is 
primarily directed at conformational epitopes on the viral major capsid protein L1. As the 
infection is non-lytic, the host Ab response to L1 is weak and may persist for years, as an 
indication of past infection but not malignancy (Luevano et al., 2010; Stanley, 2010). 
Although anti-L1 Abs are an indication of past infection, only 50 – 70% of infected women 
seroconvert (Carter et al., 2000; Dillner, 1999).  
Abs to both HPV16 E6 and E7 proteins have been detected at low levels in both serum 
and cervical-vaginal secretions of invasive cervical cancer (ICC) patients (Bierl et al., 
2005). Their levels increase with cervical disease progression but they are not detectable 
in a subset of patients with cervical cancer (Gutierrez-Xicotencatl et al., 2016; Luevano et 
al., 2010; Reuschenbach et al., 2008; Stanley, 2003). They develop later in the course of 
ICC and are correlated with disease outcome (Gutierrez-Xicotencatl et al., 2016; Ravaggi 
et al., 2006; Silins et al., 2002). Studies of sera collected prior to the diagnosis of cervical 
cancer have shown that the presence of E6 and E7-specific Abs is associated with an 
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increased relative risk (RR=2.7) for cervical cancer, and can be detected, albeit 
infrequently, up to 5 years prior to diagnosis (Lehtinen et al., 2003). The percentage of 
women with false negative serology is dependent on the method of Ab detection (Achour 
et al., 2009; Combes et al., 2014; Kontostathi et al., 2016; Luevano et al., 2010; Waterboer 
et al., 2005; Zumbach et al., 2000).  
The diverse array of oncogenic HPV types and the technical limitations of high throughput 
protein expression and display have been impediments to HPV immune profiling and most 
research has focused on select Ags from the most common viral types (Combes et al., 
2014; Gutierrez-Xicotencatl et al., 2016; Luevano et al., 2010). Nucleic Acid 
Programmable Protein Arrays (NAPPA) (N. Ramachandran et al., 2004; N. 
Ramachandran et al., 2008) have enabled rapid profiling of the serum Ab response in the 
settings of infections (W. R. Montor et al., 2009; Prados-Rosales et al., 2014), autoimmune 
diseases (Bian et al., 2016; Miersch et al., 2013) and cancer (K. S. Anderson, D. W. 
Cramer, et al., 2015; Katchman et al., 2016; J. Wang et al., 2015). To measure the 
serologic responses across multiple HPV types, we adapted the arrays described in 
Chapter 3(Ewaisha, Meshay, Resnik, Katchman, & Anderson, 2016) for the detection of 
HPV-specific IgG Abs in sera. Full length cDNAs encoding the proteomes of 12 HPV types 
are expressed as C-terminal GST fusion proteins using mammalian in vitro 
transcription/translation and captured onto a glass slide surface (J. Wong, S. Sibani, N. N. 
Lokko, J. LaBaer, & K. S. Anderson, 2009). In a pilot study, we demonstrated that HPV 
protein arrays display immunogenic epitopes that can be detected using HPV-specific 
monoclonal Abs (MAbs) and with select sera from HPV-specific malignancies (Ewaisha et 
al., 2016). The purpose of this study was to systematically investigate the serologic 
immune profile to HPV in women with high-grade pre-invasive cervical lesions and ICC, 
and to identify serologic biomarkers for diagnosis and early detection of cervical cancer.  
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4.2. MATERIALS AND METHODS 
4.2.1. Sample Selection 
We used the Biorepository for Molecular Signatures of Cervical Cancer developed by the 
Centers for Disease Control and Prevention as a Clinical Epidemiology and Validation 
Center for NCI’s Early Detection Research Network (EDRN). Samples in the biorepository 
were collected from women attending colposcopy clinics at urban public hospitals in 
Atlanta, GA, Detroit, MI, or Galveston, TX between 2000 and 2010 and linked to 
epidemiologic and clinical data, including HPV detected in exfoliated cervical cells, age, 
race, and tissue confirmation of cervical disease status (Rajeevan et al., 2005). For this 
study, 162 samples from women with cervical intraepithelial neoplasia (CIN) grade 0 (no 
CIN), I, II, III were selected, of which 78 were CIN 0/I and 84 were CIN II/III. We used 83 
archived anonymized plasma samples from women with ICC collected in Atlanta, GA prior 
to 1997. For convenience, the term serum is used throughout the manuscript. While HPV 
vaccine history was not collected, HPV vaccination was not introduced before 2006, and 
it is unlikely that any study participants were vaccinated. Only a subset (n=51) of the ICC 
samples had information on the HPV DNA status of the tumor, of which 24 (47.1%) were 
HPV16+. Samples were collected using a standardized sample collection protocol and 
stored at -80°C until use. Written informed consent was obtained from all subjects under 
institutional review board approval. 
4.2.2. HPV Microarray Generation and Detection of Serum Abs 
Production of custom HPV protein arrays and array quality control experiments were 
performed as previously reported (Ewaisha et al., 2016) with modifications described here. 
In brief, arrays displaying codon-optimized proteomes of 2 low risk (HPV6 and 11) and 10 
high risk (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, and 58) HPV types were generated. The 
codon-optimized HPV16 L1 gene previously used (Ewaisha et al., 2016) was replaced 
 84 
with the non-codon-optimized version, which had higher protein expression. Both codon-
optimized and non-optimized HPV16 E6 and E7 were printed on the arrays for direct 
comparison of Ab reactivity. Since only the non-codon optimized HPV16 E6 and HPV16 
E7 (Ewaisha et al., 2016) showed immunoreactivity, only those results are shown. All non-
codon-optimized genes were obtained by nested PCR using gene-specific primers from 
HPV16 plasmid DNA (American Type Culture Collection, Manassas, VA) as described 
(Anderson, Sibani, et al., 2011). All genes were inserted into pDONR221 vector per 
manufacturer’s instructions (Invitrogen, Carlsbad, CA), and were converted to the 
pANT7_cGST vector (http://dnasu.asu.edu/DNASU/Home.jsp) (N. Ramachandran et al., 
2004). Human IgG and the C-terminal portion of the Epstein-Barr virus-derived Ag EBNA-
1 were used as positive controls. A set of non-HPV related negative control proteins (n=93) 
were printed on the arrays and used for array signal intensity normalization and 
establishment of cut-off values. Arrays were incubated with serum samples diluted 1:50 in 
10% E. coli lysate prepared in 5% milk-PBST (0.2% tween) (J. Wang et al., 2013) and 
serum Ab detection was performed as previously described (K. S. Anderson, D. W. 
Cramer, et al., 2015; Anderson, Sibani, et al., 2011; Ewaisha et al., 2016; J. Qiu & LaBaer, 
2011).  
4.2.3. Protein Array Image Analysis and Quantification 
After serum binding and IgG detection, arrays were scanned by Tecan PowerScanner 
(Tecan Group, Männedorf, Switzerland). ArrayPro Analyzer version 6.3 
(MediaCybernetics, Bethesda, MD) was used to measure the signal intensity of individual 
spots on the scanned slides. Normalization of raw intensity values was performed by 
subtracting the slide background signal and dividing by the background signal subtracted 
from the median intensity of all spots. The slide background signal was determined by the 
first quartile of signal intensity of the no-DNA control spots (all material except DNA). In 
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addition, array images were qualitatively inspected to identify and confirm positive 
responses by adjusting raw images to extreme brightness and contrast using ArrayPro 
Analyzer and visual analysis of diffused signal (ring) as described previously (W. R. 
Montor et al., 2009; J. Wang et al., 2015). Each spot was scored based on the intensity 
and morphology of the ring on a scale of 0 to 5. 
4.2.4. HPV DNA Detection by L1 Consensus PCR 
For all the samples from the biorepository, HPV DNA was detected in extracts of exfoliated 
cervical cells collected in PreservCyt media as previously described (Rajeevan et al., 
2005). Briefly, 16 ml of the PreservCyt collection media was extracted using MasterPure 
Complete DNA and RNA purification kit (Epicentre, Madison, WI). HPV detection and 
typing was performed using the Roche linear array that detects 37 types. HPV results for 
the anonymized archived cervical cancer cases (n=83) were based on combined results 
of colorimetric ISH for HPV16, 18, 31, 33, 35 on formalin-fixed paraffin embedded tissue 
sections and L1 consensus PCR with MY09/11 primers and type-specific hybridization to 
6 HR types (16, 18, 31, 33, 35, 45) on DNA extracts from the same tissues (methods in 
use at the time of archiving (Unger, Vernon, Lee, Miller, & Reeves, 1998)).  
4.2.5. Statistical Analysis 
The correlation of raw signal intensities of protein expression between the arrays randomly 
selected for quality control was determined with scatter plots and the Pearson correlation 
coefficient (R) was calculated to assess consistency. Levels of protein expression on the 
arrays were measured by calculating the mean values of raw signal intensities of duplicate 
spots from two arrays. For serum Ab reactivity on protein arrays, mean values (of duplicate 
spots for a given Ag) of normalized signal intensity were compared for different disease 
groups using Fisher’s exact test (Graphpad Prism version 5.0c, San Diego, CA). A p-value 
of <0.05 was considered significant. Seropositivity for any given Ag was defined as the 
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median of normalized signal intensity values of all negative control proteins (n=93) in all 
sera (n=234) +3 standard deviations or spots that were positive by visual analysis. A total 
of 245 serum samples were tested on the arrays, of which 11 (4.5%; n=7 ICC, n=4 CIN) 
were excluded from the analysis due to high background. High array background was 
defined as an array with normalized signal intensity values for ≥14 out of 93 negative 
control spots exceeding the 75th percentile + 1.5*interquartile range of this negative 
control protein across all arrays. 
 
4.3. RESULTS 
4.3.1. Characteristics of Study Samples 
Our primary goal was to determine the prevalence and specificity of HPV-specific Ab 
responses in women with cervical cancer precursors and with ICC. Age, race, and HPV 
DNA status of patients contributing samples to the study are shown in Table 4-1. Ab levels 
were compared in women with CIN 0/I (n=78) and CIN II/III (n=84) who were referred to 
colposcopy because of abnormalities in cervical cancer screening, and in women with ICC 
(n=83). Women with CIN 0/I were chosen as the relevant control population to determine 
the utility of these biomarkers within a high-risk population. As expected, women with CIN 
0/I had a lower frequency of cervical high-risk (HR) HPV than women with CIN II/III (57.7% 
vs. 97.6%, p<0.0001). Infection with 2 or more HPV types was detected in more than 35% 
of women in both CIN 0/I and CIN II/III (Table 4-1). Women with CIN II/III were as expected 
significantly younger than women with ICC (mean 30.0 yrs vs. 52.0 yrs, p<0.0001). There 
was also a lower frequency (p<0.0015) of HPV16 in CIN 0/I (19.2%) than CIN II/III (63.1%) 
and ICC (47.1%). The clinics participating in the EDRN study had a high proportion of 




Table 4-1. Characteristics of Study Samples. 
Characteristics Disease Status 
CIN 0/I 
N = 78 
CIN II/III 
N = 84 
ICC 
N = 83 
N (%) N (%) N (%)* 
Age in yrs, Mean 28.7  30.0   52.0 
  < 30 51 (65.3) 45 (53.6) 3/79 (3.8) 
  ≥ 30 27 (34.6) 39 (46.4) 76/79 (96.2) 
Race    
  Black  71 (91.0) 55 (65.5) 64/79 (81.0) 
  Other 7 (9.0) 29 (34.5) 15/79 (19.0) 
HPV16 DNA status†    
  HPV16+ 15 (19.2) 53 (63.1) 24/51 (47.1) 
HPV DNA status overall†    
  Negative 23 (29.5) 2 (2.4) 12/51 (23.5) 
  1 HPV type 29 (37.2) 46 (54.8) 39/51 (76.5) 
  2 HPV types 10 (12.8) 19 (22.6) 0/51 (0) 
  ≥ 3 HPV types 16 (20.5) 17 (20.2) 0/51 (0) 
  Any HR HPV‡ 45 (57.7) 82 (97.6) 39/51 (76.5) 
*N varies for each category because of missing information. The numbers of samples are 
shown.  
†HPV testing methods used for anonymized archived samples differed from those used in 
biorepository, so results are not directly comparable.  
‡The following HPV types were considered as high-risk types for this analysis -HPV16, 18, 




4.3.2. Production and Reproducibility of NAPPA HPV Protein Arrays 
The quality and reproducibility of the array printing were evaluated by picogreen staining 
of DNA and measuring protein expression with anti-GST Abs (Figure 4-1A). Three arrays 
were printed on each slide and the correlation coefficients of anti-GST signal intensities 
were determined for intra-array (R=0.98) and intra-batch replicate arrays (R=0.90) from 
two subarrays on the same slide or two randomly selected slides within the print batch 




Figure 4-1. Reproducibility of Printing and Protein Expression on NAPPA. (A) Left: 
Picogreen staining to detect DNA content printed on the microarrays. Right: Image of anti-
GST binding to measure the level of protein display. (B) Plots of protein signal intensities 
from all spots from two subarrays on the same slide or two randomly selected slides within 
the print run. 
 
 
4.3.3. HPV-Specific Ab Prevalence 
There was no significant difference (p=0.46) in the percentages of negative control spots 
(displaying the non-HPV related proteins; n=93) that exceeded the cut-off value between 
arrays probed with CIN 0/I (0.71%), CIN II/III (0.81%), and ICC (1.77%) sera.  
The prevalence of HPV-specific serum IgG Abs among women with CIN 0/I, CIN II/III, and 
ICC is summarized in Table 4-2. At least one of the HPV-specific Abs was detected in 
serum from women with CIN 0/I (46.1%), CIN II/III (59.8%), and ICC (68.4%). Abs to any 
early (E) HPV protein were detected more frequently in women with ICC (46.1%) and CIN 
II/III (39.0%) than women with CIN 0/I (23.7%, p<0.04). Abs to any L1 protein had the 
highest prevalence (28.9%, 34.1%, and 44.7% in CIN 0/I, CIN II/III, and ICC, respectively). 
Of the E Abs, anti-E7 Abs were the most frequently detected (CIN 0/I, 6.6%; CIN II/III, 
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19.5%; and ICC, 30.3%). The least frequently detected Abs were E1 and E2-Abs in CIN 
0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC (7.9%). The sensitivity [proportion of 
cases with at least one HPV Ag-specific Ab detected] was comparable when restricted to 
cases known to have HPV16 (as opposed to any other oncogenic HPV) DNA detected; 
59.6% vs 59.8% for CIN II/III and 81.8% vs 68.4% for ICC, (p-value N.S.). Among all 
women (irrespective of HPV DNA status), Abs to HPV16 Ags were detected in only 6.6%, 
19.5%, and 35.5% in CIN 0/I, CIN II/III, and ICC, demonstrating the importance of multi-
antigenic immunoprofiling. 
 
Table 4-2. Prevalence of Positive Antibody Response (1) to Each HPV Protein From Any HPV 
Type (2). 
 No. + (%) 
 CIN 0/I CIN II/III ICC Total 
 Total HPV16+(3) Total HPV16+(3) Total HPV16+(3)  
HPV Antibodies N=76 N=14 N=82 N=52 N=76 N=22(4)  
E1 1 (1.3) 0 (0) 1 (1.2) 0 (0) 6 (7.9)* 1 (4.5) 8 (3.4) 
E2 1 (1.3) 0 (0) 4 (4.9) 1 (1.9) 11 (14.5) 5 (22.7) 16 (6.8) 
E4 5 (6.6) 0 (0) 14 (17.1) 5 (9.6) 12 (15.8) 4 (18.2) 31 (13.2) 
E5 5 (6.6) 1 (7.1) 4 (4.9) 3 (5.8) 12 (15.8) 6 (27.3) 21 (9.0) 
E6 3 (3.9) 0 (0) 8 (9.8) 5 (9.6) 12 (15.8)* 5 (22.7) 23 (9.8) 
E7 5 (6.6) 0 (0) 16 (19.5)* 10 (19.2) 23(30.3)* 8 (36.4)* 44 (18.8) 
Any E (2) 18 (23.7) 2 (14.3) 32 (39.0)* 19 (36.5) 35 (46.1)* 15 (68.2)* 85 (36.3) 
L1 22 (28.9) 4 (28.6) 28 (34.1) 16 (30.8) 34 (44.7) 12 (54.5) 84 (35.9) 
L2 8 (10.5) 0 (0) 5 (6.1) 5 (9.6) 13 (17.1) 6 (27.3) 26 (11.1) 
Any L (2) 25 (32.9) 4 (28.6) 32 (39.0) 20 (38.5) 38 (50.0) 14 (63.6)* 95 (40.6) 
Any E and/or L(2) 35 (46.1) 4 (28.6) 49 (59.8) 31 (59.6) 52 (68.4)* 18 (81.8)* 136 (58.1) 
Any HPV16 Ag 5 (6.6) 0 (0) 16 (19.5)* 11 (21.2) 27 (35.5)* 10 (45.5)* 48 (20.5) 
(1) Cut-off values defined as the median of normalized signal intensity values of all negative control proteins +3 
standard deviations in all sera (n=234) or spots that were positive by visual analysis. 
(2) Any positive vs. all negative from any of the 12 HPV types tested. 
(3) HPV16 DNA detected in cervix. HPV testing methods used for anonymized archived samples differed from those 
used in biorepository. 
(4) HPV DNA status was known for only a subset (n=51) of the ICC samples. 




4.3.4. Type-Specific Ab Response 
To determine whether patients with a specific HPV infection develop type-specific Abs, 
there are multiple challenges. First, a significant number of women with CIN have multiple 
HPV types detected (33.3% of CIN 0/I and 42.8% of CIN II/III, Table 4-1), and past 
exposure to other HPV types cannot be excluded. Second, there is likely serologic cross-
reactivity across HPV types. Figure 4-2A shows Abs from an ICC patient reacting with E4 
protein from 4 different HPV types (16, 31, 35, and 45). As examples, Figures 4-2B and 
4-2C show serum from two women with CIN II/III with HPV16 DNA and Abs against HPV16 
E4 and HPV52 E4 (B) and HPV 58 E4 (C).  
To determine whether there is any correlation between HPV DNA types detected in the 
patient and type-specific serum Abs, we analyzed the data in two ways. In Table 4-3, 
subjects were stratified based on cervical HPV DNA status. For example, among women 
with successful Ab testing, cervical HPV16 DNA was detected in 18.4% of those with CIN 
0/I; 63.4% of CIN II/III; and 46.8% of ICC. The type-specific Ab detection rate in this group 
was 0%, 21.2%, and 45.5% for CIN 0/I, CIN II/III and ICC. For the most common HPV 
DNA detected in cervical samples in CIN II/III, HPV16, 31, 35, and 52, the range of 
detection of type-specific Abs was 8.3 – 25.0%. In Table 4-4, subjects were stratified by 
type-specific seropositivity to evaluate the proportion with detection of type-specific HPV 
DNA in the cervix. Women with HPV16 Abs and CIN II/III had the highest type-specific 





Figure 4-2. Detection of IgG in Human Serum Using HPV Protein Arrays. (A) 
Detection of IgG Abs in serum from a patient with ICC. Immunoreactivity to the positive 
control EBV EBNA-1 protein, and HPV E4 protein from 4 different HPV types (16, 31, 35, 
and 45) are detected. (B) and (C) Detection of IgG Abs in sera from two women with CIN 
II/III. Immunoreactivity to HPV16 E4, HPV52 E4 (B) and HPV58E4 (C) as well as EBNA-
1 protein, is shown. Dark spots represent the individual proteins (HPV Ags and non HPV-
related controls in random order) displayed on the arrays after adjusting the raw images 


















 Total Ab+(3) Total Ab+(3) Total Ab+(3) 
HPV6 3 1 (1.3) 0 (0) 2 (2.4) 0 (0) 0 (0) 0 (0) 
11 2 1 (1.3) 0 (0) 1 (1.2) 0 (0) 0 (0) 0 (0) 
16 88 14 (18.4) 0 (0) 52 (63.4) 11 (21.2) 22 (46.8) 10 (45.5) 
18 16 3 (3.9) 1 (33.3) 5 (6.1) 1 (20.0) 8 (17.0) 2 (25.0) 
31 20 2 (2.6) 0 (0) 16 (19.5) 4 (25.0) 2 (4.3) 0 (0) 
33 10 2 (2.6) 0 (0) 5 (6.1) 0 (0) 3 (6.4) 1 (33.3) 
35 16 5 (6.6) 2 (40.0) 10 (12.2) 2 (20.0) 1 (2.1) 1 (100.0) 
39 5 3 (3.9) 1 (33.3) 2 (2.4) 1 (50.0) 0 (0) 0 (0) 
45 10 5 (6.6) 1 (20.0) 5 (6.1) 1 (20.0) 0 (0) 0 (0) 
51 7 4 (5.3) 1 (25.0) 2 (2.4) 0 (0) 1 (2.1) 0 (0) 
52 21 9 (11.8) 1 (11.1) 12 (14.6) 1 (8.3) 0 (0) 0 (0) 
58 14 10 (13.2) 1 (10.0) 3 (3.7) 0 (0) 1 (2.1) 0 (0) 
  
 
Table 4-4. Prevalence of Type-Specific HPV DNA in Women with Known Seropositivity. 












 Total DNA+(5) Total DNA+(5) Total DNA+(5) 
HPV6 24 4 (5.3) 0 (0) 10 (12.2) 0 (0) 10 (13.2) 0 (0) 
11 25 5 (6.6) 0 (0) 8 (9.8) 0 (0) 12 (15.8) 0 (0) 
16 46 5 (6.6) 0 (0) 14 (17.1) 11 (78.6) 27 (35.5) 10 (37.0) 
18 50 11 (14.5) 1 (9.0) 15 (18.3) 1 (6.7) 24 (31.6) 2 (8.3) 
31 37 5 (6.6) 0 (0) 11 (13.4) 4 (36.4) 21 (27.6) 0 (0) 
33 58 14 (18.4) 0 (0) 18 (22.0) 0 (0) 26 (34.2) 1 (3.8) 
35 78 21 (27.6) 2 (9.5) 19 (23.2) 2 (10.5) 38 (50.0) 1 (2.6) 
39 51 10 (13.2) 1 (10.0) 20 (24.4) 1 (5.0) 21 (27.6) 0 (0) 
45 26 5 (6.6) 1 (20.0) 4 (4.9) 1 (25.0) 17 (22.4) 0 (0) 
51 24 5 (6.6) 1 (20.0) 6 (7.3) 0 (0) 13 (17.1) 0 (0) 
52 31 5 (6.6) 1 (20.0) 7 (8.5) 1 (14.2) 19 (25.0) 0 (0) 
58 18 4 (5.3) 1 (25.0) 5 (6.1) 0 (0) 9 (11.8) 0 (0) 
(1) of women with the corresponding HPV DNA type in the cervix.  
(2) The ICC samples with unknown tumor DNA status were excluded from the analysis in 
table 3A. 
(3) Positive for any Ab specific to the given HPV type. 
(4) of women with serum Abs to any Ag of the corresponding HPV type. 




4.3.5. Cross-Reactivity of Serologic Responses 
We determined the prevalence of Abs against homologous Ags (i.e. all E7 Ags) from more 
than one HPV type in all sera (n=234) from the three cervical disease groups under 
investigation (Table 4-5). Abs against L2 were the most cross-reactive, while anti-E1 Abs 
were the least cross-reactive. Of sera that had Abs against any L2 Ag, 57.7% were positive 
for L2 from at least 6 HPV types. For E1, all 8 women who had specific Abs were positive 
for E1 from only one HPV type. 8.1% of all women had Abs to E7 from at least 2 HPV 
types. The percentages of sera with cross-reactive Abs to at least one other HPV type 
were as follows: E2 (6.3%), E4 (29.0%), E5 (14.3%), E6 (17.4%), E7 (43.2%), L1 (39.3%), 
and L2 (73.1%). 
 




Abs(1)  E1 E2 E4 E5 E6 E7 L1 L2 
 No.  0 1 7 3 1 10 17 3 
=2 % of total(2)  0.0 0.4 3.0 1.3 0.4 4.3 7.3 1.3 
 % of positive(3) 0.0 6.3 22.6 14.3 4.3 22.7 20.2 11.5 
 No.  0 0 1 0 3 9 9 1 
=3 % of total(2)  0.0 0.0 0.4 0.0 1.3 3.8 3.8 0.4 
 % of positive(3) 0.0 0.0 3.2 0.0 13.0 20.5 10.7 3.8 
 No.  0 0 1 0 0 3 3 0 
=4 % of total(2)  0.0 0.0 0.4 0.0 0.0 1.3 1.3 0.0 
 % of positive(3) 0.0 0.0 3.2 0.0 0.0 6.8 3.6 0.0 
 No.  0 0 0 0 0 0 2 0 
=5 % of total(2) 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 
 % of positive(3) 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 
 No.  0 0 0 0 0 1 2 15 
≥6 % of total(2)  0.0 0.0 0.0 0.0 0.0 0.4 0.9 6.4 
 % of positive(3) 0.0 0.0 0.0 0.0 0.0 2.3 2.4 57.7 
(1) Number of homologous Ags from different HPV types to which Abs were detected in 
sera from all three disease groups (n=234). 
(2) Percentage of women who had Abs to a given Ag from one or more HPV types over 
the total number of women. 
(3) Percentage of women who had Abs to a given Ag from multiple HPV types over the 
number of women who had Abs to this Ag from at least one HPV type. 
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4.4. DISCUSSION 
There is a clinical need for circulating biomarkers that identify high-risk HPV infection for 
early detection and treatment of cervical disease. Here, we have used our custom HPV 
protein microarrays, displaying the proteomes of two low-risk and ten high-risk HPV types, 
to characterize the diversity of the immune response in cervical cancer and in pre-invasive 
cervical disease. We find that 20 – 46% of patients with CIN and ICC have a broad range 
of Abs to HPV early proteins in their sera and these biomarkers correlate with disease 
severity.  
Up to 80% of patients with HPV-associated oropharyngeal cancer (HPVOPC) have 
detectable serum HPV16 Abs to E Ags (K. S. Anderson, K. R. Dahlstrom, et al., 2015; K. 
S. Anderson, J. E. Gerber, et al., 2015; Kreimer et al., 2013). Abs against the oncogenic 
proteins E6 and E7 are also highly specific to ICC. As a result, most cervical cancer studies 
have focused on E6, E7, and L1 Abs from HPV16 and 18 (Achour et al., 2009; Gutierrez-
Xicotencatl et al., 2016; Reuschenbach et al., 2008; Waterboer et al., 2005). In the only 
previous study of Abs to entire HPV proteomes using slide-based protein microarrays, 
high levels of Abs were detected against E7 but not E6 or L1 in ICC sera, possibly due to 
the difficulty of expressing larger-sized proteins (Luevano et al., 2010). In that study and 
others (Gutierrez-Xicotencatl et al., 2016; Lehtinen et al., 2003; Stanley, 2003), no 
significant difference in Ab response between CIN II/III and asymptomatic controls was 
detected.  
While L-specific Abs were detected in serum from women in all three groups of cervical 
disease in our study, Abs against any E protein were, as expected, more prevalent in ICC 
and CIN II/III than women with CIN 0/I. Anti-E7 Abs were the most frequently detected E-
Abs, and our data of E7-specific Abs in ICC is consistent with previous studies. Using 
ELISA (Achour et al., 2009; Silins et al., 2002; Tjiong et al., 2001) and Luminex bead 
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arrays (Castellsague et al., 2014; Lang Kuhs et al., 2015; Reuschenbach et al., 2008), 
anti-E7 Abs were detected in 13 – 53% of women with ICC and in ~60% of ICC (and 10% 
of healthy controls) using protein microarrays (Luevano et al., 2010).  
As cervical disease progresses towards malignancy, infectious viral particle production 
becomes limited to a small area near the surface of the cervical epithelium (Doorbar, 2006; 
Griffin et al., 2012). E4 plays a role in viral synthesis and possibly viral release (Doorbar, 
2013). The expression of E4 in CIN II and III is restricted to this subset of cells and is 
generally lost in ICC (Doorbar, 2006). Expression of E4 protein in tissue has been 
proposed as an early detection marker (Griffin et al., 2012) but specific serum Abs may 
provide a more convenient detection method. Our data show that E4-specific Abs develop 
early in disease progression, with 16 – 17% prevalence in both CIN II/III and ICC. Anti-E4 
Abs have been reported in sera from women with CIN II/III (34%) and ICC (29%) (Pedroza-
Saavedra et al., 2000), which is consistent with our findings and the predicted level of E4 
expression especially in CIN II/III.  
Viral integration into the host genome, with loss of E2 expression, is a frequent hallmark 
of HPV-associated cancers, leading to derepression of E6 and E7 expression. Since E2 
Ag is expressed in CIN II/III (Xue et al., 2010), we predicted that E2 Abs would also be 
detected early in CIN II/III. E2-specific Abs were detected in both CIN II/III (4.9%) and at 
higher (p<0.05) frequency in ICC (14.5%) but were at low prevalence. E2-specific IgG Abs 
have been reported in 24% of women with CIN I-III (compared to 13% of healthy controls) 
(Marais, Rose, & Williamson, 1997) and in 12% of women with ICC (compared to 2% of 
healthy controls) (Combes et al., 2014), consistent with our data. Since the majority (64%) 
of patients with HPVOPC have Abs against HPV16 E2 (K. S. Anderson, K. R. Dahlstrom, 
et al., 2015; K. S. Anderson, J. E. Gerber, et al., 2015), our data suggest that these two 
tumor sites may have significant differences in viral integration and expression of E2 Ag, 
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or exposure of E2 Ag to B cells. In cervical disease, E1 Abs have been reported to have 
a low prevalence (10% and 0.3% in ICC and healthy controls, respectively) (Combes et 
al., 2014). We also found an overall low prevalence of anti-E1 Abs in cervical disease, as 
opposed to a 60% prevalence in HPVOPCs (K. S. Anderson, K. R. Dahlstrom, et al., 2015; 
K. S. Anderson, J. E. Gerber, et al., 2015).  
Only a few studies have investigated the immune response against multiple HPV types 
(Combes et al., 2014; Gutierrez-Xicotencatl et al., 2016; Luevano et al., 2010; Waterboer 
et al., 2005). Only one study displayed multiple HPV proteomes on protein arrays 
(Luevano et al., 2010) and the others have used glutathione S-transferase-based multiplex 
serology to evaluate serum Abs against only E6, E7, and L1 Ags from multiple HPV types 
(Combes et al., 2014; Waterboer et al., 2005). The question of cross-reactivity of Abs 
against Ags from closely-related viral types has therefore not been adequately addressed. 
We and others have previously demonstrated that MAbs raised against specific HPV 
proteins may cross-react with homologous proteins from different HPV types due to 
sequence similarity (Ewaisha et al., 2016; Luevano et al., 2010). Here, we detected cross-
reactive Abs including against the E4 Ag. The E4 ORF is the most divergent between HPV 
types (Bell et al., 2007). The range of amino acid sequence similarity between E4 from the 
non-HPV16 types detected in the 3 sample sera illustrated in Figure 4-2 and HPV16 E4 
is 42 – 59%. It is therefore not known if Abs to multiple homologous E4 proteins reflect 
cross-reactivity with conserved epitopes or prior multiple HPV infections. We also 
observed Abs against L2 from at least 6 HPV types in 57.7% of women who had L2-
specific Abs (Table 4-4), which likely indicates cross-reactivity, given the high (46 – 63%) 
sequence conservation of the L2 protein, and the interest in developing it as a vaccine 
(Karanam, Jagu, Huh, & Roden, 2009). Abs against L1 from three or more HPV types 
were also detected in 19% of women positive for L1 Abs. This is consistent with previously 
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reported L1 cross-reactivity detected by an HPV16 L1-specific MAb (Luevano et al., 2010). 
Overall, these data suggest that these HPV arrays will have limited utility as surrogate 
markers for HPV typing.  
While not directly compared in this study, the signal intensity of Ab binding on the arrays 
(Ewaisha et al., 2016) and on RAPID ELISA (K. S. Anderson, K. R. Dahlstrom, et al., 2015; 
K. S. Anderson, J. E. Gerber, et al., 2015) are consistently weaker in cervical disease than 
in HPVOPC (unpublished observations). Additionally, despite tissue expression of the 
oncoproteins E6 and E7 in ICC, we and others (Luevano et al., 2010; Reuschenbach et 
al., 2008; Stanley, 2003) have reported specific serum Abs in less than half of the patients, 
while they are detected in up to 75% of HPVOPC cases (K. S. Anderson, K. R. Dahlstrom, 
et al., 2015). Anti-E6 Abs have been detected in HPVOPC and cervical cancer cases 
years prior to the establishment of a clinical diagnosis (Kreimer et al., 2013; Lehtinen et 
al., 2003), suggesting these may be useful for early detection. The Ab response to the E 
proteins in high grade pre-invasive cervical lesions, however, has been difficult to detect 
in previous studies (Lehtinen et al., 2003; Luevano et al., 2010; Stanley, 2003). Even 
though we detect E-specific Abs in a subset of CIN II/III, the frequencies are low. The 
presence of both viral DNA and viral oncoproteins in HPVOPC tumors suggest that both 
cancer sites have similar pathogenetic mechanisms (Gillison et al., 2008). Therefore, it is 
likely that the close proximity of lymphoid tissue in the tonsils results in a more potent 
immune induction in HPVOPC compared with cervical disease.  
The lack of infrastructure and resources in LMICs hampers large-scale implementation of 
Pap test screening (Kontostathi et al., 2016; Wentzensen & von Knebel Doeberitz, 2007; 
Wright, 2006). In low-resource environments, visual examination with acetic acid (VIA) is 
an inexpensive alternative (Sankaranarayanan et al., 2007). It results in a 25% reduction 
in cervical cancer incidence and a 35% reduction in cervical cancer mortality after a single 
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screen (Sankaranarayanan et al., 2007; Shastri et al., 2014), with significant downstaging 
of cervical cancers (Shastri et al., 2014). However, VIA has low sensitivity in women older 
than 50 years, poor reproducibility between operators and it requires continuous training 
and supervision. The absence of HPV nucleic acid in the cervix is a good negative 
predictor of cervical disease but HPV testing is not recommended for women <30 years 
old because transient infection reduces specificity (Arbyn et al., 2012; Goodman, 2015). 
In pooled analyses, HPV testing is more sensitive (90 – 95% for CIN II/III) than cervical 
cytology alone or VIA but lacks the specificity (89%) for a reliable biomarker (Arbyn et al., 
2012). To date, there are no established tissue, blood, or vaginal biomarkers other than 
HPV nucleic acid and cytology for CIN II/III in high risk patients. Biomarkers such as 
serology that identify high-risk HPV infection and invasive cervical cancers (ICC) could 





CHAPTER 5 : IDENTIFICATION OF CIRCULATING MARKERS OF PRE-EXISTING 
IMMUNITY TO STREPTOCOCCUS PYOGENES CRISPR/CAS9 IN HUMANS 
 
This chapter is in revisions in Nature Communications and has been published as a 
preprint on BioRxiv: 
Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. 
R., and Anderson, K. S. (2018). Multifunctional CRISPR/Cas9 with engineered 
immunosilenced human T cell epitopes. bioRxiv. 
 
ABSTRACT 
The application of Cas9 protein for genetic and epigenetic therapies in humans raises 
concerns over immunogenicity of this foreign protein. This chapter investigates potential 
biomarkers of immunity to the CRISPR/Cas9 system that is currently in clinical trials for 
cancer. Pre-existing B cell and T cell immune responses to the Streptococcus pyogenes 
Cas9 protein were detected in humans. Two immunodominant T cell epitopes for HLA-
A*02:01 were identified and a single mutation in the anchor residue of one or both of these 
epitopes significantly reduced the protein immunogenicity while maintaining its function 
and specificity in the CRISPR/Cas9 system. The identified immune responses could serve 
as immune biomarkers that help guide decisions of using this therapeutic in humans. 
 
5.1.  INTRODUCTION AND BACKGROUND 
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 
technology has raised hopes for developing personalized gene therapies for complex 
diseases such as cancer as well as genetic disorders, and is currently entering clinical 
trials (Cyranoski, 2016; Reardon, 2016). The history of gene therapy has included both 
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impressive success stories and serious immunologic adverse events (Cavazzana-Calvo 
et al., 2000; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2002; Howe et al., 2008; Manno 
et al., 2006; Marshall, 1999). The expression of Streptococcus pyogenes Cas9 protein 
(SpCas9) in mice has evoked both cellular and humoral immune responses (Chew et al., 
2016; D. Wang et al., 2015), which raises concerns regarding its safety and efficacy as a 
gene or epi-gene therapy in humans. These pre-clinical models and host immune 
reactions to other exogenous gene delivery systems (Mays & Wilson, 2011; Federico 
Mingozzi & High, 2013; Yin et al., 2014) suggest that the pathogenic “non-self” origin of 
Cas9 may be immunogenic in humans.  
Both B cell and T cell host responses specific to either the transgene or the viral 
components of adenoviral (Ahi, Bangari, & Mittal, 2011; Aldhamen & Amalfitano, 2016) 
and adeno-associated viral (AAV) (Mays & Wilson, 2011; Federico Mingozzi & High, 2013) 
vectors have been detected, despite relatively low immunogenicity of AAV vectors. In the 
case of AAV, specific neutralizing Abs and T cells are frequently detected in healthy 
donors (Boutin et al., 2010; F. Mingozzi et al., 2007; Scallan et al., 2006; Thwaite et al., 
2015) and, specific CD8+ T cells have been shown to expand following gene delivery (F. 
Mingozzi et al., 2007). There has been recent progress in developing strategies to 
overcome this problem, such as capsid engineering and transient immunosuppression 
(Bartel, Schaffer, & Buning, 2011; Martino et al., 2013; F. Mingozzi et al., 2013). The 
potential consequences of immune responses to expressed proteins from viral vectors or 
transgenes include neutralization of the gene product; destruction of the cells expressing 
it, leading to loss of therapeutic activity or tissue destruction; induction of immune memory 
that prevents re-administration; and fulminant innate inflammatory responses (Brunetti-
Pierri & Ng, 2009; Halbert et al., 1998; H. Jiang et al., 2006; Kay, 2011; Nathwani et al., 
2011; Nayak & Herzog, 2010). More potent immune responses to gene therapies have 
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been observed in humans and non-human primate models compared to mice (Gao et al., 
2009; Manno et al., 2006).  
Of the Cas9 orthologs derived from bacterial species (Esvelt et al., 2013; Hirano et al., 
2016; Jinek et al., 2014; Ran et al., 2015; Zetsche et al., 2015), the SpCas9 is the best 
characterized. S. pyogenes is a ubiquitous pathogen, with an annual incidence of 700 
million worldwide (Carapetis, Steer, Mulholland, & Weber, 2005), but immunity to SpCas9 
in humans has not been reported. Here, we sought to characterize the pre-existing 
immune response to SpCas9 in healthy individuals and to identify the immunodominant T 
cell epitopes with the aim of developing SpCas9 proteins that have diminished capacity to 
invoke human adaptive response. 
 
5.2. METHODS 
5.2.1. Detection of Cas9-Specific Serum Abs in Healthy Controls 
Healthy control sera (n = 183) used in this study, and previously described 47, are a subset 
of a molecular epidemiology study of head and neck cancer at the MD Anderson Cancer 
Center, collected between January 2006 and September 2008. S. pyogenes lysate was 
prepared by sonication of bacterial pellets from overnight cultures of S. pyogenes ATCC 
19615 in the presence of 1 pill of cOmplete Protease Inhibitor (Sigma-Aldrich) after 3 
cycles of freezing and thawing. Serum Ab detection was performed using ELISA. 96-well 
plates were coated with 20 μg/mL of recombinant S. pyogenes Cas9 nuclease (New 
England Biolabs, Ipswich, MA) or S. pyogenes lysate. Sera were diluted 1:50 in 10% E. 
coli lysate prepared in 5% milk-PBST (0.2% tween) 48, incubated with shaking for 2 hrs 
at room temperature, and added to the specified wells in duplicate. Horseradish 
peroxidase (HRP) anti-human IgG Abs (Jackson ImmunoResearch Laboratories, West 
Grove, PA) were added at 1:10,000, and detected using Supersignal ELISA Femto 
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Chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA). Luminescence 
was detected as relative light units (RLU) on a Glomax 96 Microplate Luminometer 
(Promega, Madison, WI) at 425 nm. To establish cut-off values, a RLU ratio > (the mean 
+ 3 standard deviations) of 125 randomly chosen control samples was designated positive 
(Fig. 5-1, dotted and dashed lines for bacterial lysate and Cas9 protein, respectively). 
5.2.2. Cas9 Candidate T cell Epitope Prediction 
We used our previously described prediction strategies (Chowell et al., 2015; Krishna & 
Anderson, 2016) to predict candidate Cas9 T cell epitopes. Briefly, we predicted MHC 
class I restricted 9-mer and 10-mer candidate epitopes derived from the Cas9 protein 
(Uniprot - Q99ZW2) for HLA A*02:01. The protein reference sequence was entered into 5 
different prediction algorithms; 3 MHC-binding: IEDB-consensus binding (Moutaftsi et al., 
2006), NetMHCpan binding (Hoof et al., 2009), Syfpeithi (Rammensee, Bachmann, 
Emmerich, Bachor, & Stevanović, 1999) and 2 antigen-processing algorithms: IEDB-
consensus processing, ANN processing (Tenzer et al., 2005). The individual scores from 
each of the prediction algorithms were then normalized within the pool of predicted 
peptides after exclusion of poor binders as previously detailed (Chowell et al., 2015; 
Krishna & Anderson, 2016), and the average normalized binding scores were used to re-
rank the candidate peptides. The top 38 candidate peptides (Table 5-1) were selected for 
experimental testing.  
In brief, the IEDB consensus MHC-binding prediction algorithm (http://www.iedb.org/) was 
applied to obtain a list of high binding Cas9 peptides, each of which was assigned a 
normalized binding score (Sb). The immunogenicity score (Si) was calculated for each 




5.2.3. Ex vivo Stimulation and Epitope Mapping of Cas9 by ELISpot 
All peripheral blood mononuclear cells (PBMCs) were obtained from healthy individuals 
using informed consent, protocol MOD00006783 under ASU’s Institutional Review Board. 
PBMCs were isolated from fresh heparinized blood by Ficoll–Hypaque (GE Healthcare, 
UK) density gradient centrifugation and stimulated as previously described (Krishna & 
Anderson, 2016). Briefly, predicted Cas9 peptides with Sb < 0.148 (N=38) were 
synthesized (> 80% purity) by Proimmune, UK. Each peptide was reconstituted at 1mg/mL 
in sterile PBS and pools were created by mixing 3-4 candidate peptides. Sterile 
multiscreen ELISpot plates (Merck Millipore, Billerica, MA, USA) were coated overnight 
with 5μg/well of anti-IFN-γ capture Ab (clone D1K, Mabtech, USA) diluted in sterile PBS. 
Frozen PBMCs were thawed rapidly and recombinant human IL-2 (20U/mL, R&D 
Systems) was added. They were then stimulated in triplicates with 10μg/mL Cas9 peptide 
pools (or individual peptides), pre-mixed CEF pool as a positive control (ProImmune, UK), 
or DMSO as a negative control in the anti-IFN-γ-coated ELISpot plates, (Merck Millipore, 
Billerica, MA, USA) and incubated in a 37°C, 5% CO2 incubator for 48 hrs. Plates were 
washed three times for 5 min each with ELISpot buffer (PBS + 0.5% FBS) and incubated 
with 1μg/mL anti-IFN-γ secondary detection Ab (clone 7-B6-1, Mabtech, USA) for 2 hrs at 
room temperature, washed and incubated with 1μg/mL Streptavidin ALP conjugate for 1 
hr at room temperature. The wells were washed again with ELISpot buffer and spots were 
developed by incubating for 8-10 min with detection buffer (33μL NBT, 16.5μL BCIP, in 
100mM Tris-HCl pH 9, 1mM MgCl2, 150mM NaCl). Plates were left to dry for 2 days and 
spots were read using the AID ELISpot reader (Autoimmun Diagnostika GmbH, Germany). 
The average number of spot forming units for each triplicate was calculated for each test 
peptide or peptide pool and subtracted from the background signal.  
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5.2.4. Autologous APC Generation from Healthy Individual PBMCs 
Autologous CD40L-activated B cell APCs were generated from healthy donors by 
incubating whole PBMCs with irradiated (32 Gy) K562-cell line expressing human CD40L 
(KCD40L) at a ratio of 4:1 (800,000 PBMCs to 200,000 irradiated KCD40Ls) in each well. 
The cells were maintained in B cell media (BCM) consisting of IMDM (Gibco, USA), 10% 
heat-inactivated human serum (Gemini Bio Products, CA, USA), and Antibiotic-
Antimycotic (Anti-Anti, Gibco, USA). BCM was supplemented with 10 ng/mL recombinant 
human IL-4 (R&D Systems, MN, USA), 2μg/mL Cyclosporin A (Sigma-Aldrich, CA, USA), 
and insulin transferrin supplement (ITES, Lonza, MD, USA). APCs were re-stimulated with 
fresh irradiated KCD40Ls on days 5 and 10, after washing with PBS and expanding into 
a whole 24-well plate. After two weeks, APC purity was assessed by CD19+ CD86+ 
expressing cells using flow cytometry and were used for T cell stimulation after >90% 
purity. APCs were either restimulated up to 4 weeks or cryopreserved for re-expansion as 
necessary.  
5.2.5. T cell Stimulation by Autologous APCs 
Antigen-specific T cells were generated by stimulating healthy donor B cell APCs 
bypeptide pulsing of specific Cas9 epitopes. Peptide pulsing of APCs was done under 
BCM 5% human serum, with recombinant IL-4. Twenty-four hours later, on day 1, APCs 
were washed and incubated with thawed whole PBMCs at a ratio of 1:2 (200,000 APCs : 
400,000 PBMCs) in a 24-well plate in BCM supplemented with 20U/mL recombinant 
human IL-2 (R&D Systems, MN, USA) and 5ng/mL IL-7 (R&D Systems, MN, USA). On 
day 5, partial media exchange was performed by replacing half the well with fresh BCM 
and IL-2. On day 10, fresh APCs were peptide pulsed in a new 24-well plate. On day 11, 
expanded T cells were restimulated with peptide-pulsed APCs similar to day 1. T cells 
were used for T cell assays or immunophenotyped after day 18.  
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5.2.6. Flow Cytometry Staining for T cells  
Cells were washed once in MACS buffer (containing PBS, 1% BSA, 0.5mM EDTA), 
centrifuged at 550g for 5 min and re-suspended in 200μL MACS buffer. Cells were stained 
in 100μL of staining buffer containing anti-CD137, conjugated with phycoerythrin (PE, 
clone 4B4-1; BD Biosciences, USA), anti-CD8-PC5 (clone B9.11; Beckman Coulter 
1:100), anti-CD4 (clone SK3; BioLegend, 1:200), anti-CD14 (clone 63D3; BioLegend, 
1:200), and anti-CD19 (clone HIB19; BioLegend,1:200), all conjugated to Fluorescein 
isothiocyanate (FITC) for exclusion gates, for 30 min on ice. Samples were covered and 
incubated for 30 min on ice, washed twice in PBS, and resuspended in 1mL PBS prior to 
analysis. 
5.2.7. Pentamer Staining for T cell Immunophenotyping  
The following HLA-A*02:01 PE-conjugated Cas9 pentamers were obtained from 
ProImmune: F2A-D-CUS-A*02:01-ILEDIVLTL-Pentamer, 007-Influenza A MP 58-66-
GILGFVFTL-Pentamer. T cells were washed twice in MACS buffer with 5% human serum 
and centrifuged at 550g for 5 min each time. They were then re-suspended in 100μL 
staining buffer (MACS buffer, with 5% human serum and 1mM Dasatanib (ThermoFisher 
Scientific, MA, USA). Each of the pentamers was added to resuspended T cells, 
stimulated with the respective peptide or APCs at a concentration of 1:100. Samples were 
incubated at room temperature for 30 min in the dark, then washed twice in MACS buffer. 
Cells were stained in 100μL MACS buffer with anti-CD8-PC5, anti-CD4-FITC, anti-CD14-
FITC, and anti-CD19-FITC for exclusion gates. Samples were then washed twice with 
PBS and analyzed by flow cytometry. For flow cytometric analysis, all samples were 
acquired with Attune flow cytometer (ThermoFisher Scientific, MA, USA) and analyzed 
using the Attune software. Gates for expression of different markers and pentamers were 
determined based on flow minus one (FMO) samples for each color after doublet 
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discrimination. Percentages from each of the gated populations were used for the 
analysis. 
5.2.8. Vector Design and Construction 
Modified Cas9 plasmids - Human codon-optimized Streptococcus pyogenes Cas9 
sequence was amplified from pSpCas9 (pX330; Addgene plasmid ID: 42230), using 
forward and reverse primers and inserted within gateway entry vectors using golden gate 
reaction. Desired mutations were designed within gBlocks (Integrated DNA 
Technologies). The gblocks and amplicons were then cloned into entry vectors using 
golden gate reaction. All the primers and gblocks sequences are listed in Appendix B. 
Next, the Cas9 vectors and CAG promoter cassettes were cloned into an appropriate 
gateway destination vector via LR reaction (Invitrogen). 
U6-sgRNA-MS2 plasmids - These plasmids were constructed by inserting either 14bp or 
20bp spacers of gRNAs (Appendix B) into sgRNA (MS2) cloning backbone (Addgene 
plasmid ID: 61424) at BbsI site. All the gRNA sequences are listed in Appendix B. 
5.2.9. Cell Culture for Endogenous Target Mutation and Activation 
HEK293FT cell line was purchased from ATCC and maintained in Dulbecco’s modified 
Eagle’s medium (DMEM - Life Technologies) containing 10% fetal bovine serum (FBS - 
Life Technologies), 2mM glutamine, 1.0 mM sodium pyruvate (Life Technologies) and 1% 
penicillin-streptomycin (Life Technologies) in incubators at 37 °C and 5% CO2. 
Polyethylenimine (PEI) was used to transfect HEK293FT cells seeded into 24-well plates. 
Transfection complexes were prepared according to manufacturer’s instructions. 
5.2.10. Fluorescent Reporter Assay for Quantifying Cas9 Function 
HEK293FT cells were co-transfected with 10 ng gRNA, 200 ng Cas9 constructs, 100 ng 
reporter plasmid and 25 ng EBFP2 expressing plasmid as the transfection control. 
Fluorescent reporter experiments were performed 48 hrs after transfection. Flow 
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cytometry data were analyzed using FlowJo. Cells were gated for positive EBFP 
expression to remove the un-transfected cells from the analysis. Un-transfected controls 
were included in each experiment. 
5.2.11. Quantitative RT-PCR Analysis 
HEK293FT cells were co-transfected with 10 ng gRNA, 200 ng Cas9 constructs, 100 ng 
MS2-P65-HSF1 (Addgene plasmid ID: 61423) and 25 ng transfection control. Cells were 
lysed, and RNA was extracted using RNeasy Plus mini kit (Qiagen) 72 hrs post 
transfection, followed by cDNA synthesis using the High-Capacity RNA-to-cDNA Kit 
(Thermo fisher). qRT-PCR was performed using SYBR Green PCR Master Mix (Thermo 
fisher). All analyses were normalized to 18s rRNA (ΔCt) and fold-changes were calculated 
against un-transfected controls (2−ΔΔCt). Primer sequences for qPCR are listed in 
Appendix B. 
5.2.12. Endogenous Indel Analysis 
HEK293FT cells were co-transfected with 200ng of Cas9 plasmids, 10ng of gRNA coding 
cassette and and 25 ng transfection control. 72 hrs later, transfected cells were 
dissociated and spun down at 200 g for 5 min at room temperature. Genomic DNA was 
extracted using 50 µl of QuickExtract DNA extraction solution (Epicentre) according to the 
manufacturer’s instructions. Genomic DNA was amplified by PCR using primers flanking 
the targeted region. Illumina Tru-Seq library was created by ligating partial adaptors and 
a unique barcode to the DNA samples. Next, a small number of PCR cycles were 
performed to complete the partial adaptors. Equal amounts of each sample were then 
pooled and sequenced on Illumina Tru-Seq platform with 2x150 run parameters, which 
yielded approximately 80,000 reads per sample. Sequencing was performed using a 
2x150 paired-end (PE) configuration by CCIB DNA Core Facility at Massachusetts 
General Hospital (Cambridge, MA, USA). The reads were aligned to the target gene 
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reference in Mus musculus genome using Geneious software, 9-1-5. To detect the indels 
(insertions and deletions of nucleic acid sequence at the site of double-strand break), each 
mutation was evaluated carefully in order to exclude the ones that are caused by 
sequencing error or any off-target mutation. The variant frequencies (percentage to total) 
assigned to each read containing indels were summed up. i.e. indel percentage = total 
number of indel containing reads/ total number of reads. The minimum number of 
analyzed reads per sample was 70,000. 
5.2.13. RNA Sequencing for Quantifying Activator Specificity  
HEK293FT cells were co-transfected with 10 ng gRNA for MIAT locus, 200 ng Cas9 
constructs, 100 ng MS2-P65-HSF1 (Addgene plasmid ID: 61423) and 25 ng transfection 
control. Total RNA was extracted 72 hrs post transfection using RNeasy Plus mini kit 
(Qiagen) and sent to UCLA TCGB core on dry ice. Ribosomal RNA depletion, and single 
read library preparation were performed at UCLA core followed by RNA sequencing using 
NextSeq500. Coverage was 14 million reads per sample. FASTQ files with single-ended 
75 bp reads were then aligned to the human GRCh38 reference genome sequence 
(Ensembl release 90) with STAR (Dobin et al., 2013), and uniquely-mapped read counts 
(an average of 14.8 million reads per sample) were obtained with Cufflink (Trapnell et al., 
2012). The read counts for each sample were then normalized for the library size to CPM 
(counts per million reads) with edgeR (Robinson, McCarthy, & Smyth, 2010). Custom R 
scripts were then used to generate plots. 
 
5.3. RESULTS 
5.3.1. Detection of Cas9-Specific Serum Abs in Healthy Controls 
We first determined whether healthy individuals have detectable IgG Abs to SpCas9. Of 
143 healthy control sera screened, 70 (49.0%) had detectable Abs against S. pyogenes 
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lysate using ELISA (Figure 5-1). This positive subset along with 12 sera that were 
borderline negative for Abs to S. pyogenes lysate were screened for Abs against 
recombinant SpCas9 (Figure 5-1), of which 36.6% were positive. At least 21.0% (n=30) 
of healthy individuals in this study had Cas9-specific Abs (Figure 5-1).  
 
Figure 5-1. Detection of Pre-existing SpCas9-Specific Antibodies in Healthy 
Individuals. Specific serum Abs were detected against S. pyogenes lysate in 49.0% 
(above the dotted line) of 143 healthy controls (left). The subset shown in black circles 
was screened for Abs against recombinant Cas9 protein (right), of which 36.6% (21.0% of 
total samples screened) were positive (above the dashed line). Nucleic Acid 
Programmable Protein Arrays (NAPPA).  
 
 
5.3.2. Cas9 Candidate T cell Epitope Prediction 
We predicted HLA-A*02:01-restricted T cell epitopes derived from SpCas9 using a model 
based on both HLA binding and biochemical properties of immunogenicity (Chowell et al., 
2015) (Table 5-1). We plotted the calculated normalized binding (Sb) and immunogenicity 
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(Si) scores for each peptide (Figure 5-2) to predict the more immunogenic epitopes, which 
are expected to have both high HLA binding (low Sb) and more hydrophobicity (high Si).  
 
 
Figure 5-2. Plot of Sb and Si of Predicted HLA-A*02:01 Epitopes for the SpCas9 
Protein. Red dots represent the immunodominant and subdominant epitopes as found by 
IFN-γ ELISpot.  
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Table 5-1. Predicted Cas9 Immunogenic T Cell Epitopes. 
    Binding  Protein Processing    
Rank Position Sequence Code IEDB NetMHC Syfpeithi  IEDB ANN Sb Si Sb.Si 
1 988-997 YLNAVVGTAL γ 1.25 21.5 24  0.27 0.02 0.068 0.975 0.002 
2 1281-1290 ILADANLDKV  1.25 11.37 31  -0.06 -0.49 0.003 0.447 0.002 
3 236-244 GLFGNLIAL δ 0.6 10.12 29  1.15 1.04 0.020 0.900 0.002 
4 240-248 NLIALSLGL α 1.7 61.18 25  0.15 0.22 0.061 0.903 0.006 
5 615-623 ILEDIVLTL β 1.5 53.29 29  0.28 0.56 0.023 0.710 0.007 
6 614-623 DILEDIVLTL  4.6 3105.79 28  -1.53 -1.02 0.063 0.888 0.007 
7 719-727 SLHEHIANL  1.4 9.14 30  0.93 0.82 0.013 0.380 0.008 
8 415-423 HLGELHAIL  4.4 276.73 25  -0.75 -0.81 0.071 0.876 0.009 
9 300-308 ILLSDILRV  0.3 6.51 29  0.67 0.7 0.019 0.404 0.011 
10 1086-1095 VLSMPQVNIV  3.65 178.87 26  -1.05 -1.43 0.059 0.758 0.014 
11 719-728 SLHEHIANLA  4.7 60.17 19  -0.98 -1.74 0.126 0.890 0.014 
12 1194-1203 LIIKLPKYSL  8.5 966.31 25  -0.97 -1.04 0.090 0.841 0.014 
13 1346-1355 TLIHQSITGL  1.95 57.8 27  0.12 -0.06 0.043 0.632 0.016 
14 1197-1207 KLPKYSLFEL  1.2 10.93 27  0.9 0.5 0.040 0.579 0.017 
15 1041-1050 NIMNFFKTEI  2.65 314.8 19  -1.03 -0.9 0.121 0.857 0.017 
16 512-520 SLLYEYFTV  0.4 4.56 25  0.67 0.55 0.056 0.678 0.018 
17 1309-1318 IIHLFTLTNL  4.25 1083.6 24  -1.04 -0.78 0.085 0.787 0.018 
18 661-670 RLSRKLINGI  3.5 278.03 24  -0.82 -1.05 0.078 0.746 0.020 
19 1227-1236 ALPSKYVNFL  4.3 111.14 27  0.05 -0.26 0.051 0.594 0.021 
20 996-1004 ALIKKYPKL  2.6 154.09 28  -0.27 0 0.037 0.407 0.022 
21 221-229 RLENLIAQL  4.2 242.87 26  -0.46 -0.46 0.061 0.581 0.026 
22 1237-1245 YLASHYEKL  1.2 10.3 26  0.9 0.84 0.050 0.446 0.027 
23 1265-1273 YLDEIIEQI  0.3 4.8 26  0.62 0.6 0.046 0.399 0.028 
24 1042-1050 IMNFFKTEI  3.2 131.4 21  -0.69 -0.87 0.103 0.724 0.028 
25 815-824 YLQNGRDMYV  0.25 13.01 22  -0.18 -0.07 0.083 0.627 0.031 
26 1212-1220 RMLASAGEL  3.2 333.2 22  -0.64 -0.51 0.095 0.650 0.033 
27 1020-1029 KMIAKSEQEI  3.1 64.01 21  -0.36 -0.9 0.103 0.671 0.034 
28 793-801 SQILKEHPV  2.8 191.23 16  -1.4 -1.36 0.149 0.766 0.035 
29 742-750 KVVDELVKV  2.8 44.75 24  -0.06 -0.26 0.074 0.505 0.036 
30 1181-1190 FLEAKGYKEV  3.25 105.27 21  -1.08 -1.42 0.103 0.651 0.036 
31 160-169 HMIKFRGHFL  4.75 324.13 21  -0.59 -0.73 0.110 0.628 0.041 
32 551-559 LLFKTNRKV  3 381.3 25  -1.52 -1.25 0.067 0.368 0.043 
33 141-149 KLVDSTDKA  3.4 274.05 20  -1.48 -1.17 0.114 0.520 0.055 
34 472-481 TITPWNFEEV  4.45 124.55 21  -0.84 -1.21 0.107 0.429 0.061 
35 194-203 QLFEENPINA  1.65 67.94 17  -0.71 -0.79 0.135 0.469 0.072 
36 518-527 FTVYNELTKV  2.55 169.93 20  -1.12 -1.15 0.111 0.216 0.087 
37 473-481 ITPWNFEEV  6.4 351.14 18  -1.25 -1.65 0.143 0.229 0.110 
38 970-978 FQFYKVREI  2.7 135.61 16  -0.66 -0.39 0.148 0.229 0.114 
The table shows Cas9 HLA-A*02:01 epitopes predicted using an integrative prediction model and ranked according to 
their Sb.Si score (the lower the more immunogenic). The immunodominant and subdominant epitopes as confirmed by 




5.3.3. Ex vivo Stimulation and Epitope Mapping of Cas9 by ELISpot 
We then investigated whether peripheral blood mononuclear cells (PBMCs) derived from 
healthy individuals had measurable T cell reactivity against the predicted SpCas9 MHC 
class I epitopes. We synthesized 38 peptides (Table 5-1) and grouped them into 10 pools 
of 3-4 peptides each. We measured peptide-specific T cell immunity using IFN-γ secretion 
ELISpot assays in PBMCs derived from 12 healthy individuals (HLA-A*02:01, n=10; non-
HLA-A*02:01, n=2) and identified immunoreactive epitopes within pools 3 or 5 in 83.0% of 
the donors tested (90% of the HLA-A*02:01 donors; Figure 5-3). The seven individual 
peptides from pools 3 and 5 were evaluated by IFN-γ ELISpot and the dominant 
immunogenic epitopes were SpCas9_240-248 and SpCas9_615-623, designated 
peptides α and β, from pools 5 and 3, respectively. The subdominant epitopes were found 
to be γ and δ from pools 3 and 5, respectively. Both peptides α and β are located in the 
REC lobe of the Cas9 protein (Figure 5-5) that binds the sgRNA and the target DNA 
heteroduplex (Nishimasu et al., 2014) .The position of peptides α and β within the protein 
structure is shown in Figure 5-4. The individual peptides within pools that were positive 
for any donor were evaluated for this donor by IFN-γ ELISpot. The immunoreactivity and 
position of the 38 predicted peptides (a few of which are overlapping) within the SpCas9 
protein are shown in Figure 5-5.  
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Figure 5-3 Detection of Pre-existing T Cell Immune Response to SpCas9 in Healthy 
Donors. IFN-γ ELISpot assay of T cell reactivity of 12 healthy donors (non-HLA-A*02:01 
are shown as open circles; n=2) to 38 predicted epitopes grouped in 10 pools, CEF 
(positive control), and DMSO (negative control). Peptides α and δ were in pool 5 while β 
and γ were in pool 3. 
 
 
Figure 5-4. 3D Structure of the SpCas9 Protein. The location of the identified 






Figure 5-5. IFN-γ ELISpot Reactivity of Healthy Donor T Cells (N=12) to Epitopes 
Across the Different Domains of the S. pyogenes Cas9 Protein. Donors 1-10 were 





5.3.4. Sequence Similarity of Identified T cell Epitopes 
Peptides α and β are shown as red dots on the epitope prediction plot (Fig. 5-2) and their 
sequences and predicted ranking are shown in Table 5-1. As predicted, these peptides 
had low Sb and high Si values. Both the immunodominant (α and β) and subdominant (γ 
and δ) T cell epitopes identified by IFN-γ ELISpot were within the top 5 most immunogenic 
epitopes predicted by the previously described immunogenicity model (Chowell et al., 
2015). Their ranking as predicted by the consensus method hosted on the IEDB server 
using default settings was 14, 5, 18, and 4, respectively. Sequence similarity of peptides 
α and β to amino acid sequences in known proteins was investigated using Protein BLAST 
and the IEDB epitope database (Vita et al., 2015). This was done to investigate whether 
there is any chance that the T cell immune response that we are detecting in healthy 
individuals could be due to previous exposure to another protein of similar sequence. A 
 115 
peptide was considered ‘similar’ to α or β if at least 7 of 9 (78%) amino acid residues (that 
are not the second or ninth) were matching. None of these two peptides resembled known 
epitopes in the IEDB database, but similarity to other Cas9 orthologs and other bacterial 
proteins was detected (Tables 5-2 and 5-3). Epitope β has sequence similarity to a peptide 
derived from the Neisseria meningitidis peptide chain release factor 2 protein (ILEDIVLTL 






Table 5-2. Sequence Homology of Epitope α to Amino Acid Sequences from Known Proteins. 
  
 Sequence Similarity (%) Protein  Sequence ID Source 
1 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
 WP_014612333.1 Streptococcus dysgalactiae 
2 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_054279288.1 Streptococcus phocae 
3 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
 WP_067062573.1 Streptococcus pantholopis 
4 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_048800889.1 Streptococcus constellatus 
5 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_002304487.1 Streptococcus mutans 
6 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_049516684.1 Streptococcus anginosus 
7 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_003079701.1 Streptococcus macacae 
8 NLIALSLGL 9/9 (100%) type II CRISPR RNA-guided endonuclease 
Cas9 
GAD40915.1 Streptococcus intermedius  
SK54 
9 NLIAFSLGL 8/9 (89%) Full=RNA polymerase-associated protein 





10 NLISLSLGL 8/9 (89%) type II CRISPR RNA-guided  
endonuclease Cas9 
 WP_096633625.1 Streptococcus parauberis 
11 NLIALALGL 8/9 (89%) type II CRISPR RNA-guided endonuclease 
Cas9 






 Sequence Similarity (%) Protein  Sequence ID Source 
12 NLIALALGL 8/9 (89%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_058692367.1 Streptococcus gallolyticus 




14 NLIALALGL 8/9 (89%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_018363470.1 Streptococcus caballi 




16 NLIALALGL 8/9 (89%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_014334983.1 Streptococcus infantarius 
17 DLIALYLGL 7/9 (78%) Full=NADH-quinone oxidoreductase 
subunit N; AltName: Full=NADH 
dehydrogenase I subunit N;  
AltName: Full=NDH-1 subunit N 
A8I421.1 Azorhizobium caulinodans  
ORS 571 
18 NLLALALGL 7/9 (78%) type II CRISPR RNA-guided endonuclease 
Cas9 
 WP_007896501.1 Streptococcus 
pseudoporcinus 
19 NLIGLALGL 7/9 (78%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_061587801.1 Streptococcus oralis 
20 NLVALALGL 7/9 (78%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_074862269.1 Streptococcus equinus 
21 NLVALVLGL 7/9 (78%) type II CRISPR RNA-guided endonuclease 
Cas9 
WP_020917064.1 Streptococcus lutetiensis 
22 SLIAFSLGL 7/9 (78%) ectoine/hydroxyectoine ABC transporter 
permease subunit EhuD 
WP_086160327.1 Streptomyces sp. SCSIO 
03032 
23 YLIALALGL 7/9 (78%) ectoine/hydroxyectoine ABC transporter 
permease subunit EhuD 






Table 5-3. Sequence Homology of Epitope β to Amino Acid Sequences from Known Proteins. 
 Sequence Similarity (%) Protein  Sequence ID Source 
1 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_084916602.1 Streptococcus dysgalactiae 
2 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_074484960.1 Streptococcus henryi 
3 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_003088697.1 Streptococcus ratti 
4 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_044681799.1 Streptococcus suis 
5 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_024786433.1 Streptococcus mutans 
6 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_057491067.1 Streptococcus orisasini 
7 ILEDIVLTL 9/9 (100%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_082312238.1 Streptococcus intermedius 
8 ILEGIVLTL 8/9 (89%) peptide chain release factor 2  NP_275123.1 Neisseria meningitidis MC58 
9 ILEDIVQTL 8/9 (89%) 
type II CRISPR RNA-guided  
endonuclease Cas9  EAO61901.1 Streptococcus agalactiae 
10 ILEDIVQTL 8/9 (89%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_070454905.1 
Streptococcus sp. 
HMSC063D10 
11 VLEDIVLTL 8/9 (89%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_075346866.1 Streptococcus sp. 'caviae' 
12 VLEDIVLSL 7/9 (78%) 
type II CRISPR RNA-guided  







 Sequence Similarity (%) Protein  Sequence ID Source 
13 ILENIVHTL 7/9 (78%) 
type II CRISPR RNA-guided  
endonuclease Cas9  KYF37509.1 Streptococcus mitis 
14 ILENIVHTL 7/9 (78%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_084972088.1 Streptococcus oralis 
15 ILENIVHTL 7/9 (78%) 
type II CRISPR RNA-guided  
endonuclease Cas9  WP_045635197.1 Streptococcus gordonii 
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5.3.5. Detection of Cas9-Specific T Cell Immune Response Against the Identified 
Immunodominant Epitopes 
Antigen-specific T cells were expanded for 18 days in vitro by coculturing healthy donor 
PBMCs with peptide β-pulsed autologous antigen presenting cells (APCs). Cas9-specific 
CD8+ T cell responses were assessed by flow cytometry. CD8+ T cells specific for the 
HLA-A*0201/β pentamer were detected after stimulation (3.09%; Fig. 5-6A).  
We next hypothesized that mutation of the MHC-binding anchor residues of the identified 
immunogenic epitopes would abolish specific T cell recognition (Fig. 5-6A). The epitope 
anchor residues (2nd and 9th) are not only necessary for peptide binding to the MHC groove 
but are also crucial for recognition by the T cell receptor (Chowell et al., 2015). The 
percentage of CD8+ pentamerβ+ T cells dropped to 0.3% when APCs were pulsed with 
the mutated peptide (β2; Fig. 5-6B) compared with 3.09% with the wild type peptide (β; 
Fig. 5-6A). We then examined the reactivity of healthy donor T cells to modified peptides 
α or β with mutations in residues 2, 9, or both (sequences are shown in Table 5-4) using 
IFN-γ ELISpot assay. The epitope-specific T cell reactivity was markedly reduced with the 
mutant peptides (Fig. 5-7, 5-8). The average reduction for the responsive HLA-A*02:01 




Figure 5-6. Detection of Cas9-Specific T Cells Recognizing the Immunodominant 
Epitope β in a Healthy Individual and Reduction of the Immune Recognition by 
Mutating One Anchor Residue of the Epitope. A. Epitope β-specific CD8+ T cell 
response detected using β-specific pentamer in PBMCs stimulated with peptide β-pulsed 
antigen presenting cells. B. The percentage of CD8+ pentamerβ+ T cells was reduced to 
0.3% when APCs were pulsed with the mutated peptide β2. 
 
 
Table 5-4. Positions, Sequences and IEDB HLA Binding Percentile Rank of Epitopes α and β 



















α (240-248) NLIALSLGL     1.7  β (615-623)  ILEDIVLTL     1.5 
α2 NGIALSLGL     26  β2  IGEDIVLTL     23 
α9 NLIALSLGG     14  β9  ILEDIVLTG     12 






Figure 5-7. Reduced T Cell Response to Epitopes α and β After Mutation of the 
Anchor Residues. IFN-γ ELISpot for 12 healthy donor PBMCs stimulated with wild type 























































Figure 5-8. SpCas9 Immunodominant Epitope-Specific CD8+ T Cell Recognition Is 
Abolished After Anchor Residue Mutation. IFN-γ ELISpot assay in triplicate wells 
comparing T cell reactivity to wild type or mutated epitopes α and β. These results are 
representative of 12 donors and two independent replicates. 
 
 
5.3.6. Mutated Cas9 Proteins Have Lower Immune Recognition and Maintain their 
Function and Specificity 
We then generated modified Cas9 constructs by mutating the second residue of peptide 
α (L241G; Cas9-α2), peptide β (L616G; Cas9-β2), or both (Cas9-α2β2). To measure the 
effect of mutating the anchor residue of the immunogenic epitopes on T cell recognition of 
the Cas9 protein, we transiently transfected healthy donor B cell APCs with mRNA 
encoding WT Cas9, Cas9-α2, Cas9-β2, or Cas9-α2β2. Protein expression was confirmed 
by Western blot and the levels were comparable for all four constructs (data not shown). 
The T cell response measured by IFN-γ ELISpot after coculturing of transfected APCs 
with autologous PBMCs was significantly decreased for the modified Cas9 proteins 
(Figure 5-9). These results demonstrate that mutating the anchor amino acid residue at a 
highly immunogenic epitope can influence the overall immunogenicity of Cas9. Hence, 
engineering Cas9 variants with reduced immunogenicity potential can be used in 
conjunction with other strategies for safer CRISPR therapies and even possibly reduce 
the dosage of systemic immunosuppression needed for patients. Introduction of the β2 
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mutation was the most effective in reducing T cell immunogenicity (5.5-fold, p<0.0001). 
This mutation in the REC1 domain (Figure 5-4 and 5-5) is not located in any of the two 
regions that are absolutely essential for DNA cleavage, the repeat-interacting (97–150) 
and the anti-repeat-interacting (312–409) regions (Nishimasu et al., 2014). 
 
Figure 5-9. Mutated Cas9 Proteins Have Lower Immune Recognition. IFN-γ ELISpot 
comparing T cell reactivity to APCs expressing WT or modified Cas9 proteins. APCs 
expressing FluM1 were used as a positive control. APCs expressing GAPDH or spiked 




We then tested the function of Cas9-β2 in comparison with wild type Cas9 (WT-Cas9) in 
the context of DNA cleavage and transcriptional modulation. To examine the nuclease 
activity of Cas9-β2 and compare with WT-Cas9, we targeted Cas9-β2 or WT-Cas9 to an 
endogenous locus (EMX-1) and measured percent indel formation (Figure 5-10). Our data 
demonstrate that Cas9-β2 retains nuclease capacity in the locus we studied (Fig. 5-10B) 




Figure 5-10. Mutated Cas9 Retains Its Nuclease Function at an Endogenous Locus. 
A. Schematic of the experiment assessing mutagenesis capacity of Cas9-β2. Cells were 
transfected with either WT-Cas9, Cas9-β2, or an empty plasmid as well as 20nt gRNA 
targeting EMX-1 locus. 72 hrs after the transfection, percent cleavage was assessed by 
DNA extraction and illumina sequencing. B. Percentage of indel formation in EMX-1 locus. 
Data represent mean +/-SD of three individual transfections. 
 
 
Figure 5-11. Mutated Cas9 Retains Its Nuclease Function at a Synthetic Promoter. 
A. Schematic of the experiment assessing Cas9-β2 cleavage capacity at a synthetic 
promoter. Cells were transfected with either WT-Cas9, Cas9- β2 or an empty plasmid as 
well as 20nt gRNA targeting a synthetic CRISPR promoter that harbors two gRNA target 
sites flanking a mini-CMV promoter. The targeting and cleavage at the promoter should 
disrupt the promoter and decrease EYFP expression. B. Each individual dot EYFP 
expression 48 hours after the transfection in cells expressing >2x102 A.U. of a transfection 




Next, we determined whether Cas9-β2 can successfully recognize and bind its target DNA 
leading to transcriptional modulation. We first tested this in the context of enhanced 
transgene expression from a synthetic CRISPR responsive promoter in HEK293 cells 
using 14nt gRNAs and aptamer-mediated recruitment of transcriptional modulators similar 
to what we had shown before (Fig. 5-12). Having shown successful transgene activation, 
we then investigated whether this variant retains such capacity within the chromosomal 
contexts of endogenous genes. We transfected the cells with plasmids encoding Cas9-β2 
or WT-Cas9 and 14nt gRNAs against two different endogenous genes (TTN and MIAT). 
qRT-PCR analysis showed that this variant successfully led to target gene expression 
(Fig. 5-13A-C). To further characterize Cas9-β2 specificity, we performed genome-wide 
RNA sequencing after targeting Cas9-β2 or WT-Cas9 to the MIAT locus for transcriptional 
activation. The results demonstrated no significant increase in undesired off-target activity 





Figure 5-12. Mutated Cas9 Retains Its Transcriptional Modulation Capacity at a 
Synthetic Promoter. A. Schematic of the experiment assessing Cas9-β2 transcriptional 
activation capacity at a synthetic promoter. Cells were transfected with either WT-Cas9, 
Cas9- β2 or an empty plasmid as well as aptamer binding transcriptional activation 
domains, and14nt gRNA targeting a synthetic CRISPR promoter that harbors multiple 
target sites upstream of a mini-CMV promoter. The targeting at the promoter should 
should enable iRFP expression. B. Data shows mean+/-SD of geometric mean of iRFP 
expression 48 hrs after the transfection in cells expressing >2x102 A.U of a transfection 






Figure 5-13. Mutated Cas9 Retains its Specificity and Transcriptional Modulation 
Capacity at an Endogenous Chromosomal Locus. A. Schematic of the experiment 
assessing gRNA binding, DNA targeting and transcriptional modulation with Cas9-β2. 
Cells were transfected with either WT-Cas9, Cas9-β2, or an empty plasmid as well as 14nt 
gRNA targeting TTN or MIAT in the presence of MS2-P65-HSF1 (transcriptional 
modulation). 72 hrs after the transfection, mRNA was assessed by qRT-PCR. B, C. Shown 
is the mRNA level relative to an untransfected control experiment. Each individual dot 
represents an individual transfection. D. Mean expression levels of 24,078 protein-coding 
and non-coding RNA genes for WT-Cas9 and Cas9-β2 (each in duplicate) are shown. For 
visualization purposes, the values were transformed to a log2(CPM+1) scale. MIAT, the 
gRNA target gene, is highlighted in red, and R denotes Pearson correlation coefficient 
between two groups. 
 
 
To show the extensibility of our approach, we tested the function of Cas9-α2, with a 
mutation located in the REC2 domain (Figures 5-4 and 5-5). Cas9-α2 also demonstrated 
DNA cleavage and transcriptional modulation functionality comparable with WT-Cas9 
(Fig. 5-14). This is consistent with a previous study which showed that Cas9 with a deleted 
REC2 domain retains its nuclease activity (Nishimasu et al., 2014). When T cells were 
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stimulated with APCs spiked with peptide α2, the percentage of CD8+ CD137+ T cells (a 
marker of T cell activation (Wolfl et al., 2007)) was decreased by 2.3 fold as compared to 
WT peptide α stimulation (Fig. 5-15).  
 
Figure 5-14. Cas9-α2 Retains Its Nuclease and Transcriptional Modulation 
Activities. A. Analysis of mutagenesis capacity of Cas9-α2 as compared to WT-Cas9 in 
a synthetic promoter. Data shows mean+/-SD of geometric mean of EYFP expression 72 
hrs after the transfection in cells expressing >2x102 A.U of a transfection marker measured 
by flow cytometry (n=2 individual transfections). B. Mutagenesis in endogenous EMX-1 
locus. Percentage of indel formation in EMX-1 locus. Data is mean +SD of three individual 
transfections. C. Transcriptional modulation by Cas9-α2 at a synthetic promoter. Data is 
mean+/-SD of geometric mean of iRFP expression 72 hrs after the transfection in cells 
expressing >2x102 A.U of a transfection marker measured by flow cytometry (n=3 
individual transfections). D, E. Shown is mRNA level relative to an untransfected control 
experiment. Each individual dot represents individual transfections. Note for A and C WT-
Cas9 and no Cas9 data is also reported in Fig.5-10 and 5-11. For B-E WT-Cas9 and no 






Figure 5-15. Mutation of the Second Residue of Epitope α Reduces Its 
Immunogenicity. Activated CD8+CD137+ T cells detected in PBMCs stimulated with 




The detection of pre-existing B cell and T cell immunity to the most widely used nuclease 
ortholog of the CRISPR/Cas9 tool in a significant proportion of healthy humans confirms 
previous studies in mice (Chew et al., 2016; D. Wang et al., 2015) and sheds light on the 
need for more studies of the immunological risks of this system. The CD8+ T cell immunity 
we observed is likely memory responses, as they are observed without ex vivo stimulation. 
Following 18 days of T cell stimulation by peptides α or β, expansion of naïve T cells is 
not precluded. This suggests that the expression of Cas9 in naïve individuals may trigger 
a T cell response that could prevent subsequent administration. This could be avoided by 
switching to Cas9 orthologs from other bacterial species, but attention needs to be given 
to individual and distinct immune repertoires. This practice can be difficult given the 
epitope conservation across Cas9 proteins from multiple Streptococcus species and 
resemblance to sequences from other bacterial proteins such as the common pathogen 
N. meningitidis, that asymptomatically colonizes the nasopharynx in 10% of the population 











can represent an attractive alternative. Selective deimmunization can be an effective 
alternative for reduction of immune response to CRISPR in patients where high-dose 
systemic immunosuppression is contraindicated, such as in patients with chronic 
infectious diseases. This strategy can be important particularly when longer expression of 
Cas9 will be desired for epigenetic therapy. 
CRISPR application for human therapies will span its use both for gene editing (through 
DNA DSB) or epigenetic therapies (without DNA DSB). In fact, recent reports shed light 
on CRISPR’s ability to activate or repress gene expression in mice (Ibrahim & Robertson, 
2018; Liao et al., 2017; Zheng et al., 2018), which open the door to a variety of new 
therapeutic applications such as activating silent genes, compensating for disrupted 
genes, cell fate reprogramming or silencing disrupted genes, without the concern over 
permanent change in DNA sequence. However, unlike the use of Cas9 for gene editing, 
which may only require Cas9 presence in cells for a few hours, current techniques for 
CRISPR-based epigenetic therapies require longer term expression of Cas9 in vivo, 
possibly for weeks and months (Liao et al., 2017; Zheng et al., 2018). The requirement for 
longer term expression of Cas9 in vivo poses the challenge of combating pre-existing 
immune response towards Cas9. This challenge will need to be addressed before 
CRISPR application for human therapies, especially for epigenetic therapies, can be fully 
implemented. 
Delivery of CRISPR in vivo by incorporating its expression cassette in adeno-associated 
virus (AAV), will most likely shape many of initial clinical trials as AAV-based gene delivery 
is one of the safest and most prevalent form of gene therapies in human. AAV will enable 
longer term expression of Cas9, desirable for epigenetic therapies. Therefore, unlike Cas9 
delivery in the form of ribonucleoprotein complexes (which are short term), it is highly likely 
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that CRISPR delivery through AAV and its expression within target cells will engage CD8+ 
T cell immunity. 
Conventional methods of deimmunizing non-human therapeutic proteins rely on trial-and-
error mutagenesis, machine learning, and often includes deletion of whole regions of the 
protein (Cantor et al., 2011; King et al., 2014; Mazor et al., 2017; Salvat et al., 2017; Tangri 
et al., 2005). Here, as a general principle, we show that alteration of one of the anchor 
residues of an immunodominant epitope abolished specific T cell recognition. However, 
HLA allotype diversity and the existence of numerous epitopes in the large Cas9 protein 
complicate the process of complete deimmunization. The overall impact of removal of 
select immunodominant epitopes remains to be seen; both reduction (Yeung et al., 2004) 
and enhancement (Mok, Lee, Wright, & Crowe, 2008) of the immunogenicity of 
subdominant epitopes have been reported with similar approaches for other proteins.  
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CHAPTER 6 : SUMMARY AND FUTURE PERSPECTIVES 
6.1. SUMMARY 
The immune response provides a valuable tool that can be harnessed for developing 
biomarkers with various applications in cancer. These range from screening seemingly 
healthy individuals to diagnosis, prognosis, monitoring recurrence and prediction of 
response to therapy. This dissertation employs classical and novel techniques to identify 
immune profiles for use as biomarkers for cancer detection and novel therapies. 
Despite hundreds of thousands of research publications reporting claimed biomarkers, the 
number in clinical use is astonishingly small. This has been a well-recognized but poorly 
addressed problem in biomarker research, that results in wasted financial and intellectual 
resources. In Chapter 2, the crucial considerations of developing pipelines for the rapid 
evaluation of circulating biomarkers are reviewed, with a focus on breast cancer as a case 
study. I discuss critical elements in biomarker study design and assay development, both 
at the discovery and the validation stages, to increase the identification of clinically useful 
markers. Factors that are needed to establish pipelines for the rapid translation of these 
biomarkers to clinical practice across multiple clinical applications were also identified.  
In Chapter 3 of this dissertation, I describe the generation and validation of custom HPV 
NAPPA arrays displaying the proteomes of 12 HPV types for immunoprofiling HPV-
associated cancers. We demonstrate robust protein expression for 98% of the Ags 
expressed. The displayed Ags retained antigenic specificity of target epitopes, as 
measured by four HPV-specific MAbs. Ab reactivity to multiple early HPV proteins were 
detected in sera from patients with HPV-associated malignancies using the arrays and 
high correlation of HPV16 IgG detection with RAPID ELISA was confirmed.  
These arrays were used in Chapter 4 to identify the immune response in cervical cancer 
and pre-invasive cervical lesions. Abs to any early (E) HPV protein were detected less 
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frequently in women with CIN 0/I (23.7%) than women with CIN II/III (39.0%) and ICC 
(46.1%, p<0.04). Of the E Abs, anti-E7 Abs were the most frequently detected (6.6%, 
19.5%, and 30.3%, respectively). The least frequently detected Abs were E1 and E2-Abs 
in CIN 0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC (7.9%). HPV16-specific Abs 
correlated with HPV16 DNA detected in the cervix in 0% of CIN 0/I, 21.2% of CIN II/III, 
and 45.5% of ICC. A significant number (29 – 73%) of E4, E7, L1, and L2 Abs had cross-
reactivity between HPV types. HPV protein arrays provide a valuable high-throughput tool 
for measuring the breadth, specificity, and heterogeneity of the serologic response to HPV 
in cervical disease.  
The CRISPR/Cas9 system has raised hopes for developing personalized gene therapies 
for cancer. However, the expression of the bacterial Cas9 nuclease in humans raises 
concerns over safety and potential immune adverse reactions. In Chapter 5, biomarkers 
of Cas9-specific B cell and T cell immunity are identified. Two immunodominant T cell 
epitopes for HLA-A*02:01 were identified and a single mutation in the anchor residue of 
one or both of these epitopes significantly reduced the protein immunogenicity while 
maintaining its function and specificity in the CRISPR/Cas9 system. The identified immune 
response may find application in informing in vivo gene therapy decisions for cancer as 
well as other diseases.  
6.2. FUTURE PERSPECTIVES 
To date, there are no established tissue, blood, or vaginal biomarkers other than HPV 
nucleic acid and cytology for CIN II/III in high risk patients. Biomarkers such as serology 
that identify high-risk HPV infection and invasive cervical cancers (ICC) could have an 
impact on the screening, detection, and treatment of cervical disease. In low-resource 
settings, a low-cost blood-based point-of-care (POC) test for HPV serology is ideal for 
population screening. Development of such test has been challenged by the difficulties of 
 135 
biomarker development for cervical disease and of achieving an analytical sensitivity high 
enough for their detection in a few drops of blood in a POC setting.  
The discovery of cervical disease immune biomarkers has been limited by several factors. 
These include the diversity of HPV types, the technical challenges of high-throughput 
study of the immune response to multiple proteins, and the heterogeneity of the immune 
response to viral proteins in HPV-associated cancers, as reported here. Since HPV16 is 
responsible for only 50-55% of cervical cancers (Bosch et al., 2008), we predicted that 
custom protein arrays displaying a broad spectrum of HPV antigens in a slide-based 
format may improve the detection of serologic responses to HPV. While we were able to 
detect an HPV-specific immune response that increases with disease severity, an 
improved signal-to-noise ratio is required for developing clinically useful biomarkers. More 
studies are needed to reach the ultimate goal of developing a panel of a limited number 
of select biomarkers that can be produced at low cost for display in a POC test with optimal 
performance for the detection of women at risk of developing cancer. This study highlights 
the importance of investigating proteins from HPV types other than the most widely studied 
HPV16 for improved sensitivity.  
One challenge with slide-based protein arrays is the possibility of diffusion of the desired 
product from one feature on the array to another, resulting in signal cross-talk. This could 
happen during the in vitro protein synthesis step in NAPPA, before the GST-tagged protein 
is fully synthesized and captured on the array surface. An innovative technology that 
addresses this problem is high-density nucleic acid programmable protein arrays (HD-
NAPPA) (Takulapalli et al., 2012). In this technique, the printing mix is deposited in 
physically isolated nanowells etched on a silicon surface on the slide. This allows both the 
protein expression and display and the immune reaction with serum antibodies to occur in 
these nanowells without diffusion to adjacent spots. This significantly enhances the signal-
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to-noise ratio and may allow detection of weak signals over background. Future studies 
evaluating potential biomarkers for cervical disease may need to use this platform as a 
discovery tool. 
Another limitation, as demonstrated here, is that the HPV-specific antibody response in 
cervical disease is weak and even absent in some women (Carter et al., 2000), especially 
compared with that detected in HPVOPC (K. S. Anderson, K. R. Dahlstrom, et al., 2015; 
K. S. Anderson, J. E. Gerber, et al., 2015). This is not surprising since the cervix acts as 
a protective niche for the virus and the host can remain ignorant of its presence for years. 
Thus, for discovery, nanowell arrays could help detect weak signals with the improved 
signal-to-noise ratio. Additionally, an important requirement for a POC test with a select 
panel of biomarkers for cervical disease is high analytical sensitivity to ensure 
reproducibility of the biomarker performance in a POC setting. This could be achieved by 
the use of fluorescent-based biorecognition instead of colorimetry (L. Lee, Nordman, 
Johnson, & Oldham, 2013; J. Smith et al., 2015), where a bright light source is used to 
actively interrogate the biorecognition site and the emitted fluorescent signal is detected 
electronically. There is a need for the development and optimization of such platform for 
use at low cost in a LMIC setting. Eventually, the serologic immune response could be 
useful in combination with other tests or as an initial screening tool in low-resource 
environments.  
The detection of pre-existing B cell and T cell immunity to the most widely used nuclease 
ortholog of the CRISPR/Cas9 tool in a significant proportion of healthy humans confirms 
previous studies in mice (Chew et al., 2016; D. Wang et al., 2015) and sheds light on the 
need for more studies of the immunological risks of this system. More studies are needed 
to explore the immune response in other HLA haplotypes and other Cas9 orthologs. 
Whether Cas9-specific B cell or T cell immunity impact the efficacy or safety of Cas9 gene 
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delivery remains to be seen. Unlike the use of Cas9 for gene editing, which may only 
require Cas9 presence in cells for a few hours, current techniques for CRISPR-based 
epigenetic therapies require longer term expression of Cas9 in vivo, possibly for weeks 
and months (Liao et al., 2017; Zheng et al., 2018). This will likely engage memory T cell 
responses which could have implications for safety and efficacy. Studies that find 
associations with the identified biomarkers of Cas9-specific immunity and clinical 
consequences are needed for the biomarkers to have clinical utility. The use of 
CRISPR/Cas9 in humans may eventually necessitate creating HLA type-specific Cas9 
variants, particularly for applications that require long-term Cas9 expression.  
The top binding T cell epitopes within Cas9 that are most promiscuous for common HLA 
class I and class II alleles have been recently predicted in silico using IEDB (Chew, 2018). 
However, this is the first study that experimentally validates predicted immunodominant 
epitopes. None of the epitopes we report overlap with the peptides previously predicted 
(Chew, 2018). This is not unsurprising since we restricted our analysis to one HLA 
haplotype. Additionally, improved algorithms are needed to predict epitopes that hold up 
in experimental validation, as we show here. The use of CRISPR/Cas9 in humans may 
eventually necessitate creating HLA type-specific Cas9 variants, particularly for 
applications that require long-term Cas9 expression.  
Generating partially immune-silenced Cas9 can be an attractive strategy to reduce the 
immune response to Cas9 particularly in patients where systemic immunosuppression will 
be contraindicated. Non-specific localized immune suppressive approaches, such as 
those used by tumor cells and some viruses may complement these strategies for 
complete deimmunization. One attractive strategy is the transient and inducible co-
expression of programmed death-ligand 1 (PD-L1) or Indoleamine 2,3-Dioxygenase 1 
(IDO1) activating gRNAs inside cells that express Cas9 to protect them against attack by 
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T cells. Alternatively, antigen presentation can be blocked by viral proteins interfering with 
antigen presentation (VIPRs), such as the adenoviral E319K or US2 and US11 from the 
human cytomegalovirus (Yewdell & Hill, 2002) or molecules that inhibit proteasomal 
antigen processing such as the Epstein-Barr virus Gly-Ala repeat (Levitskaya et al., 1995). 
We anticipate that deimmunized Cas9 will be useful in reduction of the dosage of the other 
immunomodulatory measures needed to be co-administered in patients, which could thus 
facilitate therapeutic CRISPR applications as we develop better understanding of the 
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NUCLEOTIDE SEQUENCES OF MODIFIED CAS9 GENES, GRNAS, AND PRIMERS 




































































































































































































































































Sequences of gRNAs used in Chapter 5: 
 
MIAT-14bp gRNA GAGGCTGAGCGCAC 
TTN-14bp gRNA GGAAGTCTCCTTTG 
Reporter2-20bp gRNA GTCCCCTCCACCCCACAGTG 
CR10-14bp-gRNA GCATCAGGAACATGT 
EMX1- 20bp gRNA CACC GAGTCCGAGCAGAAGAAGAA 
 
 
Sequences of primers used in Chapter 5: 
 
Cas9 fragment1- FW ttttGGTCTCTAGGTCCACCATGGACTATAAGGACCACGA 
Cas9 fragment1- RV tttggtctcaGAACAGCTGGTTGTAGGTCTGCA 
Cas9 fragment2-FW ttttGGTCTCTACCAACCGGAAAGTGACCGTGAAG 
Cas9 fragment2-RV ttttGGTCTCAAAGCTTACTTTTTCTTTTTTGCC 
qPCRMIAT-FW TGGCTGGGGTTTGAACCTTT 
qPCR-MIAT RV AGGAAGCTGTTCCAGACTGC 
qPCRTTN FW TGTTGCCACTGGTGCTAAAG 
qPCR-TTN-RV ACAGCAGTCTTCTCCGCTTC 
PCR-EMX1-FW CCATCCCCTTCTGTGAATGT 
PCR-EMX1-RV GGAGATTGGAGACACGGAGA 
 
